

CITATION REPORT

List of articles citing

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

DOI: 10.1126/science.286.5440.735
Science, 1999, 286, 735-41.

Source: <https://exaly.com/paper-pdf/30495966/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2341	Neuropathologie de la maladie d'Alzheimer. 1997 , 14, 5-23		3
2340	BACE Maps to Chromosome 11 and a BACE Homolog, BACE2, Reside in the Obligate Down Syndrome Region of Chromosome 21 . <i>Science</i> , 1999 , 286, 1255a-1255	33.3	87
2339	Alzheimer's disease. A firm base for drug development. 1999 , 402, 471-2		49
2338	Ultrafast relaxation in water. 1999 , 402, 473-475		24
2337	Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. 1999 , 402, 533-7		1319
2336	Purification and cloning of amyloid precursor protein beta-secretase from human brain. 1999 , 402, 537-40		1464
2335	Axon routing across the midline controlled by the Drosophila Derailed receptor. 1999 , 402, 540-4		114
2334	The presenilins in Alzheimer's disease--proteolysis holds the key. <i>Science</i> , 1999 , 286, 916-9	33.3	358
2333	Protein processing mechanisms: from angiotensin-converting enzyme to Alzheimer's disease. 2000 , 28, 441		3
2332	Protein processing mechanisms: from angiotensin-converting enzyme to Alzheimer's disease. 2000 , 28, 441-446		20
2331	Chapter 4. Secretase inhibitors as therapeutics for Alzheimer's disease. 2000 , 35, 31-40		11
2330	?????????????????????. 2000 , 74, 999-1003		
2329	Biowissenschaften. 2000 , 48, 116-116		
2328	A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. 2000 , 11 Spec No, 213-328		66
2327	Molecular genetics of Alzheimer's disease: the role of beta-amyloid and the presenilins. 2000 , 13, 377-84		60
2326	A beta peptides and calcium influence secretion of the amyloid protein precursor from chick sympathetic neurons in culture. 2000 , 61, 449-57		10
2325	Alzheimer's disease cybrids replicate Aβ amyloid abnormalities through cell death pathways. 2000 , 48, 148-155		154

2324	Immunization for Alzheimer's disease: A shot in the arm or a whiff?. 2000 , 48, 553-555	1
2323	The selective muscarinic M1 agonist AF102B decreases levels of total A β in cerebrospinal fluid of patients with Alzheimer's disease. 2000 , 48, 913-918	132
2322	The use of seldi proteinchip arrays to monitor production of Alzheimer's betaamyloid in transfected cells. 2000 , 6, 459-69	67
2321	Intracellular site of gamma-secretase cleavage for Abeta42 generation in neuro 2a cells harbouring a presenilin 1 mutation. 2000 , 267, 2036-45	13
2320	Purification and characterization of active recombinant human napsin A. 2000 , 267, 2573-80	17
2319	Therapeutic approaches to Alzheimer's disease. 2000 , 4, 377-82	51
2318	The aging process: where are the drug opportunities?. 2000 , 4, 371-6	8
2317	Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. 2000 , 176, 60-7	53
2316	Applied genomics: integration of the technology within pharmaceutical research and development. 2000 , 11, 602-9	34
2315	Identification of beta-secretase-like activity using a mass spectrometry-based assay system. 2000 , 18, 66-70	38
2314	Does Alzheimer disease tilt the scales of amyloid degradation versus accumulation?. 2000 , 6, 133-4	34
2313	The potential of BACE inhibitors for Alzheimer's therapy. 2000 , 18, 125-6	19
2312	New familial forms of cerebral amyloid and dementia. 2000 , 5, 575-6	7
2311	Presenilin-1 mutations in Alzheimer's disease. 2000 , 405, 531-2	139
2310	A massive cool dust torus around eta Carinae?. 2000 , 405, 532	11
2309	Alzheimer's disease. Closing in on gamma-secretase. 2000 , 405, 627, 629	33
2308	Semiconductor physics. Half-matter, half-light amplifier. 2000 , 405, 629-30	33
2307	Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. 2000 , 2, 428-34	503

2306	Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. 2000 , 407, 48-54	829
2305	Apolipoprotein E receptors: linking brain development and Alzheimer's disease. 2000 , 1, 51-8	172
2304	Alzheimer's disease: model behaviour. 2000 , 408, 915-6	11
2303	The Big Bang is bang on. 2000 , 408, 916-7	1
2302	Neurodegeneration. Battling the killer proteins. 2000 , 408, 902-3	2
2301	Amyloid precursor protein β secretase (BACE) mRNA expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines and growth factors. 2000 , 20, 289-296	37
2300	Secretases as targets for the treatment of Alzheimer's disease. 2000 , 6, 392-7	35
2299	Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. 2000 , 35, 1317-25	106
2298	The processing and biological function of the human amyloid precursor protein (APP): lessons from different cellular models. 2000 , 35, 843-50	12
2297	Remarkable roles of proteolysis on and beyond the cell surface. 2000 , 12, 606-12	217
2296	Notch and presenilins in vertebrates and invertebrates: implications for neuronal development and degeneration. 2000 , 10, 50-7	62
2295	Neurons bearing presenilins: weapons for defense or suicide?. 2000 , 4, 249-261	16
2294	Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. 2000 , 88, 93-113	133
2293	Cloning, expression and functional characterization of rat napsin. 2000 , 1492, 207-10	7
2292	Alzheimer's disease: a dysfunction of the amyloid precursor protein(1). 2000 , 886, 54-66	121
2291	Platelets as a peripheral district where to study pathogenetic mechanisms of alzheimer disease: the case of amyloid precursor protein. 2000 , 405, 277-83	56
2290	Metabolism of amyloid precursor protein in COS cells transfected with a beta-secretase candidate. 2000 , 33, 213-9	
2289	A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration. 2000 , 19, 2786-92	190

2288	A yeast genetic assay for caspase cleavage of the amyloid-beta precursor protein. 2000 , 15, 29-37	7
2287	The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. 2000 , 21, 83-95	71
2286	Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease. 2000 , 22, 81-98	36
2285	Progress report on Alzheimer's disease: Taking the next steps. 2000 , 26, 38-125	1
2284	The cholinergic neuronal phenotype in Alzheimer's disease. 2000 , 15, 45-64	52
2283	Apoptosis and Alzheimer's disease. 2000 , 107, 1325-44	126
2282	Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. 2000 , 20, 8745-9	116
2281	Amyloid-beta and treatment opportunities for Alzheimer's disease. 2000 , 2, 231-59	5
2280	Presenilin 2 Mutation Does Not Influence Expression and Concentration of APP Forms in Human Platelets. 2000 , 6, 816-824	5
2279	. 2000 ,	
2278	Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. 2000 , 97, 1456-60	724
2277	Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties. 2000 , 275, 21099-106	173
2276	Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. 2000 , 275, 34086-91	265
2275	Presenilin 1 regulates pharmacologically distinct gamma -secretase activities. Implications for the role of presenilin in gamma -secretase cleavage. 2000 , 275, 26277-84	90
2274	Expression analysis of BACE2 in brain and peripheral tissues. 2000 , 275, 20647-51	224
2273	In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. 2000 , 97, 7609-14	188
2272	D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. 2000 , 97, 5440-4	377
2271	Cell-free assays for gamma-secretase activity. 2000 , 14, 2383-6	103

2270	The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture. 2000 , 54, 2045-54	126
2269	Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid beta-protein generation. 2000 , 97, 9299-304	134
2268	Inhibiting amyloid precursor protein C-terminal cleavage promotes an interaction with presenilin 1. 2000 , 275, 20794-8	31
2267	Molecules of the brain. 2000 , 35, 41-8, 51-4	3
2266	Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. 2000 , 217, 58-68	53
2265	[Diagnostic steps in Alzheimer dementia before treatment with new antidementives]. 2000 , 68, 257-61	1
2264	Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. 2000 , 54, 2212-7	145
2263	Fibrillar amyloid-beta production, accumulation, and recycling in transgenic mice pancreatic acinar cells and macrophages. 2000 , 7, 95-104	7
2262	A common enzyme connects notch signaling and Alzheimer's disease. 2000 , 14, 2799-806	181
2261	Amyloid beta peptide: a century of discoveries. 2000 , 7, 7-9	2
2260	Human bleomycin hydrolase regulates the secretion of amyloid precursor protein. 2000 , 14, 1837-47	32
2259	Fibrillar amyloid beta-protein mediates the pathologic accumulation of its secreted precursor in human cerebrovascular smooth muscle cells. 2000 , 275, 9782-91	42
2258	Autocatalytic proteolysis of the transcription factor-coactivator C1 (HCF): a potential role for proteolytic regulation of coactivator function. 2000 , 97, 9425-30	24
2257	Maturation and pro-peptide cleavage of beta-secretase. 2000 , 275, 30849-54	201
2256	Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. 2000 , 275, 33729-37	319
2255	The role of presenilin-1 in the gamma-secretase cleavage of the amyloid precursor protein of Alzheimer's disease. 2000 , 275, 1525-8	34
2254	Neuroscience in Public View. 2000 , 6, 67-68	
2253	In search of gamma-secretase: presenilin at the cutting edge. 2000 , 97, 5690-2	65

2252	The origins of Alzheimer disease: a is for amyloid. 2000 , 283, 1615-7	216
2251	BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. 2000 , 97, 9712-7	335
2250	A loss of function mutant of the presenilin homologue SEL-12 undergoes aberrant endoproteolysis in <i>Caenorhabditis elegans</i> and increases abeta 42 generation in human cells. 2000 , 275, 40925-32	34
2249	Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells. 2000 , 275, 36794-802	65
2248	Inhibitors of beta-amyloid formation based on the beta-secretase cleavage site. 2000 , 268, 133-5	38
2247	Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase. 2000 , 300, 241-8	48
2246	Review: model peptides and the physicochemical approach to beta-amyloids. 2000 , 130, 153-73	103
2245	ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. 2000 , 16, 609-19	141
2244	X11 alpha and x11 beta interact with presenilin-1 via their PDZ domains. 2000 , 16, 557-65	86
2243	Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. 2000 , 7, 321-31	847
2242	Binding partners of Alzheimer's disease proteins: are they physiologically relevant?. 2000 , 7, 135-51	55
2241	Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. 2000 , 7, 682-9	189
2240	Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. 2000 , 157, 277-86	603
2239	Molecular genetics of Alzheimer's disease. 2000 , 47, 183-99	249
2238	Beta-secretase revealed: starting gate for race to novel therapies for Alzheimer's disease. 2000 , 21, 161-3	28
2237	In search of an enzyme: the beta-secretase of Alzheimer's disease is an aspartic proteinase. 2000 , 23, 565-70	46
2236	Positive-negative epitope-tagging of beta amyloid precursor protein to identify inhibitors of A beta processing. 2000 , 84, 115-26	9
2235	Prometteuse enzyme□ 2000 , 2000, 11	

2234	Genetic polymorphisms in the cathepsin D and interleukin-6 genes and the risk of Alzheimer's disease. 2000 , 288, 21-4	105
2233	The genetic association between Cathepsin D and Alzheimer's disease. 2000 , 289, 61-5	39
2232	Expression of beta-secretase mRNA in transgenic Tg2576 mouse brain with Alzheimer plaque pathology. 2000 , 292, 107-10	52
2231	Genomic structure, expression pattern, and chromosomal localization of the human calsenilin gene: no association between an exonic polymorphism and Alzheimer's disease. 2000 , 294, 135-8	4
2230	Molecular misreading: a new type of transcript mutation expressed during aging. 2000 , 21, 879-91	58
2229	Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. 2000 , 27, 419-22	283
2228	Neuronal models to study amyloid precursor protein expression and processing in vitro. 2000 , 1502, 53-62	3
2227	Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. 2000 , 1502, 76-84	138
2226	Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. 2000 , 6, 625-36	350
2225	Part V. Genetic advances and biological markers for Alzheimer's disease. 2000 , 46, 731-43	0
2224	Part VI. Primary drug therapies for Alzheimer's disease. 2000 , 46, 745-60	1
2223	Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. 2000 , 100, 391-8	1188
2222	The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region. 2000 , 468, 59-64	105
2221	Regulation of APP cleavage by alpha-, beta- and gamma-secretases. 2000 , 483, 6-10	360
2220	Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. 2000 , 9, 2589-98	112
2219	Alzheimer's disease: transgenic mouse models and drug assessment. 2000 , 42, 107-14	6
2218	Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. <i>Science</i> , 2000 , 290, 150-3	33.3 668
2217	Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. 2000 , 39, 6951-9	252

2216	Protease inhibitors: current status and future prospects. 2000 , 43, 305-41	784
2215	Balance in Psychiatric Education. 2000 , 24, 164-167	2
2214	A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein beta-secretase. 2000 , 89, 177-84	71
2213	Design of Potent Inhibitors for Human Brain Memapsin 2 (-Secretase). 2000 , 122, 3522-3523	219
2212	Anti-Aging Medicine LiteratureWatch. 2000 , 3, 113-126	
2211	Proteolytic activation of recombinant pro-memapsin 2 (pro-beta-secretase) studied with new fluorogenic substrates. 2000 , 39, 12450-6	114
2210	Beta amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium: usage of a novel blood brain barrier endothelial cell model system. 2000 , 7, 153-65	30
2209	Regulation of amyloid precursor protein (APP) secretion by protein kinase calpha in human ntera 2 neurons (NT2N). 2000 , 39, 7428-35	28
2208	Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's gamma-secretase: implications for inhibitor design. 2000 , 43, 3434-42	64
2207	Fenchylamine sulfonamide inhibitors of amyloid beta peptide production by the gamma-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer's disease. 2000 , 43, 2297-9	61
2206	L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. 2000 , 39, 8698-704	351
2205	A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's beta -secretase. 2000 , 275, 37712-7	210
2204	Protein kinase C regulation of intracellular and cell surface amyloid precursor protein (APP) cleavage in CHO695 cells. 2000 , 39, 15282-90	29
2203	Treatment of Alzheimer's disease: rationale and strategies. 2000 , 18, 807-28	30
2202	The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. 2000 , 18, 903-22	122
2201	Goals for research on bipolar disorder: the view from NIMH. 2000 , 48, 436-41	22
2200	Neuropathologie de la maladie d'Alzheimer. 2000 , 11, 5-23	
2199	Presenilins as therapeutic targets for the treatment of Alzheimer's disease. 2001 , 7, 264-9	43

2198	Cholinesterase inhibitors for Alzheimer's disease. 2001 , 61, 41-52	172
2197	Alzheimer's disease and related disorders. 2001 , 85, 803-17	15
2196	Zinc enhances synthesis of presenilin 1 in mouse primary cortical culture. 2001 , 285, 680-8	20
2195	Protein kinase C epsilon suppresses Aβ production and promotes activation of alpha-secretase. 2001 , 285, 997-1006	73
2194	Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain. 2001 , 8, 173-80	69
2193	A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. 2001 , 8, 890-9	462
2192	Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. 2001 , 8, 1094-101	77
2191	beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. 2001 , 158, 173-7	55
2190	Accumulation of amyloid beta-protein in the low-density membrane domain accurately reflects the extent of beta-amyloid deposition in the brain. 2001 , 158, 2209-18	41
2189	beta-amyloid: friend or foe. 2001 , 56, 388-91	14
2188	Cysteine 73 in bleomycin hydrolase is critical for amyloid precursor protein processing. 2001 , 283, 994-9	14
2187	The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice. 2001 , 22, 49-61	129
2186	Inflammation, autotoxicity and Alzheimer disease. 2001 , 22, 799-809	413
2185	beta-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease. 2001 , 49, 72-85	39
2184	Sequence, genomic structure and tissue expression of Human BRI3, a member of the BRI gene family. 2001 , 266, 95-102	48
2183	Three novel alternatively spliced isoforms of the human beta-site amyloid precursor protein cleaving enzyme (BACE) and their effect on amyloid beta-peptide production. 2001 , 307, 9-12	55
2182	Amyloid beta secretase gene (BACE) is neither mutated in nor associated with early-onset Alzheimer's disease. 2001 , 313, 105-7	43
2181	The functional gamma-secretase inhibitor prevents production of amyloid beta 1-34 in human and murine cell lines. 2001 , 315, 145-8	39

2180	Human Nck-associated protein 1 and its binding protein affect the metabolism of beta-amyloid precursor protein with Swedish mutation. 2001 , 316, 50-4	8
2179	Viral-based gene transfer to the mammalian CNS for functional genomic studies. 2001 , 24, 706-12	47
2178	Expression of human brain carboxypeptidase B, a possible cleaving enzyme for beta-amyloid precursor protein, in peripheral fluids. 2001 , 39, 313-7	7
2177	Gene expression profile in Alzheimer's brain screened by molecular indexing. 2001 , 87, 1-11	11
2176	Subcellular localization of presenilin 2 endoproteolytic C-terminal fragments. 2001 , 96, 14-20	10
2175	beta-Secretase cleavage of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimer's disease mutations. 2001 , 97, 103-13	56
2174	Amyloid beta peptide levels and its effects on hippocampal acetylcholine release in aged, cognitively-impaired and -unimpaired rats. 2001 , 21, 323-9	45
2173	Anti-amyloidogenic activity of tetracyclines: studies in vitro. 2001 , 487, 404-7	175
2172	Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. 2001 , 358, 1962-4	40
2171	New approaches to diagnose and treat Alzheimer's disease: a glimpse of the future. 2001 , 17, 393-410	17
2170	Gene identification in Alzheimer's disease. 2001 , 2, 239-49	21
2169	Human beta-secretase and Alzheimer's disease. 2001 , 5, 341-348	8
2168	Antisense strategies for the treatment of neurological disease. 2001 , 11, 547-562	
2167	Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. 2001 , 40, 3553-60	100
2166	Aspartic protease inhibitors: expedient synthesis of 2-substituted statines. 2001 , 3, 2725-8	11
2165	Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. 2001 , 44, 1905-14	189
2164	Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides. 2001 , 40, 5049-55	85
2163	Secretase targets for Alzheimer's disease: identification and therapeutic potential. 2001 , 44, 2039-60	122

2162	Follow the protons: a low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases. 2001 , 34, 790-7	174
2161	Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). 2001 , 44, 2865-8	220
2160	BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. 2001 , 10, 1317-24	571
2159	Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. 2001 , 40, 10001-6	179
2158	. 2001 ,	3
2157	Where do Alzheimer s plaques and tangles come from aging-induced protein degradation inefficiency. 2001 , 6, e1-11	1
2156	Etiology, Genetics, and Pathogenesis of Alzheimer's Disease. 2001 , 333-348	
2155	Abetapp secretases are co-expressed with Abetapp in the pancreatic islets. 2001 , 3, 393-396	21
2154	The Natural History of Alzheimer's Disease: Minding the Gaps in Understanding the Mechanisms of Neurodegeneration. 2001 , 1-21	
2153	Inflammation and Wound Healing. 2001 , 33-100	4
2152	Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase. 2001 , 21, 4987-95	110
2151	Recent advances: Psychiatry. 2001 , 323, 1228-31	10
2150	Alzheimer's disease: genes, proteins, and therapy. 2001 , 81, 741-66	4885
2149	Molecular biology of Alzheimer's dementia and its clinical relevance to early diagnosis and new therapeutic strategies. 2001 , 47, 65-71	16
2148	Down syndrome: advances in molecular biology and the neurosciences. 2001 , 22, 40-59	81
2147	Therapeutic targets in the biology of Alzheimer's disease. 2001 , 14, 341-348	11
2146	Association studies using novel polymorphisms in BACE1 and BACE2. 2001 , 12, 1799-802	40
2145	The BACE gene: genomic structure and candidate gene study in late-onset Alzheimer's disease. 2001 , 12, 631-4	51

2144	Mild Cognitive Impairment: Transition from Aging to Alzheimer's Disease. 141-151	8
2143	Characterization of Alzheimer's β Secretase Protein BACE: Processing and Other Post-translational Modifications. 739-745	
2142	Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. 2001 , 353, 663-72	40
2141	Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. 2001 , 353, 663-672	53
2140	Distribution of a Human Brain Carboxypeptidase B Capable of Cleaving β -Amyloid Precursor Protein (APP) in Normal and Alzheimer's Diseased Brain.. 2001 , 34, 275-283	
2139	Cellular distribution of napsin (kidney-derived aspartic protease-like protein, KAP) mRNA in the kidney, lung and lymphatic organs of adult and developing mice. 2001 , 64, 319-27	25
2138	Toward the Identification of β Secretase: Using Transition State Analog Inhibitors. 777-788	
2137	Alzheimer disease therapeutics. 2001 , 60, 923-8	33
2136	Mechanisms of A β Production and A β Degradation: Routes to the Treatment of Alzheimer's Disease. 421-432	1
2135	Amyloid Abeta levels in Alzheimer's disease - A diagnostic tool and the key to understanding the natural history of Abeta?. 2001 , 3, 305-312	12
2134	Functional Analysis of β Secretase Using Mutagenesis and Structural Homology Modeling. 799-807	
2133	Accelerated A β Generation in a Cell Model of Alzheimer's Disease-related Endosomal/Lysosomal System Upregulation. 461-467	
2132	Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. 2001 , 21, 5703-14	174
2131	Alzheimer's disease: molecular concepts and therapeutic targets. 2001 , 88, 261-7	42
2130	Amyloid metabolism and secretases in Alzheimer's disease. 2001 , 1, 422-7	19
2129	Pharmacotherapy for Alzheimer's disease. 2001 , 1, 428-34	19
2128	New developments in animal models of Alzheimer's disease. 2001 , 1, 451-7	33
2127	Neuroimaging in Alzheimer's disease: relevance for treatment. 2001 , 3, 13-9	6

2126	Mutations in the open reading frame of the beta-site APP cleaving enzyme (BACE) locus are not a common cause of Alzheimer's disease. 2001 , 3, 203-6	31
2125	Neurotoxic Aβ peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. 2001 , 76, 1050-6	165
2124	β-Amyloid efflux mediated by p-glycoprotein. 2001 , 76, 1121-8	289
2123	The multiple paradoxes of presenilins. 2001 , 76, 1621-7	36
2122	The role of presenilins in gamma-secretase activity: catalyst or cofactor?. 2001 , 76, 1612-4	7
2121	Nicastrin, a key regulator of presenilin function, is expressed constitutively in human neural cell lines. 2001 , 21, 115-22	7
2120	Neurotoxic traffic: uncovering the mechanics of amyloid production in Alzheimer's disease. 2001 , 2, 75-81	19
2119	Endosomal sorting of amyloid precursor protein-P-selectin chimeras influences secretase processing. 2001 , 2, 908-16	24
2118	The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase. 2001 , 268, 5329-36	97
2117	Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons. 2001 , 13, 1653-7	12
2116	The amyloid-beta peptide and its role in Alzheimer's disease. 2001 , 7, 227-49	83
2115	Neuronal and glial beta-secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology. 2001 , 64, 437-46	88
2114	Calcium ionophore A23187 specifically decreases the secretion of beta-secretase cleaved amyloid precursor protein during apoptosis in primary rat cortical cultures. 2001 , 63, 429-37	20
2113	Neuronal localization of the TNFα converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques. 2001 , 49, 40-6	72
2112	Presenilin mutations and calcium signaling defects in the nervous and immune systems. 2001 , 23, 733-44	59
2111	Molecular cloning and characterization of cDNA encoding cardosin B, an aspartic proteinase accumulating extracellularly in the transmitting tissue of <i>Cynara cardunculus</i> L. 2001 , 45, 529-39	55
2110	New applications of alphavirus-based expression vectors. 2001 , 35, 203-12	1
2109	Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. 2001 , 17, 101-18	359

2108	The beta-secretase, BACE: a prime drug target for Alzheimer's disease. 2001 , 17, 157-70	137
2107	Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics. 2001 , 17, 233-57	11
2106	Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization. 2001 , 17, 259-67	32
2105	Novel functional assay for proteases and modulators. Application in beta-secretase studies. 2001 , 18, 1-10	10
2104	Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. 2001 , 85, 1372-82	120
2103	Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease. 2001 , 8, 1161-6	68
2102	Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. 2001 , 414, 643-8	507
2101	Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. 2001 , 4, 231-2	902
2100	BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. 2001 , 4, 233-4	935
2099	Presenilins and the intramembrane proteolysis of proteins: facts and fiction. 2001 , 3, E221-5	45
2098	Magnetic minerals. Keystone-like crystals in cells of hornet combs. 2001 , 411, 654	15
2097	Alzheimer's disease. Molecular consequences of presenilin-1 mutation. 2001 , 411, 654-6	11
2096	Molecular consequences of presenilin-1 mutation. 2001 , 411, 655-655	1
2095	Nanoindentation. Simulation of defect nucleation in a crystal. 2001 , 411, 656	213
2094	Metalloproteinases in biology and pathology of the nervous system. 2001 , 2, 502-11	845
2093	Increased neuronal and glial expression of protein kinase C isoforms in neocortex of transgenic Tg2576 mice with amyloid pathology. 2001 , 13, 269-278	
2092	Drug discovery of the future: the implications of the human genome project. 2001 , 19, 496-9	35
2091	Genetic risk factors in familial Alzheimer's disease. 2001 , 122, 1951-60	22

2090	Platelet amyloid precursor protein forms in AD: a peripheral diagnostic tool and a pharmacological target. 2001 , 122, 1997-2004	18
2089	Acidic pH promotes the formation of toxic fibrils from beta-amyloid peptide. 2001 , 893, 287-91	91
2088	Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. 2001 , 919, 115-21	179
2087	Transcranial magnetic stimulation as a therapeutic tool in psychiatry: what do we know about the neurobiological mechanisms?. 2001 , 35, 193-215	171
2086	Emerging antisense technologies for gene functionalization and drug discovery. 2001 , 6, 97-101	6
2085	TACE and other ADAM proteases as targets for drug discovery. 2001 , 6, 417-426	150
2084	Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease. 2001 , 6, 1207-1219	25
2083	The cell biology of Alzheimer's disease: uncovering the secrets of secretases. 2001 , 11, 585-90	154
2082	Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. 2001 , 17, 532-7	253
2081	Presenilins, Amyloid precursor protein and the molecular basis of Alzheimer's disease. 2001 , 1, 91-103	19
2080	Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease. 2001 , 1, 194-206	18
2079	A fluid connection: cholesterol and Abeta. 2001 , 98, 5371-3	175
2078	Subcellular compartment and molecular subdomain of beta-amyloid precursor protein relevant to the Abeta 42-promoting effects of Alzheimer mutant presenilin 2. 2001 , 276, 21678-85	47
2077	A splice variant of beta-secretase deficient in the amyloidogenic processing of the amyloid precursor protein. 2001 , 276, 12019-23	60
2076	Mechanism of Inhibition of beta-site amyloid precursor protein-cleaving enzyme (BACE) by a statine-based peptide. 2001 , 276, 23790-4	33
2075	BACE2 functions as an alternative alpha-secretase in cells. 2001 , 276, 34019-27	129
2074	A portrait of Alzheimer secretases--new features and familiar faces. <i>Science</i> , 2001 , 293, 1449-54	33:3 439
2073	The functions of the amyloid precursor protein gene. 2001 , 12, 1-39	28

2072	Alzheimer's Disease: Physiological and Pathogenetic Role of the Amyloid Precursor Protein (APP), its A β Amyloid Domain and Free A β Amyloid Peptide. 2001 , 97-117	3
2071	Secretases as therapeutic targets for the treatment of Alzheimer's disease. 2001 , 8, 124-42	25
2070	Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. 2001 , 98, 13554-9	223
2069	Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. 2001 , 98, 7605-10	178
2068	Processing of the insulin-like growth factor-II?mannose 6-phosphate receptor in isolated liver subcellular fractions. 2001 , 79, 469-477	3
2067	Statine-derived tetrapeptide inhibitors of Bsecretase. 2001 , 11, 1047-1050	2
2066	PS1 N- and C-terminal fragments form a complex that functions in APP processing and Notch signaling. 2001 , 98, 12186-90	75
2065	Retention of the Alzheimer's amyloid precursor fragment C99 in the endoplasmic reticulum prevents formation of amyloid beta-peptide. 2001 , 276, 20267-79	46
2064	The Role of presenilins in gamma-secretase activity. 2001 , 276, 5413-6	108
2063	Abeta immunization: moving Abeta peptide from brain to blood. 2001 , 98, 8931-2	21
2062	Convertases other than furin cleave beta-secretase to its mature form. 2001 , 15, 1810-2	30
2061	Conservation of the biochemical mechanisms of signal transduction among mammalian Notch family members. 2001 , 98, 9026-31	106
2060	FLASH coordinates NF-kappa B activity via TRAF2. 2001 , 276, 25073-7	39
2059	Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. 2001 , 98, 3334-9	392
2058	Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. 2001 , 98, 11039-41	179
2057	Characterization of the glycosylation profiles of Alzheimer's beta -secretase protein Asp-2 expressed in a variety of cell lines. 2001 , 276, 16739-48	67
2056	Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. 2001 , 276, 12991-8	201
2055	Pharmacological knock-down of the presenilin 1 heterodimer by a novel gamma -secretase inhibitor: implications for presenilin biology. 2001 , 276, 45394-402	67

2054	The protease inhibitor, MG132, blocks maturation of the amyloid precursor protein Swedish mutant preventing cleavage by beta-Secretase. 2001 , 276, 4476-84	55
2053	Prodomain processing of Asp1 (BACE2) is autocatalytic. 2001 , 276, 23322-8	33
2052	Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. 2001 , 276, 42645-57	103
2051	Multiple effects of aspartate mutant presenilin 1 on the processing and trafficking of amyloid precursor protein. 2001 , 276, 43343-50	78
2050	The beta-amyloid precursor protein functions as a cytosolic anchoring site that prevents Fe65 nuclear translocation. 2001 , 276, 6545-50	108
2049	Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment. 2001 , 58, 442-6	58
2048	Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. 2001 , 10, 1665-71	145
2047	Molecules involved in reactive sprouting in the hippocampus. 2001 , 12, 195-215	33
2046	The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. 2001 , 276, 10366-73	102
2045	Amyloid-beta induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain. 2001 , 276, 23645-52	114
2044	The Aetiology of Alzheimer's Disease: Diverse Routes into a Common Tau Pathway. 2001 , 97-132	1
2043	Phosphorylation regulates intracellular trafficking of beta-secretase. 2001 , 276, 14634-41	219
2042	The potency and specificity of the interaction between the IA3 inhibitor and its target aspartic proteinase from <i>Saccharomyces cerevisiae</i> . 2001 , 276, 2023-30	30
2041	Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. 2001 , 276, 10879-87	241
2040	A novel gamma -secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor. 2001 , 276, 481-7	124
2039	The transmembrane domain of the Alzheimer's beta-secretase (BACE1) determines its late Golgi localization and access to beta -amyloid precursor protein (APP) substrate. 2001 , 276, 36788-96	146
2038	Processing of beta-secretase by furin and other members of the proprotein convertase family. 2001 , 276, 4211-7	150
2037	Pro-apoptotic function of calsenilin/DREAM/KCHIP3. 2001 , 15, 589-91	66

2036	Beta-amyloid therapies in Alzheimer's disease. 2001 , 10, 593-605	21
2035	Rapid genetic selection of inhibitor-resistant protease mutants: clinically relevant and novel mutants of the HIV protease. 2001 , 17, 1249-55	5
2034	New concepts in the drug therapy of Alzheimer's disease. 2001 , 2, 1975-83	4
2033	The discrepancy between presenilin subcellular localization and gamma-secretase processing of amyloid precursor protein. 2001 , 154, 731-40	143
2032	Intracellular amyloid-beta 1-42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis. 2002 , 277, 15666-70	140
2031	A new functional screening system for identification of regulators for the generation of amyloid beta-protein. 2002 , 277, 39627-33	17
2030	Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. 2002 , 277, 4687-93	196
2029	Pharmacotherapy of agitation and psychotic symptoms in Alzheimer's disease. 2002 , 2, 655-64	1
2028	Apical sorting of beta-secretase limits amyloid beta-peptide production. 2002 , 277, 5637-43	54
2027	Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. 2002 , 277, 16278-84	134
2026	Differential roles of JIP scaffold proteins in the modulation of amyloid precursor protein metabolism. 2002 , 277, 27567-74	63
2025	Localization of a fibrillar amyloid beta-protein binding domain on its precursor. 2002 , 277, 36392-8	41
2024	Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP). 2002 , 277, 3767-75	130
2023	The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. 2002 , 11, 2615-24	525
2022	Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo. 2002 , 277, 35460-5	56
2021	Protein aggregates and dementia: is there a common toxicity?. 2002 , 72, 152-61	47
2020	Alzheimer's disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases Abeta secretion: role for altered lysosomal hydrolase distribution in beta-amyloidogenesis. 2002 , 277, 5299-307	79
2019	Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. 2002 , 277, 31499-505	118

2018	Soluble metalloendopeptidases and neuroendocrine signaling. 2002 , 23, 647-64	76
2017	Papain-like Cysteine Proteases and Their Implications in Neurodegenerative Diseases. 2002 , 47-61	3
2016	Evidence for D-aspartyl-beta-amyloid secretase activity in human brain. 2002 , 61, 125-31	10
2015	Chemotherapeutic agents against malaria: what next after chloroquine?. 2002 , 2, 1173-85	26
2014	Beta-secretase as a therapeutic target for inhibitor drugs. 2002 , 9, 1135-44	70
2013	The search for gamma-secretase and development of inhibitors. 2002 , 9, 1087-106	41
2012	Sequential assistance of molecular chaperones and transient formation of covalent complexes during protein degradation from the ER. 2002 , 158, 247-57	186
2011	Mapping the Progress of Alzheimer's and Parkinson's Disease. 2002 ,	2
2010	Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of calpains enhances endosomal generation of beta-cleaved C-terminal APP fragments. 2002 , 277, 36415-24	91
2009	Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. 2002 , 90, 1197-204	115
2008	Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease?. 2002 , 293-301	24
2007	Gonadal Steroids, Learning, and Memory. 2002 , 265-327	29
2006	Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. 2002 , 59, 1381-9	588
2005	Mouse models of Alzheimer's disease: a quest for plaques and tangles. 2002 , 43, 89-99	41
2004	Immunohistochemical localization of napsin and its potential role in protein catabolism in renal proximal tubules. 2002 , 65, 359-68	30
2003	Contributions of mitochondrial alterations, resulting from bad genes and a hostile environment, to the pathogenesis of Alzheimer's disease. 2002 , 53, 387-409	27
2002	Genetically engineered models of neurodegenerative diseases. 2002 , 1841-1862	1
2001	Amyloid (Tace, Bace) and Presenilin Proteases Associated with Alzheimer's Disease. 2002 , 155-178	

2000	Levels of beta-secretase BACE and alpha-secretase ADAM10 mRNAs in Alzheimer hippocampus. 2002 , 13, 2031-3	58
1999	Peripheral blood abnormalities in Alzheimer disease: evidence for early endothelial dysfunction. 2002 , 16, 150-5	24
1998	BetaAPP and furin mRNA concentrates in immature senile plaques in the brain of Alzheimer patients. 2002 , 61, 815-29	29
1997	Mutational analysis of residues in two consensus motifs in the active sites of cathepsin E. 2002 , 132, 493-9	11
1996	Gamma-secretase inhibition. 2002 , 30, 534-7	10
1995	Lysosomal Cysteine Proteases and Their Protein Inhibitor. 2002 , 227-240	
1994	Proteolysis of Mutant Gene Products are Key Mechanisms in Neurodegenerative Diseases. 2002 , 269-282	
1993	The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. 2002 , 277, 28530-6	109
1992	The Prohormone Convertases and Precursor Processing in Protein Biosynthesis. 2002 , 22, 163-198	2
1991	Cellular Limited Proteolysis of Precursor Proteins and Peptides. 2002 , 22, 237-258	4
1990	The Neuropathology of Alzheimer's Disease. 223-226	
1989	Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. 2002 , 41, 3128-36	98
1988	Expedient solid-phase synthesis of fluorogenic protease substrates using the 7-amino-4-carbamoylmethylcoumarin (ACC) fluorophore. 2002 , 67, 910-5	125
1987	A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. 2002 , 41, 2825-35	318
1986	Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3. 2002 , 41, 10963-7	184
1985	A cell biological perspective on Alzheimer's disease. 2002 , 18, 25-51	185
1984	Localization of beta-secretase memapsin 2 in the brain of Alzheimer's patients and normal aged controls. 2002 , 175, 10-22	36
1983	The carboxyl-terminus of BACE contains a sorting signal that regulates BACE trafficking but not the formation of total A(beta). 2002 , 19, 175-85	95

1982	Insights into Abeta and presenilin from a canine model of human brain aging. 2002 , 9, 1-10	32
1981	Oxidative stress increases expression and activity of BACE in NT2 neurons. 2002 , 10, 279-88	322
1980	Prediction of the tertiary structure of the beta-secretase zymogen. 2002 , 292, 702-8	91
1979	Protein ectodomain shedding. 2002 , 102, 4627-38	209
1978	Design of substrate-based inhibitors of human beta-secretase. 2002 , 45, 259-62	102
1977	Caspase-3-mediated cleavage of amyloid precursor protein and formation of amyloid Beta peptide in traumatic axonal injury. 2002 , 19, 601-14	80
1976	Structure and mechanism of the pepsin-like family of aspartic peptidases. 2002 , 102, 4431-58	286
1975	Specificity of memapsin 1 and its implications on the design of memapsin 2 (beta-secretase) inhibitor selectivity. 2002 , 41, 8742-6	53
1974	The role of beta-amyloid in Alzheimer's disease. 2002 , 86, 629-39	5
1973	Disordered proteins in dementia. 2002 , 34, 259-71	17
1972	Pharmacogenomics for the treatment of dementia. 2002 , 34, 357-79	39
1971	The peptidase zymogen proregions: nature's way of preventing undesired activation and proteolysis. 2002 , 8, 511-31	47
1970	Splice variants of the beta-site APP-cleaving enzyme BACE1 in human brain and pancreas. 2002 , 293, 30-7	50
1969	BACE1 interacts with nicastrin. 2002 , 293, 1228-32	29
1968	alpha- and beta-secretase: profound changes in Alzheimer's disease. 2002 , 299, 373-6	159
1967	Memapsin 2 (beta-secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2. 2002 , 524, 183-7	101
1966	Solution studies and structural model of the extracellular domain of the human amyloid precursor protein. 2002 , 83, 3513-24	24
1965	Recombinant insect cell expression and purification of human beta-secretase (BACE-1) for X-ray crystallography. 2002 , 26, 139-48	21

1964	FAD-linked mutations in presenilin 1 alter the length of Abeta peptides derived from betaAPP transmembrane domain mutants. 2002 , 1586, 199-209	11
1963	Alzheimer's disease and the amyloid cascade hypothesis: ten years on. 2002 , 2, 87-92	82
1962	Correlation between beta-amyloid peptide production and human APP-induced neuronal death. 2002 , 23, 1199-204	14
1961	Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. 2002 , 23, 1205-14	64
1960	Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides. 2002 , 23, 1285-97	132
1959	Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. 2002 , 23, 1343-50	117
1958	Is gamma-secretase a multienzyme complex for membrane protein degradation? Models and speculations. 2002 , 23, 1317-21	13
1957	Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. 2002 , 23, 1051-72	115
1956	Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. 2002 , 23, 957-76	112
1955	Amyloid binding ligands as Alzheimer's disease therapies. 2002 , 23, 1039-42	72
1954	Emerging Alzheimer's disease therapies: inhibition of beta-secretase. 2002 , 23, 1017-22	49
1953	gamma-Secretase: characterization and implication for Alzheimer disease therapy. 2002 , 23, 1023-30	31
1952	Chronic gliosis triggers Alzheimer's disease-like processing of amyloid precursor protein. 2002 , 113, 785-96	46
1951	Dementia epidemiology. 2002 , 86, 573-90	63
1950	Biological Research on Dementias. 287-322	
1949	. 2002 ,	6
1948	Pharmacological Treatment of Dementia: A Review. 2002 , 199-271	3
1947	Alzheimer's disease: targets for drug development. 2002 , 2, 1-9	8

1946 Metalloendopeptidase EC 3.4.24.15 in Neurodegeneration. **2002**, 101-116

1945 Pharmacogenomics in Alzheimer's disease. **2002**, 2, 59-84

28

1944 The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. **2002**, 22, 1858-67

600

1943 Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer b-amyloid peptide in vitro and in patients. **2002**, 7, a50

34

1942 Des protéines et des mutations : une nouvelle vision (moléculaire) des maladies neuro-dégénératives. **2002**, 196, 85-94

6

1941 Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer's disease. **2002**, 74, 265-84

19

1940 Searching for an in vivo site for nascent amyloid fibril formation. **2002**, 4, 105-14

6

1939 Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. **2002**, 7, a50-9

29

1938 Implications of amyloid precursor protein and subsequent beta-amyloid production to the pharmacotherapy of Alzheimer's disease. **2002**, 22, 1547-63

8

1937 Amyloid fibril proteins. **2002**, 123, 1625-36

54

1936 Beta-secretase (BACE) as a drug target for Alzheimer's disease. **2002**, 54, 1589-602

179

1935 Modulation of Ca²⁺ channel currents in primary cultures of rat cortical neurones by amyloid beta protein (1-40) is dependent on solubility status. **2002**, 956, 254-61

65

1934 Secretases as targets for the treatment of Alzheimer's disease: the prospects. **2002**, 1, 409-16

88

1933 Platelet-activating factor acetylhydrolase activity in cerebrospinal fluid of children with acute systemic or neurological illness. **2002**, 51, 760-3

6

1932 Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. **2002**, 51, 767-71

33

1931 Activity of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: correlations with gadolinium-enhancing lesions and ventricular volume. **2002**, 51, 763-7

42

1930 Mitochondrial DNA nucleotide changes C14482G and C14482A in the ND6 gene are pathogenic for Leber's hereditary optic neuropathy. **2002**, 51, 774-8

46

1929 Human herpesvirus 6 encephalitis associated with hypersensitivity syndrome. **2002**, 51, 771-4

73

1928	Brain proteasomal function in sporadic Parkinson's disease and related disorders. 2002 , 51, 779-82	74
1927	Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. 2002 , 51, 783-6	494
1926	High headache prevalence among women with hemochromatosis: the Nord-Trøndelag health study. 2002 , 51, 786-9	16
1925	Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy. 2002 , 51, 790-3	41
1924	Alzheimer's disease: beta-Amyloid protein and tau. 2002 , 70, 392-401	80
1923	Beta-secretase as a target for the treatment of Alzheimer's disease. 2002 , 70, 373-9	62
1922	Pharmacogenomic approaches in Alzheimer's disease drug development. 2002 , 56, 67-73	10
1921	Therapeutic strategies of Alzheimer's disease through manipulation of A β metabolism: a focus on A β -degrading peptidase, neprilysin. 2002 , 56, 171-183	4
1920	Beta-sheet breaker strategy for the treatment of Alzheimer's disease. 2002 , 56, 184-193	36
1919	Secretases as targets for beta-amyloid lowering drugs. 2002 , 56, 201-210	7
1918	Targeting APP metabolism for the treatment of Alzheimer's disease. 2002 , 56, 211-227	13
1917	Role of amyloid β -peptides in the regulation of central cholinergic function and its relevance to Alzheimer's disease pathology. 2002 , 56, 248-263	8
1916	Current drug targets for Alzheimer's disease treatment. 2002 , 56, 267-281	146
1915	Cholinergic abnormalities in Alzheimer's disease: are there new targets for drug development?. 2002 , 56, 369-379	2
1914	Lipid rafts play an important role in A β biogenesis by regulating the beta-secretase pathway. 2002 , 19, 31-5	73
1913	Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. 2002 , 2, 457-64	44
1912	Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. 2002 , 32, 59-62	102
1911	The beta-amyloid precursor protein (APP) and Alzheimer's disease: does the tail wag the dog?. 2002 , 3, 763-70	60

1910	ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways. 2002 , 80, 1019-28	25
1909	Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. 2002 , 80, 799-806	108
1908	The disulphide bonds in the catalytic domain of BACE are critical but not essential for amyloid precursor protein processing activity. 2002 , 80, 1079-88	26
1907	A series of C-terminal amino alcohol dipeptide A beta inhibitors. 2002 , 12, 3051-3	15
1906	Potential novel targets for Alzheimer pharmacotherapy: I. Secretases. 2002 , 27, 169-83	23
1905	Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. 2000 , 75, 2133-43	143
1904	Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles. 2002 , 81, 237-56	48
1903	Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. 2002 , 81, 481-96	199
1902	Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?. 2002 , 81, 1-8	199
1901	A non-amyloidogenic function of BACE-2 in the secretory pathway. 2002 , 81, 1011-20	90
1900	Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. 2002 , 82, 563-75	64
1899	Failure of the interaction between presenilin 1 and the substrate of gamma-secretase to produce Abeta in insect cells. 2002 , 83, 390-9	7
1898	Secretases as targets for drug design in Alzheimer's disease. 2002 , 32, 60-8	11
1897	Pro-domain removal in ASP-2 and the cleavage of the amyloid precursor are influenced by pH. 2002 , 3, 25	19
1896	The amyloid precursor protein interacts with neutral lipids. 2002 , 269, 2238-46	15
1895	Toxicity of substrate-bound amyloid peptides on vascular smooth muscle cells is enhanced by homocysteine. 2002 , 269, 3014-22	30
1894	The three typical aspartic proteinase genes of Arabidopsis thaliana are differentially expressed. 2002 , 269, 4675-84	32
1893	Enzymic properties of recombinant BACE2. 2002 , 269, 5668-77	11

1892	A novel application of a [3+2] cycloaddition reaction for the synthesis of the piperazinone rings of pseudotheonamides A 1 and A 2. 2002 , 43, 1897-1900	16
1891	Genetically engineered mouse models of neurodegenerative diseases. 2002 , 5, 633-9	190
1890	Alzheimer's disease: treatments in discovery and development. 2002 , 5 Suppl, 1055-7	130
1889	Therapeutic strategies for human amyloid diseases. 2002 , 1, 267-75	205
1888	Therapeutic strategies for Alzheimer's disease. 2002 , 1, 859-66	144
1887	Serpinopathies and the conformational dementias. 2002 , 3, 759-68	188
1886	gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?. 2002 , 3, 281-90	461
1885	Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. 2002 , 3, 862-72	778
1884	Signal transduction through tyrosine-phosphorylated carboxy-terminal fragments of APP via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain. 2002 , 973, 323-33	31
1883	The contingency of contingent valuation. How much are people willing to pay against Alzheimer's disease?. 2002 , 2, 219-40	26
1882	Expression of beta-Secretase mRNA in the brain of rats with immunohistochemical destruction of basal forebrain cholinergic system. 2002 , 134, 236-40	
1881	Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei. 2002 , 22, 699-709	27
1880	Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. 2002 , 22, 545-63	60
1879	Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer's disease. 2002 , 8, 539-50	114
1878	The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. 2002 , 21, 5691-700	149
1877	Gamma-secretase: substrates and inhibitors. 2002 , 26, 81-95	19
1876	Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. 2002 , 1, 1-31	147
1875	The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. 2002 , 2, 1-10	63

1874	Peptide nucleic acids targeted to the amyloid precursor protein. 2003 , 20, 261-5	4
1873	What can rodent models tell us about cognitive decline in Alzheimer's disease?. 2003 , 27, 249-76	21
1872	Protein accumulation in traumatic brain injury. 2003 , 4, 59-72	107
1871	Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Lewy bodies. 2003 , 28, 1743-56	63
1870	Alzheimer's beta-secretase cleaves a glycosyltransferase as a physiological substrate. 2004 , 20, 59-62	11
1869	Guinea pigs as a nontransgenic model for APP processing in vitro and in vivo. 2003 , 28, 637-44	36
1868	Electrophoretic mobility of Alzheimer's amyloid-beta peptides in urea-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 2003 , 323, 103-13	24
1867	KMI-008, a novel beta-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides. 2003 , 13, 4273-6	80
1866	Association study between Alzheimer's disease and genes involved in Aβ biosynthesis, aggregation and degradation: suggestive results with BACE1. 2003 , 250, 956-61	38
1865	RIPped out by presenilin-dependent gamma-secretase. 2003 , 15, 829-41	53
1864	Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. 2003 , 13, 71-8	187
1863	The pharmacology of amyloid precursor protein processing. 2003 , 38, 145-57	42
1862	The association of beta-site APP cleaving enzyme (BACE) C786G polymorphism with Alzheimer's disease. 2003 , 961, 88-91	12
1861	Smooth muscle cells and the pathogenesis of cerebral microvascular disease ("angiomyopathies"). 2003 , 74, 148-59	13
1860	Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. 2003 , 41, 169-79	128
1859	Cloning and expression of the rat BACE1 promoter. 2003 , 73, 73-80	44
1858	Proteasome-mediated degradation of the C-terminus of the Alzheimer's disease beta-amyloid protein precursor: effect of C-terminal truncation on production of beta-amyloid protein. 2003 , 74, 378-85	51
1857	Identity and function of gamma-secretase. 2003 , 74, 353-60	84

1856	Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. 2003 , 74, 386-92	119
1855	Distinct presenilin-dependent and presenilin-independent gamma-secretases are responsible for total cellular Abeta production. 2003 , 74, 361-9	39
1854	Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway. 2003 , 74, 393-405	35
1853	Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease. 2003 , 23, 48-88	71
1852	Specific BACE1 genotypes provide additional risk for late-onset Alzheimer disease in APOE epsilon 4 carriers. 2003 , 119B, 44-7	33
1851	Influence of prednisolone on β secretase enzyme activity in vitro. 2003 , 32, 83-87	
1850	Alzheimer vaccine: amyloid-beta on trial. 2003 , 25, 283-8	22
1849	Cell-based assay for beta-secretase activity. 2003 , 323, 7-11	16
1848	Green tea catechins as a BACE1 (beta-secretase) inhibitor. 2003 , 13, 3905-8	139
1847	Design and synthesis of statine-containing BACE inhibitors. 2003 , 13, 4335-9	38
1846	Measuring human beta-secretase (BACE1) activity using homogeneous time-resolved fluorescence. 2003 , 319, 49-55	48
1845	Molecular pathomechanisms of Alzheimer's disease. 2003 , 666-667, 507-513	3
1844	Treatment of mild cognitive impairment: rationale, present and future strategies. 2003 , 179, 83-93	14
1843	Efficient inhibition of beta-secretase gene expression in HEK293 cells by tRNAVal-driven and CTE-helicase associated hammerhead ribozymes. 2003 , 270, 3962-70	8
1842	Employing a superior BACE1 cleavage sequence to probe cellular APP processing. 2003 , 84, 1006-17	41
1841	Caenorhabditis elegans early embryogenesis and vulval morphogenesis require chondroitin biosynthesis. 2003 , 423, 439-43	177
1840	GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. 2003 , 423, 435-9	993
1839	Role of protein kinase Calpha in the regulated secretion of the amyloid precursor protein. 2003 , 8, 209-16	37

1838	Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. 2003 , 9, 3-4	606
1837	Mild cognitive impairment clinical trials. 2003 , 2, 646-53	119
1836	Comparison of batch and perfusion culture in combination with pilot-scale expanded bed purification for the production of soluble recombinant beta-secretase. 2003 , 19, 37-44	16
1835	Alzheimer's disease: Mechanisms and development of therapeutic strategies. 2003 , 3, 175-188	
1834	Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. 2003 , 125, 16416-22	86
1833	Aspartic peptidase inhibitors: implications in drug development. 2003 , 38, 89-119	81
1832	Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets. 2003 , 16, 93-7	12
1831	Gamma-secretase activity is present in rafts but is not cholesterol-dependent. 2003 , 42, 13977-86	71
1830	Distinct mechanisms by mutant presenilin 1 and 2 leading to increased intracellular levels of amyloid beta-protein 42 in Chinese hamster ovary cells. 2003 , 42, 1042-52	37
1829	In vitro characterization of the presenilin-dependent gamma-secretase complex using a novel affinity ligand. 2003 , 42, 8133-42	75
1828	Biochemical and structural characterization of the interaction of memapsin 2 (beta-secretase) cytosolic domain with the VHS domain of GGA proteins. 2003 , 42, 12174-80	74
1827	gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins. 2003 , 42, 6664-73	91
1826	Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase. 2003 , 46, 1799-802	81
1825	Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. 2003 , 43, 545-84	717
1824	The beta-amyloid-related proteins presenilin 1 and BACE1 are axonally transported to nerve terminals in the brain. 2003 , 184, 1053-7	44
1823	BACE1 and BACE2 in pathologic and normal human muscle. 2003 , 179, 150-8	35
1822	BACE-2 is overexpressed in Down's syndrome. 2003 , 182, 335-45	38
1821	The ubiquitin-like domain of Herp is involved in Herp degradation, but not necessary for its enhancement of amyloid beta-protein generation. 2003 , 553, 151-6	34

1820	Comparative studies of active site-ligand interactions among various recombinant constructs of human beta-amyloid precursor protein cleaving enzyme. 2003 , 410, 307-16	18
1819	Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. 2003 , 301, 231-5	245
1818	Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. 2003 , 307, 922-7	69
1817	Glycobiology in the field of aging research--introduction to glycoogerontology. 2003 , 85, 13-24	16
1816	Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. 2003 , 70, 1-32	545
1815	Association analysis between anterior-pharynx defective-1 genes polymorphisms and Alzheimer's disease. 2003 , 350, 77-80	13
1814	Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. 2003 , 24, 637-43	114
1813	High cholesterol affects platelet APP processing in controls and in AD patients. 2003 , 24, 631-6	20
1812	Quantification and distribution of beta-secretase alternative splice variants in the rat and human brain. 2003 , 115, 63-8	36
1811	Beta-secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease. 2003 , 116, 155-8	51
1810	Three CCAAT-boxes and a single cell cycle genes homology region (CHR) are the major regulating sites for transcription from the human cyclin B2 promoter. 2003 , 312, 225-37	48
1809	Human beta-secretase activity in yeast detected by a novel cellular growth selection system. 2003 , 1620, 167-78	19
1808	Identification of neuronal plasma membrane microdomains that colocalize beta-amyloid and presenilin: implications for beta-amyloid precursor protein processing. 2003 , 120, 291-300	23
1807	Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's disease. 2003 , 122, 213-28	76
1806	Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. 2003 , 43, 1-16	233
1805	BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. 2003 , 24, 646-55	134
1804	Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. 2003 , 35, 1505-35	152
1803	Neuronal and microglial cathepsins in aging and age-related diseases. 2003 , 2, 367-81	105

1802	No alterations of hippocampal neuronal number and synaptic bouton number in a transgenic mouse model expressing the beta-cleaved C-terminal APP fragment. 2003 , 12, 110-20	37
1801	Presenilin-1 interacts directly with the beta-site amyloid protein precursor cleaving enzyme (BACE1). 2003 , 13, 238-45	37
1800	Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. 2003 , 14, 291-301	39
1799	Human beta-secretase (BACE) and BACE inhibitors. 2003 , 46, 4625-30	139
1798	New amide-bearing benzolactam-based protein kinase C modulators induce enhanced secretion of the amyloid precursor protein metabolite sAPPalpha. 2003 , 46, 364-73	45
1797	Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. 2003 , 13, 781-9, ix	60
1796	Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase. 2003 , 163, 97-107	154
1795	Synthesis of potent beta-secretase inhibitors containing a hydroxyethylamine dipeptide isostere and their structure-activity relationship studies. 2003 , 1, 2468-73	65
1794	APP processing is regulated by cytoplasmic phosphorylation. 2003 , 163, 83-95	348
1793	Endoproteolysis of beta-secretase (beta-site amyloid precursor protein-cleaving enzyme) within its catalytic domain. A potential mechanism for regulation. 2003 , 278, 17141-9	34
1792	Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells. 2003 , 278, 31512-20	69
1791	Cholesterol: from heart attacks to Alzheimer's disease. 2003 , 44, 1423-30	56
1790	The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. 2003 , 278, 48713-9	209
1789	Folding and stability of the extracellular domain of the human amyloid precursor protein. 2003 , 278, 34259-67	22
1788	Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. 2003 , 278, 5531-8	51
1787	Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway. 2003 , 278, 28294-302	130
1786	Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation. 2003 , 278, 23648-55	81
1785	Identification of a mutant amyloid peptide that predominantly forms neurotoxic protofibrillar aggregates. 2003 , 278, 23187-95	36

1784	Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. 2003 , 278, 24294-301	120
1783	The mechanism of gamma-secretase: multiple inhibitor binding sites for transition state analogs and small molecule inhibitors. 2003 , 278, 28968-75	67
1782	Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. 2003 , 278, 19054-61	43
1781	Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors. 2003 , 278, 16528-33	109
1780	Genetic programming by the proteolytic fragments of the amyloid precursor protein: somewhere between confusion and clarity. 2003 , 14, 317-41	23
1779	Positive and negative regulation of APP amyloidogenesis by sumoylation. 2003 , 100, 259-64	126
1778	Membrane topology of gamma-secretase component PEN-2. 2003 , 278, 20117-23	71
1777	Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta -secretase (BACE1). 2003 , 278, 14865-71	87
1776	Library generation via postcondensation modifications of isocyanide-based multicomponent reactions. 2003 , 369, 469-96	35
1775	22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. 2003 , 278, 13244-56	184
1774	Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. 2003 , 278, 4458-66	67
1773	Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. 2003 , 100, 11735-40	306
1772	Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. 2003 , 116, 3339-46	216
1771	BACE1- and BACE2-expressing human cells: characterization of beta-amyloid precursor protein-derived catabolites, design of a novel fluorimetric assay, and identification of new in vitro inhibitors. 2003 , 278, 25859-66	58
1770	Identification of phospholipid scramblase 1 as a novel interacting molecule with beta -secretase (beta -site amyloid precursor protein (APP) cleaving enzyme (BACE)). 2003 , 278, 15239-45	43
1769	The transmembrane domain region of nicastrin mediates direct interactions with APH-1 and the gamma-secretase complex. 2003 , 278, 43284-91	63
1768	Kinetic studies on beta-site amyloid precursor protein-cleaving enzyme (BACE). Confirmation of an iso mechanism. 2003 , 278, 4582-9	39
1767	Characterization of the ectodomain shedding of the beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). 2003 , 278, 36264-8	46

1766	Frameshifted beta-amyloid precursor protein (APP+1) is a secretory protein, and the level of APP+1 in cerebrospinal fluid is linked to Alzheimer pathology. 2003 , 278, 39637-43	9
1765	Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. 2003 , 278, 31261-8	174
1764	Autosomal recessive hypercholesterolemia protein interacts with and regulates the cell surface level of Alzheimer's amyloid beta precursor protein. 2003 , 278, 31843-7	24
1763	Amyloid, presenilins, and Alzheimer's disease. 2003 , 9, 117-26	25
1762	βSecretase can cleave amyloid precursor protein fragments independent of γ- and βSecretase pre-cutting. 2003 , 12, 57	
1761	BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimers Disease Therapies. 2003 , 3, 47-55	
1760	Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity. 2003 , 278, 21286-94	51
1759	A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. 2003 , 4, 97-112	170
1758	The risk of dementia in relation to statins and other lipid lowering agents. 2003 , 25, 601-4	18
1757	Pharmakotherapie der Demenzen. 2003 , 30, 512-518	
1756	Autonomic Sudomotor Dysfunction in Alzheimers Disease. 2003 , 3, 77-84	
1755	Physiologic and pathologic events mediated by intramembranous and juxtamembranous proteolysis. 2003 , 2003, RE4	27
1754	Molecular identification of AMY, an Alzheimer disease amyloid-associated protein. 2003 , 62, 1108-17	14
1753	Pharmacotherapy for Alzheimer's disease: 2002. 2003 , 26, 93-101	12
1752	Polymorphism in the BACE gene influences the risk for Alzheimer's disease. 2003 , 14, 1243-6	31
1751	Chapter 5. Secretase inhibitors for Alzheimer's disease. 2003 , 38, 41-50	11
1750	The secretases of Alzheimer's disease. 2003 , 54, 233-61	28
1749	gamma-Secretase inhibitors--from molecular probes to new therapeutics?. 2003 , 41, 99-127	3

1748	Emerging therapeutics for Alzheimer's disease: an avenue of hope. 2003 , 8, 834-45	8
1747	Neurobiologic Basis of Age-Related Dementing Disorders. 2003 , 1095-1111	
1746	. 2003 ,	9
1745	App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. 2003 , 23, 6788-92	181
1744	Pharmacological Treatment of Dementia: A Review. 2003 , 199-278	1
1743	Molecular Mechanisms of Neurodegenerative Disorders. 377-409	
1742	Genetics of early-onset Alzheimer dementia. 2003 , 3, 497-519	34
1741	Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. 2003 , 23, 7504-9	424
1740	The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. 2003 , 23, 8867-71	188
1739	Transgenic mouse models of neurodegenerative disease. 2004 , 533-557	
1738	Alzheimer disease: mechanistic understanding predicts novel therapies. 2004 , 140, 627-38	206
1737	Apoptosis: a key in neurodegenerative disorders. 2004 , 1, 355-71	79
1736	Islet-brain (IB)/JNK-interacting proteins (JIPs): future targets for the treatment of neurodegenerative diseases?. 2004 , 1, 111-27	12
1735	Structural features of human memapsin 2 (beta-secretase) and their biological and pathological implications. 2004 , 36, 787-92	5
1734	ApoE: crossroads between Alzheimer's disease and atherosclerosis. 2004 , 4, 279-85	7
1733	ADAM proteases: protective role in Alzheimer's and prion diseases?. 2004 , 1, 165-74	17
1732	Molecular mechanisms, emerging etiological insights and models to test potential therapeutic interventions in Alzheimer's disease. 2004 , 1, 295-306	5
1731	The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease. 2004 , 1, 47-54	97

1730	Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease". 2004 , 11, 1065-84	44
1729	A beta-secretase (BACE1) inhibitor hispidin from the mycelial cultures of <i>Phellinus linteus</i> . 2004 , 70, 143-6	63
1728	[Psychotropic drug treatment in dementia disorders]. 2004 , 129, 1434-40	0
1727	Structural bioinformatics and its impact to biomedical science. 2004 , 11, 2105-34	603
1726	Amyloid beta-peptide: the inside story. 2004 , 1, 231-9	62
1725	Secretases as therapeutic targets in Alzheimer's disease: patents 2000-2004. 2004 , 14, 1403-1420	12
1724	Fluorescent-conjugated polymer superquenching facilitates highly sensitive detection of proteases. 2004 , 101, 7511-5	198
1723	The human amyloid-beta precursor protein 770 mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates. 2004 , 279, 5829-36	24
1722	Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. 2004 , 24, 865-74	183
1721	A lipid boundary separates APP and secretases and limits amyloid beta-peptide generation. 2004 , 167, 809-12	66
1720	Fatty acids increase presenilin-1 levels and [gamma]-secretase activity in PSwt-1 cells. 2004 , 45, 2368-76	25
1719	The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. 2004 , 279, 29639-46	82
1718	Amino-truncated amyloid beta-peptide (A β 5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain. 2004 , 18, 1755-7	44
1717	The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. 2004 , 117, 4435-48	283
1716	Ectodomain shedding and intramembrane cleavage of mammalian Notch proteins is not regulated through oligomerization. 2004 , 279, 50864-73	61
1715	Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the gamma-secretase complex. 2004 , 279, 3685-93	58
1714	Association of the Neprilysin gene with susceptibility to late-onset Alzheimer's disease. 2004 , 17, 164-9	33
1713	Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. 2004 , 24, 10908-17	149

1712	Effects of RNA interference-mediated silencing of gamma-secretase complex components on cell sensitivity to caspase-3 activation. 2004 , 279, 34130-7	24
1711	Internalization of exogenously added memapsin 2 (beta-secretase) ectodomain by cells is mediated by amyloid precursor protein. 2004 , 279, 37886-94	19
1710	Proteolytic processing of amyloid-beta precursor protein by secretases does not require cell surface transport. 2004 , 279, 47101-8	33
1709	Pathogenic factors in vascular dementia and Alzheimer's disease. Multiple actions of heparin that probably are beneficial. 2004 , 18, 278-98	14
1708	BACE1 and presenilin: two unusual aspartyl proteases involved in Alzheimer's disease. 2004 , 1, 168-74	21
1707	Intracellular domain generation of amyloid precursor protein by β cleavage depends on C-terminal fragment by β -secretase cleavage. 2004 , 13, 121	
1706	Alzheimer's disease: from bench to bedside. 2004 , 18, 177-195	
1705	Protein trafficking and Alzheimer's disease. 2004 , 1, 1-10	19
1704	Translational regulation of BACE-1 expression in neuronal and non-neuronal cells. 2004 , 32, 1808-17	71
1703	Munc13-1-mediated vesicle priming contributes to secretory amyloid precursor protein processing. 2004 , 279, 27841-4	27
1702	Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1. 2004 , 279, 39010-6	24
1701	Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation. 2004 , 101, 2794-9	80
1700	Binding sites of gamma-secretase inhibitors in rodent brain: distribution, postnatal development, and effect of deafferentation. 2004 , 24, 2942-52	40
1699	Human BACE forms dimers and colocalizes with APP. 2004 , 279, 39710-7	62
1698	Demonstration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. 2004 , 117, 5437-45	97
1697	Presenilin 1 stabilizes the C-terminal fragment of the amyloid precursor protein independently of gamma-secretase activity. 2004 , 279, 25333-8	18
1696	Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme. 2004 , 279, 53205-12	90
1695	Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. 2004 , 279, 10542-50	182

1694	Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice. 2004 , 279, 52535-42	34
1693	Beta galactosidase enzyme fragment complementation as a high-throughput screening protease technology. 2004 , 9, 398-408	32
1692	The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. 2004 , 279, 18146-56	158
1691	Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. 2004 , 101, 2548-53	181
1690	Degradation of BACE by the ubiquitin-proteasome pathway. 2004 , 18, 1571-3	129
1689	Functional characterization of the 5' flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression. 2004 , 18, 1037-9	55
1688	BACE1 suppression by RNA interference in primary cortical neurons. 2004 , 279, 1942-9	117
1687	Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. 2004 , 101, 11141-6	277
1686	Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. 2004 , 279, 43419-26	151
1685	Processing of Notch and amyloid precursor protein by gamma-secretase is spatially distinct. 2004 , 101, 17050-5	94
1684	Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. 2004 , 279, 50647-50	111
1683	The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. 2004 , 18, 1309-11	36
1682	Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. 2004 , 62, 498-501	130
1681	Amyloid-beta protein precursor (AbetaPP) intracellular domain-associated protein-1 proteins bind to AbetaPP and modulate its processing in an isoform-specific manner. 2004 , 279, 49105-12	37
1680	CSF biomarkers for mild cognitive impairment. 2004 , 256, 224-34	122
1679	Clearing amyloid through the blood-brain barrier. 2004 , 89, 807-11	298
1678	In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. 2004 , 89, 1409-16	100
1677	Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. 2004 , 90, 1132-43	79

1676	PEN-2 enhances gamma-cleavage after presenilin heterodimer formation. 2004 , 90, 1402-13	22
1675	Apoptotic cell death influences the signaling activity of the amyloid precursor protein through ShcA and Grb2 adaptor proteins in neuroblastoma SH-SY5Y cells. 2004 , 90, 1359-70	22
1674	Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. 2004 , 91, 521-36	185
1673	Biochemical and kinetic characterization of BACE1: investigation into the putative species-specificity for beta- and beta'-cleavage sites by human and murine BACE1. 2004 , 91, 1249-59	17
1672	Insights into the phosphoregulation of beta-secretase sorting signal by the VHS domain of GGA1. 2004 , 5, 437-48	59
1671	Enhanced generation of intracellular Abeta42 amyloid peptide by mutation of presenilins PS1 and PS2. 2004 , 19, 258-264	44
1670	Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism. 2004 , 66, 1-16	53
1669	Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. 2004 , 22, 1302-6	1160
1668	Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. 2004 , 10 Suppl, S26-33	138
1667	Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. 2004 , 10, 959-65	234
1666	Expression of the Alzheimer protease BACE1 is suppressed via its 5'-untranslated region. 2004 , 5, 620-5	97
1665	Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. 2004 , 9, 664-83	228
1664	Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. 2004 , 10 Suppl, S51-7	69
1663	Strategies for disease modification in Alzheimer's disease. 2004 , 5, 677-85	361
1662	Beta-secretase-cleaved amyloid precursor protein in Alzheimer brain: a morphologic study. 2004 , 8, 127-34	18
1661	Increased beta-secretase activity and expression in rats following transient cerebral ischemia. 2004 , 1009, 1-8	165
1660	Proteases and lipoprotein receptors in Alzheimer's disease. 2004 , 41, 139-78	4
1659	BACE1: the beta-secretase enzyme in Alzheimer's disease. 2004 , 23, 105-14	252

1658	Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation. 2004 , 24, 115-22	25
1657	Involvement of proteases in glycosyltransferase secretion: Alzheimer's beta-secretase-dependent cleavage and a following processing by an aminopeptidase. 2004 , 21, 25-9	10
1656	Backbone resonance assignments of the 45.3 kDa catalytic domain of human BACE1. 2004 , 29, 425-6	11
1655	BACE1 overexpression regulates amyloid precursor protein cleavage and interaction with the ShcA adapter. 2004 , 1030, 330-8	9
1654	BACE1 gene expression and protein degradation. 2004 , 1035, 49-67	6
1653	Inflammation, neurodegenerative diseases, and environmental exposures. 2004 , 1035, 117-32	94
1652	Transgenic BACE expression in mouse neurons accelerates amyloid plaque pathology. 2004 , 111, 413-25	39
1651	Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). 2004 , 111, 523-36	143
1650	Proteolytic generation and aggregation of peptides from transmembrane regions: lung surfactant protein C and amyloid beta-peptide. 2004 , 61, 326-35	25
1649	Profiling proteins related to amyloid deposited brain of Tg2576 mice. 2004 , 4, 3359-68	60
1648	Intraneuronal amyloid-beta1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. 2004 , 88, 1140-50	103
1647	X11alpha impairs gamma- but not beta-cleavage of amyloid precursor protein. 2004 , 88, 971-82	35
1646	The 1239G/C polymorphism in exon 5 of BACE1 gene may be associated with sporadic Alzheimer's disease in Chinese Hans. 2004 , 124B, 54-7	13
1645	No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population. 2004 , 125B, 87-91	21
1644	Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling. 2004 , 77, 250-7	42
1643	Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. 2004 , 332, 153-9	496
1642	Crystallization of glycosylated human BACE protease domain expressed in <i>Trichoplusia ni</i> . 2004 , 1698, 255-9	5
1641	Phe*-Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR. 2004 , 14, 239-43	39

1640	P3 cap modified Phe*-Ala series BACE inhibitors. 2004 , 14, 245-50	31
1639	Rational design and synthesis of selective BACE-1 inhibitors. 2004 , 14, 601-4	42
1638	KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine. 2004 , 14, 1527-31	65
1637	Hydroxytriamides as potent gamma-secretase inhibitors. 2004 , 14, 1917-21	21
1636	Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. 2004 , 101, 3632-7	432
1635	Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. 2004 , 43, 9999-10007	7
1634	Insights from modeling the tertiary structure of human BACE2. 2004 , 3, 1069-72	81
1633	Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42. 2004 , 43, 13532-40	118
1632	Acetylcholinesterase inhibitors: novel activities of old molecules. 2004 ,	
1631	Acetylcholinesterase inhibitors: novel activities of old molecules. 2004 , 50, 441-51	222
1630	Role of hydrogen peroxide in the aetiology of Alzheimer's disease: implications for treatment. 2004 , 21, 81-100	93
1629	Flap position of free memapsin 2 (beta-secretase), a model for flap opening in aspartic protease catalysis. 2004 , 43, 4689-95	117
1628	Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase. 2004 , 47, 158-64	87
1627	Gene structure and organization of the human beta-secretase (BACE) promoter. 2004 , 18, 1034-6	155
1626	Therapeutic targets from a Drosophila model of Alzheimer's disease. 2004 , 4, 513-6	13
1625	Got RIP? Presenilin-dependent intramembrane proteolysis in growth factor receptor signaling. 2004 , 15, 337-51	72
1624	Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. 2004 , 36, 2531-40	250
1623	Aberrant expressions of pathogenic phenotype in Alzheimer's diseased transgenic mice carrying NSE-controlled APPsw. 2004 , 186, 20-32	53

1622	Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?. 2004 , 185, 208-19	121
1621	Yeast growth selection system for the identification of cell-active inhibitors of beta-secretase. 2004 , 1674, 29-39	17
1620	The metabolism of beta-amyloid converting enzyme and beta-amyloid precursor protein processing. 2004 , 325, 235-42	9
1619	Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. 2004 , 25, 92-7	181
1618	A general procedure for the purification of human beta-secretase expressed in Escherichia coli. 2004 , 34, 190-6	16
1617	Novel aspects of accumulation dynamics and A beta composition in transgenic models of AD. 2004 , 25, 1175-85	20
1616	Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. 2004 , 25, 1263-72	281
1615	Beta-secretase activity increases with aging in human, monkey, and mouse brain. 2004 , 164, 719-25	233
1614	Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. 2004 , 165, 357-71	212
1613	Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. 2004 , 165, 1289-300	338
1612	beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice. 2004 , 165, 1621-31	46
1611	The endocytotic pathway is required for increased A beta 42 secretion during apoptosis. 2004 , 128, 201-11	12
1610	The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain. 2004 , 15, 343-53	119
1609	APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. 2004 , 16, 124-32	74
1608	Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. 2004 , 16, 454-60	83
1607	Mutations in APP have independent effects on Abeta and CTFgamma generation. 2004 , 17, 205-18	58
1606	Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid beta-protein in cultured cells. 2004 , 367, 123-8	79
1605	Neuroprotective effects of beta-secretase inhibitors against rat retinal ganglion cell death. 2004 , 370, 61-4	15

1604	New players in old amyloid precursor protein-processing pathways. 2004 , 22, 467-74	16
1603	Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. 2004 , 22, 453-65	109
1602	BACE (beta-secretase) modulates the processing of APLP2 in vivo. 2004 , 25, 642-9	103
1601	A model for studying Alzheimer's Abeta42-induced toxicity in <i>Drosophila melanogaster</i> . 2004 , 26, 365-75	216
1600	Crystal structure of an activation intermediate of cathepsin E. 2004 , 342, 889-99	28
1599	Apo and inhibitor complex structures of BACE (beta-secretase). 2004 , 343, 407-16	171
1598	The third chains of living organisms--a trail of glycobiology that started from the third floor of building 4 in NIH. 2004 , 426, 107-21	10
1597	Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). 2004 , 47, 6447-50	259
1596	BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. 2004 , 41, 27-33	457
1595	Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease. 2004 , 562, 16-21	32
1594	The intracellular localization of amyloid beta protein precursor (AbetaPP) intracellular domain associated protein-1 (AIDA-1) is regulated by AbetaPP and alternative splicing. 2004 , 6, 67-78	27
1593	Beta-sheet breakers for Alzheimer's disease therapy. 2004 , 5, 553-8	53
1592	Down syndrome and beta-amyloid deposition. 2004 , 17, 95-100	77
1591	Novel mutations introduced at the beta-site of amyloid beta protein precursor enhance the production of amyloid beta peptide by BACE1 in vitro and in cells. 2005 , 7, 139-48; discussion 173-80	33
1590	The Amyloid β Protein. 384-491	2
1589	Expression and activity of β site amyloid precursor protein cleaving enzyme in Alzheimer's disease. 2005 , 33, 1096-1100	33
1588	Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease. 2005 , 33, 1096-100	56
1587	Proteasome-mediated effects on amyloid precursor protein processing at the gamma-secretase site. 2005 , 385, 545-50	36

1586	Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides. 2005 , 145, 97-105	8
1585	A hybrid LC-Gel-MS method for proteomics research and its application to protease functional pathway mapping. 2005 , 822, 98-111	5
1584	Molecular docking and 3D-QSAR studies on the binding mechanism of statine-based peptidomimetics with beta-secretase. 2005 , 13, 2121-31	28
1583	Water-soluble chitosan derivatives as a BACE1 inhibitor. 2005 , 13, 6551-5	73
1582	Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. 2005 , 15, 211-5	91
1581	Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase). 2005 , 15, 15-20	80
1580	Chitooligosaccharides as a novel Bsecretase inhibitor. 2005 , 61, 198-202	47
1579	Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins. 2005 , 1066, 181-221	83
1578	Genetic association of BACE1 gene polymorphism C786G with late-onset Alzheimer's disease in Chinese. 2005 , 25, 127-31	12
1577	Characterization of autocatalytic conversion of precursor BACE1 by heteronuclear NMR spectroscopy. 2005 , 44, 16594-601	6
1576	Beta-amyloid protein converting enzyme 1 and brain-specific type II membrane protein BRI3: binding partners processed by furin. 2005 , 92, 93-102	37
1575	Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. 2005 , 92, 226-34	127
1574	Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. 2005 , 92, 628-36	275
1573	Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment. 2005 , 94, 1189-201	57
1572	Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid-differentiated human neuroblastoma cells. 2005 , 95, 1059-68	53
1571	Design and characterization of a new cell-permeant inhibitor of the beta-secretase BACE1. 2005 , 145, 228-35	21
1570	Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. 2005 , 4, 134-46	60
1569	Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. 2005 , 4, 173-96	152

1568	Differential translation and fragile X syndrome. 2005 , 4, 360-84	67
1567	Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. 2005 , 38, 427-37	127
1566	Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. 2005 , 514, 1-15	72
1565	Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. 2005 , 69, 689-98	93
1564	Functional plasticity in the substrate binding site of beta-secretase. 2005 , 13, 1487-98	91
1563	Destructive potential of the aspartyl protease cathepsin D in MHC class II-restricted antigen processing. 2005 , 35, 3442-51	54
1562	Synaptic transmission and synchronous activity is disrupted in hippocampal slices taken from aged TAS10 mice. 2005 , 15, 110-7	30
1561	Transcriptome analysis of a human colorectal cancer cell line shows molecular targets of insulin-like growth factor-binding protein-4 overexpression. 2005 , 113, 588-99	3
1560	TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor. 2005 , 114, 555-62	20
1559	Model-guided microarray implicates the retromer complex in Alzheimer's disease. 2005 , 58, 909-19	294
1558	Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development. 2005 , 80, 151-9	38
1557	Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. 2005 , 53, 607-13	133
1556	Therapeutic gene silencing in neurological disorders, using interfering RNA. 2005 , 83, 413-9	25
1555	Inhibitors of proprotein convertases. 2005 , 83, 844-55	68
1554	Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease. 2005 , 164, 205-14	28
1553	Oxidative stress potentiates BACE1 gene expression and Abeta generation. 2005 , 112, 455-69	175
1552	beta-Secretase (BACE1) inhibitors from pomegranate (<i>Punica granatum</i>) husk. 2005 , 28, 1328-32	78
1551	What is the dominant Abeta species in human brain tissue? A review. 2005 , 7, 29-41	39

1550	Post-translational processing of beta-secretase in Alzheimer's disease. 2005 , 5, 1533-43	22
1549	Genes involved in Alzheimer's disease, a survey of possible candidates. 2005 , 7, 331-53	29
1548	Selected genetically engineered models relevant to human neurodegenerative disease. 2005 , 176-195	1
1547	Alzheimer's disease: overview. 2005 , 416-432	
1546	Molecular Pathology of Dementia. 2005 , 18, 258-269	
1545	Alzheimer's Disease: Clinical Features, Neuropathologies and Biochemical Abnormalities, Genetics, Models, and Experimental Therapeutics. 2005 , 445-458	2
1544	Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. 2005 , 2, e18	111
1543	The role of Abeta peptides in Alzheimer's disease. 2005 , 12, 513-9	21
1542	Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease. 2005 , 11, 3363-82	49
1541	Progress in the discovery of BACE inhibitors. 2005 , 11, 3383-404	48
1540	JLK inhibitors: isocoumarin compounds as putative probes to selectively target the gamma-secretase pathway. 2005 , 2, 327-34	6
1539	RT-PCR-Based Cloning of the Human BETA-Amyloid Precursor Protein Gene and the Construction of its Expression Plasmids. 2005 , 38, 71-88	
1538	GGA proteins mediate the recycling pathway of memapsin 2 (BACE). 2005 , 280, 11696-703	198
1537	beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. 2005 , 280, 23009-17	235
1536	BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. 2005 , 168, 291-302	120
1535	Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis. 2005 , 102, 18135-40	45
1534	Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. 2005 , 25, 436-45	314
1533	Lithium chloride increases the production of amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3. 2005 , 280, 33220-7	36

1532	BACE is degraded via the lysosomal pathway. 2005 , 280, 32499-504	135
1531	βSecretase, APP and Aβ in Alzheimer's Disease. 2005 , 79-103	44
1530	The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. 2005 , 280, 43243-56	176
1529	Amyloid Precursor Protein and Ferritin Translation: Implications for Metals and Alzheimer's Disease Therapeutics. 2005 , 215-251	2
1528	Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. 2005 , 14, 1385-409	51
1527	BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. 2005 , 280, 17930-7	96
1526	Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. 2005 , 102, 13461-6	472
1525	Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. 2005 , 25, 6755-64	134
1524	Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. 2005 , 25, 10874-83	202
1523	Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. 2005 , 25, 5533-43	101
1522	The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. 2005 , 280, 17777-85	206
1521	PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein. 2005 , 280, 13824-32	50
1520	RNA interference-mediated silencing of X11alpha and X11beta attenuates amyloid beta-protein levels via differential effects on beta-amyloid precursor protein processing. 2005 , 280, 15413-21	43
1519	The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. 2005 , 280, 28912-6	111
1518	Functional overexpression of gamma-secretase reveals protease-independent trafficking functions and a critical role of lipids for protease activity. 2005 , 280, 12523-35	34
1517	In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase. 2005 , 280, 8589-95	77
1516	High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. 2005 , 280, 32957-67	79
1515	Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. 2005 , 280, 18755-70	108

1514	gamma-Cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. 2005 , 280, 37689-97	114
1513	BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. 2005 , 25, 11693-709	436
1512	Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. 2005 , 19, 739-49	110
1511	Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. 2005 , 386, 931-40	110
1510	Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease. 2005 , 19, 171-83	40
1509	LRP and Alzheimer's disease. 2005 , 16, 123-35	50
1508	Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. 2005 , 280, 30797-806	270
1507	BACE/APPV717F double-transgenic mice develop cerebral amyloidosis and inflammation. 2005 , 2, 284-98	12
1506	Ceramide and cholesterol: possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified?. 2005 , 1, 43-50	21
1505	Structure of beta-amyloid fibrils and its relevance to their neurotoxicity: implications for the pathogenesis of Alzheimer's disease. 2005 , 99, 437-47	76
1504	The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. 2005 , 115, 1121-9	178
1503	Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase). 2005 , 44, 105-12	66
1502	The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. 2005 , 19, 989-96	68
1501	Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. 2005 , 44, 10810-21	122
1500	An inhibitor binding pocket distinct from the catalytic active site on human beta-APP cleaving enzyme. 2005 , 44, 11567-73	40
1499	Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization. 2005 , 48, 6607-19	10
1498	CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. 2005 , 5, 661-72	99
1497	Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. 2005 , 20, 625-37	65

1496	Modeling the tertiary structure of human cathepsin-E. 2005 , 331, 56-60	74
1495	Determination of hypoxic effect on neprilysin activity in human neuroblastoma SH-SY5Y cells using a novel HPLC method. 2005 , 334, 380-5	10
1494	Pin1 promotes production of Alzheimer's amyloid beta from beta-cleaved amyloid precursor protein. 2005 , 336, 521-9	52
1493	Extracellular release of BACE1 holoproteins from human neuronal cells. 2005 , 338, 800-7	23
1492	Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. 2005 , 120, 545-55	1439
1491	CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. 2005 , 107, 165-73	154
1490	Molecular biology and genetics of Alzheimer's disease. 2005 , 328, 119-30	136
1489	The amyloid precursor protein and its network of interacting proteins: physiological and pathological implications. 2005 , 48, 257-64	56
1488	Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. 2005 , 26, 373-82	308
1487	Age-dependent differential expression of BACE splice variants in brain regions of tg2576 mice. 2005 , 26, 1167-75	20
1486	Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. 2005 , 48, 5175-90	70
1485	Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. 2005 , 2, 612-26	72
1484	New prospects and strategies for drug target discovery in neurodegenerative disorders. 2005 , 2, 627-37	10
1483	Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. 2005 , 102, 19198-203	272
1482	Molecular rationale for the pharmacological treatment of Alzheimer's disease. 2005 , 22 Suppl 1, 27-37	21
1481	A continuous time-resolved fluorescence assay for identification of BACE1 inhibitors. 2005 , 3, 287-97	16
1480	Assigning the protonation states of the key aspartates in β Secretase using QM/MM X-ray structure refinement. 2006 , 2, 1057-1069	86
1479	Neuroproteases in peptide neurotransmission and neurodegenerative diseases: applications to drug discovery research. 2006 , 20, 105-19	9

1478	Alzheimer: 100 Years and Beyond. 2006 ,	5
1477	Structural models of amyloid-like fibrils. 2006 , 73, 235-82	162
1476	Acylguanidines as small-molecule beta-secretase inhibitors. 2006 , 49, 6158-61	100
1475	Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. 2006 , 20, 351-72	77
1474	Artefactual effects of lipid-based cell transfection reagents on AbetaPP processing and Abeta production. 2006 , 13, 86-92	1
1473	Alzheimer's disease. 2006 , 368, 387-403	2621
1472	Oxidative stress in Alzheimer's disease. 2006 , 13, 195-208	242
1471	Trafficking of Alzheimer's disease-related membrane proteins and its participation in disease pathogenesis. 2006 , 139, 949-55	46
1470	Presenilin function in APP processing. 2000 , 920, 158-64	17
1469	Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain. 2006 , 580, 6550-60	35
1468	N-glycosylation of human nicastrin is required for interaction with the lectins from the secretory pathway calnexin and ERGIC-53. 2006 , 1762, 802-10	17
1467	Disease-modifying therapies in Alzheimer's disease: how far have we come?. 2006 , 66, 2075-93	61
1466	In situ localization of P-glycoprotein (ABCB1) in human and rat brain. 2006 , 54, 1159-67	173
1465	Current pharmacotherapy for Alzheimer's disease. 2006 , 57, 513-33	243
1464	Formal total synthesis of the potent renin inhibitor aliskiren: application of a SmI2-promoted acyl-like radical coupling. 2006 , 71, 4766-77	42
1463	Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1. 2006 , 49, 839-42	56
1462	Deducing the transmembrane domain organization of presenilin-1 in gamma-secretase by cysteine disulfide cross-linking. 2006 , 45, 7598-604	29
1461	The involvement of lipid rafts in Alzheimer's disease. 2006 , 23, 111-22	161

1460	Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme. 2006 , 45, 6703-14		45
1459	Control of peripheral nerve myelination by the beta-secretase BACE1. <i>Science</i> , 2006 , 314, 664-6	33.3	579
1458	Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (beta-secretase) inhibitors. 2006 , 128, 5310-1		57
1457	Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. 2006 , 5, 1010-6		161
1456	Abeta 11-40/42 production without gamma-secretase epsilon-site cleavage. 2006 , 349, 1356-60		11
1455	epsilon-Glycation, APP and Abeta in ageing and Alzheimer disease: a hypothesis. 2006 , 66, 898-906		16
1454	Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor. 2006 , 355, 249-61		49
1453	Mapping of interaction domains mediating binding between BACE1 and RTN/Nogo proteins. 2006 , 363, 625-34		37
1452	Palmitic acid-treated astrocytes induce BACE1 upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons. 2006 , 406, 55-9		75
1451	Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. 2006 , 54, 24-9		50
1450	A novel fusion protein system for the production of native human pepsinogen in the bacterial periplasm. 2006 , 47, 662-71		25
1449	A novel approach to identifying beta-secretase inhibitors: bis-statine peptide mimetics discovered using structure and spot synthesis. 2006 , 27, 1877-85		12
1448	Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease. 2006 , 79, 95-111		152
1447	Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. 2006 , 27, 1060-77		59
1446	M1 receptors play a central role in modulating AD-like pathology in transgenic mice. 2006 , 49, 671-82		348
1445	Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. 2006 , 52, 15-31		257
1444	A hundred years of Alzheimer's disease research. 2006 , 52, 3-13		365
1443	Cathepsin D-mediated proteolysis of apolipoprotein E: possible role in Alzheimer's disease. 2006 , 143, 689-701		57

1442	Genetics and pathology of alpha-secretase site AbetaPP mutations in the understanding of Alzheimer's disease. 2006 , 9, 389-98	6
1441	. 2006 ,	1
1440	Alzheimer's disease, model systems and experimental therapeutics. 565-586	
1439	Statins inhibit the dimerization of beta-secretase via both isoprenoid- and cholesterol-mediated mechanisms. 2006 , 399, 205-14	43
1438	Alzheimer's Disease. 2006 ,	
1437	Effects of anoxia and hypoxia on amyloid precursor protein processing in cerebral microvascular smooth muscle cells. 2006 , 65, 610-20	15
1436	Computer-Aided Drug Design Applied to Beta and Gamma Secretase Inhibitors-Perspectives for New Alzheimer Disease Therapy. 2006 , 2, 311-328	5
1435	Animal Models of Alzheimer's Disease. 2006 , 1-73	
1434	Synaptic remodeling during aging and in Alzheimer's disease. 2006 , 9, 91-9	91
1433	Lipid Rafts in Trafficking and Processing of Prion Protein and Amyloid Precursor Protein. 2006 , 205-231	
1432	Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. 2006 , 9, 277-89	186
1431	Synthesis of New Substituted 4,5-Dihydro-3H-spiro[1,5]-benzoxazepine-2,4?-piperidine and Biological Properties. 2006 , 59, 812	6
1430	Metals and Alzheimer's disease. 2006 , 10, 145-63	265
1429	The amyloid precursor protein: beyond amyloid. 2006 , 1, 5	238
1428	Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. 2006 , 1, 8	72
1427	Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid beta-protein. 2006 , 24, 1237-44	102
1426	Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. 2001 , 11, 1-11	136
1425	Inhibition of endocytosis activates alternative degradation pathway of A β PP in cultured cells. 2006 , 6, 107-113	

1424	The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. 2006 , 96, 533-40	132
1423	Sialylation enhances the secretion of neurotoxic amyloid-beta peptides. 2006 , 96, 924-33	59
1422	The transcription factor Yin Yang 1 is an activator of BACE1 expression. 2006 , 96, 1696-707	58
1421	APPepsilon, the epsilon-secretase-derived N-terminal product of the beta-amyloid precursor protein, behaves as a type I protein and undergoes alpha-, beta-, and gamma-secretase cleavages. 2006 , 97, 807-17	18
1420	Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?. 2006 , 98, 993-1006	104
1419	BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. 2006 , 99, 1555-63	95
1418	Disease modifying therapy for AD?. 2006 , 99, 689-707	105
1417	The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. 2004 , 10, 127-46	33
1416	A Protease Activation Cascade in the Pathogenesis of Alzheimer's Disease. 2006 , 924, 117-131	68
1415	The value of transgenic models for the study of neurodegenerative diseases. 2000 , 920, 179-91	44
1414	Identifying proteases that cleave APP. 2000 , 920, 192-6	4
1413	Toward the characterization and identification of gamma-secretases using transition-state analogue inhibitors. 2000 , 920, 197-205	15
1412	Recent advances in the understanding of the processing of APP to beta amyloid peptide. 2000 , 920, 206-8	13
1411	An empirical model of gamma-secretase activity. 2000 , 920, 233-40	4
1410	Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. 2006 , 12, 1390-6	169
1409	Bace1 modulates myelination in the central and peripheral nervous system. 2006 , 9, 1520-5	483
1408	Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. 2006 , 11, 721-36	274
1407	Macrocyclic peptidomimetic inhibitors of beta-secretase (BACE): first X-ray structure of a macrocyclic peptidomimetic-BACE complex. 2006 , 16, 191-5	31

1406	BACE-1 inhibitory activities of new substituted phenyl-piperazine coupled to various heterocycles: chromene, coumarin and quinoline. 2006 , 16, 1995-9	44
1405	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. 2006 , 16, 2357-63	18
1404	A century of Alzheimer's disease. <i>Science</i> , 2006 , 314, 777-81	33:3 147 ⁸
1403	Linking molecular motors to Alzheimer's disease. 2006 , 99, 193-200	25
1402	LRP in amyloid-beta production and metabolism. 2006 , 1086, 35-53	89
1401	Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease. 2006 , 58, 686-94	68
1400	BACE1 gene promoter is differentially regulated: detection of a novel promoter region for its cell type-specific regulation. 2006 , 28, 193-210	12
1399	Functional domains of the BACE1 and BACE2 promoters and mechanisms of transcriptional suppression of the BACE2 promoter in normal neuronal cells. 2006 , 29, 65-80	22
1398	Characterization of the human beta-secretase 2 (BACE2) 5'-flanking region: identification of a 268-bp region as the basal BACE2 promoter. 2006 , 29, 81-99	12
1397	Screening a series of sialyltransferases for possible BACE1 substrates. 2006 , 23, 437-41	10
1396	Protease pathways in peptide neurotransmission and neurodegenerative diseases. 2006 , 26, 449-69	18
1395	Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. 2006 , 112, 163-74	73
1394	Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance. 2006 , 63, 1226-35	142
1393	Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. 2006 , 63, 1538-52	74
1392	Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres. 2006 , 16, 2380-6	62
1391	beta-Secretase inhibitors: modification at the P4 position and improvement of inhibitory activity in cultured cells. 2006 , 16, 4354-9	49
1390	New pathways in drug discovery for Alzheimer's disease. 2006 , 6, 372-8	12
1389	The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. 2006 , 41, 202-12	95

1388	Pathogenic mechanisms in Alzheimer's disease. 2006 , 545, 29-38	34
1387	Alzheimer's disease and post-operative cognitive dysfunction. 2006 , 41, 346-59	132
1386	Binding of trypsin to fibrillar amyloid beta-protein. 2006 , 1082, 173-81	7
1385	Pharmacological and molecular enhancement of learning in aging and Alzheimer's disease. 2006 , 99, 180-92	52
1384	Isoprenoids and Alzheimer's disease: a complex relationship. 2006 , 22, 209-22	68
1383	Norstatines from Aldehydes by Sequential Organocatalytic α -Amination and Passerini Reaction. 2006 , 2006, 4585-4595	28
1382	Amyloid beta oligomerization is induced by brain lipid rafts. 2006 , 99, 878-89	88
1381	The cathepsin D rs17571 polymorphism: effects on CSF tau concentrations in Alzheimer disease. 2006 , 27, 532-7	19
1380	Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. 2006 , 83, 1252-61	87
1379	BACE1 interacts with lipid raft proteins. 2006 , 84, 912-7	74
1378	Lactacystin decreases amyloid-beta peptide production by inhibiting beta-secretase activity. 2006 , 84, 1311-22	9
1377	Brain Imaging. 233-256	
1376	Protein-Coated Porous-Silicon Photonic Crystals for Amplified Optical Detection of Protease Activity. 2006 , 18, 1393-1396	138
1375	Subcellular trafficking of the amyloid precursor protein gene family and its pathogenic role in Alzheimer's disease. 2006 , 3, 218-26	37
1374	Control of amyloid-beta-peptide generation by subcellular trafficking of the beta-amyloid precursor protein and beta-secretase. 2006 , 3, 247-54	12
1373	Therapeutic options in Alzheimer's disease. 2006 , 6, 897-910	37
1372	An early specific cell-cell interaction occurs in the production of beta-amyloid in cell cultures. 2006 , 103, 1540-5	6
1371	The role of beta-amyloid protein in synaptic function: implications for Alzheimer's disease therapy. 2006 , 4, 149-63	34

1370	Genetically modified mice models for Alzheimer's disease. 2006 , 6, 609-27	13
1369	A two decade contribution of molecular cell biology to the centennial of Alzheimer's disease: are we progressing toward therapy?. 2006 , 254, 215-300	24
1368	Mitochondrial dysfunction and Alzheimer's disease. 2006 , 3, 515-20	47
1367	Amyloid beta: the alternate hypothesis. 2006 , 3, 75-80	82
1366	Human beta-secretase (BACE) and BACE inhibitors: progress report. 2006 , 6, 569-78	50
1365	Beta-amyloid, oxidative stress and down syndrome. 2006 , 3, 521-8	87
1364	Genetic and pharmacological basis for therapeutic inhibition of beta- and gamma-secretases in mouse models of Alzheimer's memory deficits. 2006 , 17, 429-54	25
1363	Molecular and biochemical features in Alzheimer's disease. 2006 , 12, 4389-408	62
1362	Taking down the unindicted co-conspirators of amyloid beta-peptide-mediated neuronal death: shared gene regulation of BACE1 and APP genes interacting with CREB, Fe65 and YY1 transcription factors. 2006 , 3, 475-83	26
1361	Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. 2006 , 26, 4277-88	231
1360	Hyperphosphorylation of JNK-interacting protein 1, a protein associated with Alzheimer disease. 2006 , 5, 97-113	47
1359	Neuritic deposits of amyloid-beta peptide in a subpopulation of central nervous system-derived neuronal cells. 2006 , 26, 4982-97	31
1358	PAT1a modulates intracellular transport and processing of amyloid precursor protein (APP), APLP1, and APLP2. 2006 , 281, 40114-23	29
1357	LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. 2006 , 103, 17967-72	87
1356	Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. 2006 , 26, 418-28	145
1355	Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. 2006 , 52, 1168-74	64
1354	Presenilin/gamma-secretase activity regulates protein clearance from the endocytic recycling compartment. 2006 , 20, 1176-8	52
1353	Biomedicine. Avoiding collateral damage in Alzheimer's disease treatment. <i>Science</i> , 2006 , 314, 602-3	33-3 4

1352	Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription. 2006 , 20, 285-92	113
1351	Unique neuronal functions of cathepsin L and cathepsin B in secretory vesicles: biosynthesis of peptides in neurotransmission and neurodegenerative disease. 2006 , 387, 1429-39	17
1350	Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice. 2006 , 26, 13279-86	86
1349	Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome. 2006 , 20, 1361-8	52
1348	The TGF-beta1/upstream stimulatory factor-regulated PAI-1 gene: potential involvement and a therapeutic target in Alzheimer's disease. 2006 , 2006, 15792	13
1347	Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. 2006 , 103, 443-8	332
1346	Inhibition of neprilysin by infusion of thiorphan into the hippocampus causes an accumulation of amyloid Beta and impairment of learning and memory. 2006 , 317, 334-40	36
1345	Therapeutic approaches to Alzheimer's disease. 2006 , 129, 2840-55	257
1344	Leaky scanning and reinitiation regulate BACE1 gene expression. 2006 , 26, 3353-64	71
1343	Down-regulation of endogenous amyloid precursor protein processing due to cellular aging. 2006 , 281, 2405-13	54
1342	GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing. 2006 , 26, 9913-22	55
1341	GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. 2006 , 26, 12838-46	68
1340	The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. 2006 , 26, 1596-603	224
1339	Enhanced amyloidogenic metabolism of the amyloid beta-protein precursor in the X11L-deficient mouse brain. 2006 , 281, 37853-60	43
1338	ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. 2006 , 20, 157-9	87
1337	Intra- or intercomplex binding to the gamma-secretase enzyme. A model to differentiate inhibitor classes. 2006 , 281, 31279-89	39
1336	BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. 2006 , 20, 1369-76	123
1335	Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. 2006 , 281, 14776-86	125

1334	Presenilin/gamma-secretase-mediated cleavage regulates association of leukocyte-common antigen-related (LAR) receptor tyrosine phosphatase with beta-catenin. 2007 , 282, 9063-72	42
1333	Accelerated Abeta deposition in APP ^{swe} /PS1 ^{deltaE9} mice with hemizygous deletions of TTR (transthyretin). 2007 , 27, 7006-10	108
1332	Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies. 2007 , 282, 18197-18205	146
1331	Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. 2007 , 282, 26326-34	238
1330	p53-Dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the integrity of the gamma-secretase complex but is independent of its activity. 2007 , 282, 10516-25	18
1329	Inhibition of familial cerebral amyloid angiopathy mutant amyloid beta-protein fibril assembly by myelin basic protein. 2007 , 282, 9952-9961	21
1328	RNA interference silencing of the adaptor molecules ShcC and Fe65 differentially affect amyloid precursor protein processing and Abeta generation. 2007 , 282, 4318-4325	43
1327	Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. 2007 , 27, 3639-49	286
1326	Regulation of heparan sulfate 6-O-sulfation by beta-secretase activity. 2007 , 282, 14942-51	12
1325	HtrA2 regulates beta-amyloid precursor protein (APP) metabolism through endoplasmic reticulum-associated degradation. 2007 , 282, 28285-95	48
1324	Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway. 2007 , 21, 2742-52	61
1323	Hypoxia-inducible factor 1 alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. 2007 , 282, 10873-80	285
1322	The membrane topology of RTN3 and its effect on binding of RTN3 to BACE1. 2007 , 282, 29144-51	32
1321	Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry. 2007 , 320, 1144-52	19
1320	Beta-galactoside alpha2,6-sialyltransferase I cleavage by BACE1 enhances the sialylation of soluble glycoproteins. A novel regulatory mechanism for alpha2,6-sialylation. 2007 , 282, 34896-903	42
1319	Traumatic brain injury and Alzheimer's disease: a review. 2007 , 161, 303-16	147
1318	Aspartic proteases in drug discovery. 2007 , 13, 271-85	112
1317	Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. 2007 , 4, 191-7	284

1316	Memapsin 2 (beta-secretase) inhibitor drug, between fantasy and reality. 2007 , 4, 418-22	30
1315	The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease. 2007 , 8, 509-30	67
1314	Current therapeutic options for Alzheimer's disease. 2007 , 8, 550-8	42
1313	New advances in Alzheimer's disease: from biology to therapy. 2007 , 8, 484-5	1
1312	How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARN" model (latent early-life associated regulation) may explain the triggering of AD. 2007 , 4, 219-28	111
1311	Molecular and cellular mechanisms for Alzheimer's disease: understanding APP metabolism. 2007 , 7, 687-96	64
1310	Complex translational regulation of BACE1 involves upstream AUGs and stimulatory elements within the 5' untranslated region. 2007 , 35, 2975-85	51
1309	BACE inhibitors as potential therapeutics for Alzheimer's disease. 2007 , 2, 188-99	21
1308	BACE1 and mutated presenilin-1 differently modulate Abeta40 and Abeta42 levels and cerebral amyloidosis in APPDutch transgenic mice. 2007 , 4, 127-35	18
1307	Amyloid precursor protein and presenilin involvement in cell signaling. 2007 , 4, 101-11	14
1306	A reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1. 2007 , 407, 383-95	94
1305	High-throughput screening by RNA interference: control of two distinct types of variance. 2007 , 6, 898-901	24
1304	Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production. 2007 , 27, 4052-60	87
1303	Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. 2007 , 104, 8167-72	101
1302	Cholesterol-like effects of selective cyclooxygenase inhibitors and fibrates on cellular membranes and amyloid-beta production. 2007 , 72, 141-51	30
1301	Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor. 2007 , 282, 16155-63	95
1300	Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. 2007 , 178, 829-41	299
1299	Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice. 2007 , 323, 102-8	10

1298	Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. 2007 , 282, 11982-95	113
1297	Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. 2007 , 27, 1682-91	148
1296	Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages. 2007 , 282, 35350-60	42
1295	Basic research for Alzheimer's disease drugs. 2007 , 130, 489-93	0
1294	Mild Cognitive Impairment. 2007 ,	
1293	Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease. 2007 , 30, 1-32	
1292	Oxidative stress and transcriptional regulation in Alzheimer disease. 2007 , 21, 276-91	115
1291	Therapeutic potential of amyloid degrading enzymes in Alzheimer's disease. 2007 , 2, 133-137	
1290	Maladie d'Alzheimer. 2007 , 4, 1-26	0
1289	Effects of peptides derived from BACE1 catalytic domain on APP processing. 2007 , 28, 838-44	9
1288	Spatial and temporal control of age-related APP processing in genomic-based beta-secretase transgenic mice. 2007 , 28, 75-84	14
1287	The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease. 2007 , 28, 1009-14	73
1286	No association of vacuolar protein sorting 26 polymorphisms with Alzheimer's disease. 2007 , 28, 883-4	8
1285	Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain. 2007 , 28, 1493-506	86
1284	Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. 2007 , 54, 721-37	300
1283	Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. 2007 , 56, 66-78	285
1282	Antisense inhibition at the beta-secretase-site of beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576. 2007 , 146, 143-51	29
1281	Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. 2007 , 6, 4433-9	113

1280	Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretion. 2007 , 352, 498-502	144
1279	Phosphorylation of APP695 at Thr668 decreases gamma-cleavage and extracellular Abeta. 2007 , 357, 1004-10	25
1278	Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. 2007 , 359, 46-50	80
1277	The c-Myb functions as a downstream target of PDGF-mediated survival signal in vascular smooth muscle cells. 2007 , 360, 433-6	16
1276	Visualization of beta-secretase cleavage in living cells using a genetically encoded surface-displayed [corrected] FRET probe. 2007 , 362, 25-30	14
1275	Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. 2007 , 208, 185-92	271
1274	Gamma-secretase: a complex target for Alzheimer's disease. 2007 , 7, 112-8	47
1273	Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. 2007 , 50, 12-38	114
1272	The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Abeta peptides. 2007 , 581, 1161-5	64
1271	Stable insertion of Alzheimer Abeta peptide into the ER membrane strongly correlates with its length. 2007 , 581, 3809-13	4
1270	Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. 2007 , 170, 680-92	283
1269	Links Between Amyloid and Tau Biology in Alzheimer's Disease and Their Cholinergic Aspects. 2007 , 597-656	2
1268	Metal Ions and Alzheimer's Disease. 2007 , 333-361	
1267	BACE1 expression and activity: relevance in Alzheimer's disease. 2007 , 4, 117-26	15
1266	A Brief Introduction to the History of the [A] of Alzheimer's Disease. 2007 , 1-4	
1265	Abeta Peptide and Alzheimer's Disease. 2007 ,	1
1264	Rat brain gamma-secretase activity is highly influenced by detergents. 2007 , 46, 7647-54	14
1263	Aspects of beta-amyloid as a biomarker for Alzheimer's disease. 2007 , 1, 59-78	65

1262	Autophagy, amyloidogenesis and Alzheimer disease. 2007 , 120, 4081-91	549
1261	Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase. 2007 , 50, 1124-32	141
1260	Statins reduce amyloid-beta production through inhibition of protein isoprenylation. 2007 , 282, 26832-26844	130
1259	Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. 2007 , 50, 776-81	102
1258	Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. 2007 , 50, 2399-407	85
1257	The genetics of Alzheimer's disease. 2007 , 22, 37-41	27
1256	Novel strategies for Alzheimer's disease treatment. 2007 , 7, 1853-67	22
1255	Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization. 2007 , 21, 3184-96	37
1254	Application of fragment screening by X-ray crystallography to beta-secretase. 2007 , 50, 1116-23	139
1253	Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. 2007 , 388, 247-52	37
1252	Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. 2007 , 282, 18895-906	94
1251	Alzheimer's disease and mild cognitive impairment. 2007 , 25, 577-609, v	184
1250	Morbo di Alzheimer. 2007 , 7, 1-26	
1249	Osteoimmunology. 2007 ,	1
1248	Genetics of Alzheimer's disease: a centennial review. 2007 , 25, 611-67, v	170
1247	Tyrosine 687 phosphorylated Alzheimer's amyloid precursor protein is retained intracellularly and exhibits a decreased turnover rate. 2007 , 4, 78-87	31
1246	Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. 2007 , 50, 5912-25	197
1245	Protein-protein interactions in the assembly and subcellular trafficking of the BACE (beta-site amyloid precursor protein-cleaving enzyme) complex of Alzheimer's disease. 2007 , 35, 974-9	16

1244 Alzheimer's Disease. **2007**,

1243 Retromer and sorting nexins in development. **2007**, 12, 3825-51

28

1242 Isoform specific amyloid-beta protein precursor metabolism. **2007**, 11, 85-95

17

1241 Genetically Engineered Animals. **2007**, 151-170

1240 Molecular genetics of Alzheimer's disease and other adult-onset dementias. 439-453

1239 IFN-gamma-induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT1 to BACE1 promoter in astrocytes. **2007**, 55, 253-62

87

1238 Ensemble-docking approach on BACE-1: pharmacophore perception and guidelines for drug design. **2007**, 2, 667-78

39

1237 beta-Secretase expression in normal and functionally deprived rat olfactory bulbs: inverse correlation with oxidative metabolic activity. **2007**, 501, 52-69

29

1236 Presenilin 1 is involved in the maturation of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). **2007**, 85, 153-65

24

1235 beta-amyloid precursor protein can be transported independent of any sorting signal to the axonal and dendritic compartment. **2007**, 85, 2580-90

29

1234 Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. **2007**, 85, 1194-204

156

1233 Synthesis and biological evaluation of phosphino dipeptide isostere inhibitor of human beta-secretase (BACE1). **2007**, 15, 4136-43

23

1232 Evaluating scoring functions for docking and designing beta-secretase inhibitors. **2007**, 17, 823-7

22

1231 Thiophene substituted acylguanidines as BACE1 inhibitors. **2007**, 17, 5353-6

55

1230 Development and characterization of beta-secretase monolithic micro-immobilized enzyme reactor for on-line high-performance liquid chromatography studies. **2007**, 1175, 217-26

28

1229 Characterization of a new antimentia Bsecretase inhibitory peptide from Saccharomyces cerevisiae. **2007**, 42, 83-88

23

1228 A novel monoclonal antibody specific for the amino-truncated beta-amyloid Abeta5-40/42 produced from caspase-cleaved amyloid precursor protein. **2007**, 161, 244-9

12

1227 Purification of recombinantly expressed and cytotoxic human amyloid-beta peptide 1-42. **2007**, 856, 229-33

13

1226	An AICD-based functional screen to identify APP metabolism regulators. 2007 , 2, 15	40
1225	The Alzheimer's disease beta-secretase enzyme, BACE1. 2007 , 2, 22	301
1224	BACE1 regulates voltage-gated sodium channels and neuronal activity. 2007 , 9, 755-64	244
1223	In search of partners: linking extracellular proteases to substrates. 2007 , 8, 245-57	293
1222	GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. 2007 , 26, 1702-12	232
1221	Patterns of gene expression in the limbic system of suicides with and without major depression. 2007 , 12, 640-55	154
1220	Intracellular amyloid-beta in Alzheimer's disease. 2007 , 8, 499-509	1474
1219	Receptor tyrosine kinases positively regulate BACE activity and Amyloid-beta production through enhancing BACE internalization. 2007 , 17, 389-401	29
1218	Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. 2007 , 100, 802-9	167
1217	A beta oligomers - a decade of discovery. 2007 , 101, 1172-84	1609
1216	The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. 2007 , 101, 854-62	46
1215	Regulated proteolytic processing of LRP6 results in release of its intracellular domain. 2007 , 101, 517-29	30
1214	Enhancement of alpha-secretase cleavage of amyloid precursor protein by a metalloendopeptidase nardilysin. 2007 , 102, 1595-1605	40
1213	Alzheimer's disease: the lipid connection. 2007 , 103 Suppl 1, 159-70	159
1212	A family of aspartic proteases and a novel, dynamic and cell-cycle-dependent protease localization in the secretory pathway of <i>Toxoplasma gondii</i> . 2007 , 8, 1018-34	38
1211	Contribution of CDP/Cux, a transcription factor, to cell cycle progression. 2007 , 39, 923-30	6
1210	Expression of APP pathway mRNAs and proteins in Alzheimer's disease. 2007 , 1161, 116-23	130
1209	Beta-secretase (BACE1)-inhibiting stilbenoids from <i>Smilax Rhizoma</i> . 2007 , 14, 403-8	69

1208	Intracellular pH regulates amyloid precursor protein intracellular domain accumulation. 2007 , 25, 686-96	61
1207	BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. 2007 , 26, 134-45	236
1206	Amyloid beta: Functional protein or biological junk?. 2007 , 1, 185-191	
1205	Fibrillar and oligomeric beta-amyloid as distinct local biomarkers for Alzheimer's disease. 2007 , 1097, 239-58	16
1204	The APP family of proteins: similarities and differences. 2007 , 35, 416-20	107
1203	Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of beta-amyloid. 2007 , 50, 3431-3	55
1202	Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. 2007 , 59, 332-45	257
1201	The molecular link between beta- and gamma-secretase activity on the amyloid beta precursor protein. 2007 , 64, 2211-8	44
1200	Solid Phase Synthesis of a Hydroxypyrrolidine Derivative and its Use in Solid Phase Peptide Synthesis as Constrained Statine Mimic. 2007 , 13, 337-343	3
1199	The study of Golgi apparatus in Alzheimer's disease. 2007 , 32, 1265-77	24
1198	Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease. 2007 , 113, 265-75	91
1197	Mechanisms of amyloid plaque pathogenesis. 2007 , 114, 551-71	80
1196	Neurodegeneration and Alzheimer's disease: the lesson from tauopathies. 2007 , 28, 63-71	49
1195	Tyr687 dependent APP endocytosis and Abeta production. 2007 , 32, 1-8	38
1194	Design of potent inhibitors of human beta-secretase. Part 1. 2007 , 17, 73-7	38
1193	Production, purification and functional validation of human secreted amyloid precursor proteins for use as neuropharmacological reagents. 2007 , 164, 68-74	18
1192	beta-Secretase as a therapeutic target for Alzheimer's disease. 2008 , 5, 399-408	158
1191	Nicotine leads to improvements in behavioral impairment and an increase in the nicotine acetylcholine receptor in transgenic mice. 2008 , 33, 1783-8	20

1190	Understanding BACE1: essential protease for amyloid-beta production in Alzheimer's disease. 2008 , 65, 3265-89	70
1189	Copper transport and Alzheimer's disease. 2008 , 37, 295-300	47
1188	Identification of AOSC-binding proteins in neurons. 2008 , 26, 394-399	4
1187	[Alzheimer's disease. Molecular pathology, animal models, and current treatment]. 2008 , 79 Suppl 3, 117-25; quiz 126-7	1
1186	The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer's disease. 2008 , 8, 384-91	30
1185	Beta-secretase (BACE1) inhibitors from <i>Perilla frutescens</i> var. <i>acuta</i> . 2008 , 31, 183-7	46
1184	Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. 2008 , 10, 195-207	28
1183	Protein expression of BACE1, BACE2 and APP in Down syndrome brains. 2008 , 35, 339-43	63
1182	Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease. 2008 , 9, 381-9	51
1181	Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. 2008 , 115, 599-609	240
1180	Oxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein. 2008 , 3, 5	26
1179	Differential effects of unaggregated and aggregated amyloid beta protein (1-40) on K(+) channel currents in primary cultures of rat cerebellar granule and cortical neurones. 2001 , 79, 699-712	59
1178	Neuregulin-1, a key axonal signal that drives Schwann cell growth and differentiation. 2008 , 56, 1491-7	182
1177	Design of potent aspartic protease inhibitors to treat various diseases. 2008 , 341, 523-35	49
1176	The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo. 2008 , 64, 618-27	243
1175	Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. 2008 , 5, 381-90	17
1174	BACE1 inhibitory effects of lavandulyl flavanones from <i>Sophora flavescens</i> . 2008 , 16, 6669-74	44
1173	BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs). 2008 , 18, 1011-6	40

1172	Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. 2008 , 18, 1031-6	81
1171	Novel non-peptidic and small-sized BACE1 inhibitors. 2008 , 18, 1643-7	40
1170	BACE1 inhibitors: optimization by replacing the P1' residue with non-acidic moiety. 2008 , 18, 1649-53	34
1169	Synthesis, SAR, and X-ray structure of human BACE-1 inhibitors with cyclic urea derivatives. 2008 , 18, 2900-4	21
1168	Pharmacogenomics in Alzheimer's disease. 2008 , 448, 213-357	72
1167	Targeted proteomics in Alzheimer's disease: focus on amyloid-beta. 2008 , 5, 225-37	43
1166	Animal models of Alzheimer's disease and frontotemporal dementia. 2008 , 9, 532-44	535
1165	Regulatory RNA goes awry in Alzheimer's disease. 2008 , 14, 711-2	7
1164	Imatinib buys time for brain after stroke. 2008 , 14, 712-3	15
1163	The Yin and Yang of YY1 in the nervous system. 2008 , 106, 1493-502	88
1162	Temporal correlation of the memory deficit with Alzheimer-like lesions induced by activation of glycogen synthase kinase-3. 2008 , 106, 2364-74	29
1161	Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling. 2008 , 7, 137-47	57
1160	Increased AICD generation does not result in increased nuclear translocation or activation of target gene transcription. 2008 , 314, 2419-33	38
1159	Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. 2008 , 29, 507-19	201
1158	Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice. 2008 , 9, 109	66
1157	Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. 2008 , 1214, 177-87	338
1156	Fatty acids, lipid metabolism and Alzheimer pathology. 2008 , 585, 176-96	71
1155	[3H]BMS-599240--a novel tritiated ligand for the characterization of BACE1 inhibitors. 2008 , 593, 10-5	7

1154	The ubiquitin-proteasome system in Alzheimer's disease. 2008 , 12, 363-73	178
1153	microRNAs: tiny regulators of synapse function in development and disease. 2008 , 12, 1466-76	59
1152	Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. 2008 , 12, 1848-62	90
1151	The molecular pathology of Alzheimer's disease. 2008 , 7, 1-5	18
1150	Homer2 and Homer3 interact with amyloid precursor protein and inhibit Abeta production. 2008 , 30, 353-364	26
1149	Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Abeta toxicity. 2008 , 31, 145-58	25
1148	Caspase inhibition attenuates accumulation of beta-amyloid by reducing beta-secretase production and activity in rat brains after stroke. 2008 , 32, 433-41	30
1147	Interactions between APP secretases and inflammatory mediators. 2008 , 5, 25	127
1146	Kinetic properties of cathepsin D and BACE 1 indicate the need to search for additional beta-secretase candidate(s). 2008 , 389, 313-20	25
1145	Pharmacogenomics in drug discovery and development. Preface. 2008 , 448, v-vii	5
1144	Hair Cell Regeneration, Repair, and Protection. 2008 ,	7
1143	Central Nervous System Diseases and Inflammation. 2008 ,	5
1142	Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease. 2008 , 14, 54-62	83
1141	Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders. 2008 , 52, 184-215	23
1140	Calcium dysregulation in Alzheimer's disease. 2008 , 52, 621-33	147
1139	The effect of stress on the expression of the amyloid precursor protein in rat brain. 2008 , 431, 197-200	12
1138	Cathepsin D expression is decreased in Alzheimer's disease fibroblasts. 2008 , 29, 12-22	48
1137	Activation of protein kinase C modulates BACE1-mediated beta-secretase activity. 2008 , 29, 357-67	22

1136	Platelet beta-secretase activity is increased in Alzheimer's disease. 2008 , 29, 661-8	59
1135	BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease. 2008 , 29, 861-73	89
1134	Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells. 2008 , 29, 969-80	45
1133	Aging of the brain, neurotrophin signaling, and Alzheimer's disease: is IGF1-R the common culprit?. 2008 , 29, 795-811	68
1132	Interaction between the APOE epsilon4 allele and the APH-1b c + 651T > G SNP in Alzheimer's disease. 2008 , 29, 1494-501	4
1131	Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. 2008 , 58, 42-51	455
1130	Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. 2008 , 57, 680-90	162
1129	Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. 2008 , 60, 988-1009	324
1128	The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. 2008 , 85, 393-406	176
1127	PI3-K- and PKC-dependent up-regulation of APP processing enzymes by retinoic acid. 2008 , 365, 298-303	23
1126	In vitro reconstitution of gamma-secretase activity using yeast microsomes. 2008 , 377, 141-5	28
1125	Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. 2008 , 89, 245-60	100
1124	Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability. 2008 , 51, 3313-7	54
1123	Perspectives of Alzheimer's disease treatments. 2008 , 89, 273-90	1
1122	Phosphoinositides suppress gamma-secretase in both the detergent-soluble and -insoluble states. 2008 , 283, 19283-92	35
1121	NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. 2008 , 283, 10037-47	105
1120	Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. 2008 , 283, 7745-53	147
1119	Proteolytic shedding of ST6Gal-I by BACE1 regulates the glycosylation and function of alpha4beta1 integrins. 2008 , 283, 26364-73	54

1118	Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels. 2008 , 283, 11302-11	82
1117	ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. 2008 , 49, 1254-67	45
1116	Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases. 2008 , 389, 1055-66	27
1115	BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. 2008 , 28, 8677-81	86
1114	Intracellular copper deficiency increases amyloid-beta secretion by diverse mechanisms. 2008 , 412, 141-52	69
1113	Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. 2008 , 131, 1252-8	99
1112	Association of BACE1 gene polymorphism with Alzheimer's disease in Asian populations: meta-analysis including Korean samples. 2008 , 25, 165-9	15
1111	Crystal structure of an active form of BACE1, an enzyme responsible for amyloid beta protein production. 2008 , 28, 3663-71	131
1110	Molecular genetics of Alzheimer's disease: an update. 2008 , 40, 562-83	175
1109	Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. 2008 , 28, 11622-34	198
1108	Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. 2008 , 22, 1469-78	205
1107	A novel sorting nexin modulates endocytic trafficking and alpha-secretase cleavage of the amyloid precursor protein. 2008 , 283, 14257-68	61
1106	The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. 2008 , 283, 29621-5	171
1105	Abeta46 is processed to Abeta40 and Abeta43, but not to Abeta42, in the low density membrane domains. 2008 , 283, 733-8	40
1104	Altered function of factor I caused by amyloid beta: implication for pathogenesis of age-related macular degeneration from Drusen. 2008 , 181, 712-20	64
1103	Promotion of BACE1 mRNA alternative splicing reduces amyloid beta-peptide production. 2008 , 283, 18694-701	34
1102	Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. 2008 , 283, 7733-44	110
1101	Intracellular amyloid beta-protein as a therapeutic target for treating Alzheimer's disease. 2008 , 5, 555-61	34

1100	BACE1 structure and function in health and Alzheimer's disease. 2008 , 5, 100-20	75
1099	Epsilon-secretase: reduction of amyloid precursor protein epsilon-site cleavage in Alzheimer's disease. 2008 , 5, 165-71	16
1098	Memapsin 2 (beta-secretase) inhibitors: drug development. 2008 , 5, 121-31	51
1097	The catalytic core of gamma-secretase: presenilin revisited. 2008 , 5, 147-57	32
1096	In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. 2008 , 324, 957-69	95
1095	Functional role of lipoprotein receptors in Alzheimer's disease. 2008 , 5, 15-25	106
1094	Beta-secretase: structure, function, and evolution. 2008 , 7, 278-94	69
1093	LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. 2008 , 88, 887-918	499
1092	Influence of Selected Natural Products on Neutral Endopeptidase Activity and β Amyloid Production in SK-N-SH Cells. 2008 , 46, 425-432	7
1091	Gamma-secretase inhibition and modulation for Alzheimer's disease. 2008 , 5, 158-64	54
1090	From presenilinase to gamma-secretase, cleave to capacitase. 2008 , 5, 172-8	17
1089	Processing of amyloid precursor protein and amyloid peptide neurotoxicity. 2008 , 5, 92-9	50
1088	Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. 2008 , 389, 993-1006	52
1087	Mouse models of Alzheimer's dementia: current concepts and new trends. 2008 , 149, 5952-7	26
1086	The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism. 2008 , 131, 90-108	148
1085	Membrane microdomain switching: a regulatory mechanism of amyloid precursor protein processing. 2008 , 183, 339-52	55
1084	The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. 2008 , 105, 13145-50	482
1083	The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. 2008 , 28, 1213-23	642

1082	Homophilic interactions of the amyloid precursor protein (APP) ectodomain are regulated by the loop region and affect beta-secretase cleavage of APP. 2008 , 283, 7271-9	77
1081	Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. 2008 , 22, 2970-80	148
1080	Ginkgo biloba extract and its flavonol and terpenelactone fractions do not affect beta-secretase mRNA and enzyme activity levels in cultured neurons and in mice. 2008 , 74, 6-13	8
1079	In vitro BACE-1 inhibitory phenolic components from the seeds of Psoralea corylifolia. 2008 , 74, 1405-8	68
1078	BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells. 2008 , 32, 246-51	12
1077	Inhibition of cytotoxicity and amyloid fibril formation by a D-amino acid peptide that specifically binds to Alzheimer's disease amyloid peptide. 2008 , 21, 241-6	60
1076	A rescue factor for Alzheimer's diseases: discovery, activity, structure, and mechanism. 2008 , 15, 2086-98	29
1075	Similar mechanisms regulated by gamma-secretase are involved in both directions of the bi-directional Notch-Delta signaling pathway as well as play a potential role in signaling events involving type 1 transmembrane proteins. 2008 , 3, 288-302	7
1074	GENETICS OF DEMENTIA. 2008 , 14, 29-48	
1073	Large-Scale Screens for cDNAs with in vivo Activity. 2008 , 219-230	1
1072	Alzheimer's Disease, Diagnosis and the Need for Biomarkers. 2008 , 3, 317-323	9
1071	An update on the toxicity of Abeta in Alzheimer's disease. 2008 , 4, 1033-42	28
1070	Molecular Aspects of Memory Dysfunction in Alzheimer's Disease. 2008 , 245-293	3
1069	Induction of amyloid beta accumulation by ER calcium disruption and resultant upregulation of angiogenic factors in ARPE19 cells. 2008 , 49, 2376-83	22
1068	La maladie d'Alzheimer : aspects cellulaires et moléculaires. 2008 , 192, 323-332	0
1067	Mitochondria, cognitive impairment, and Alzheimer's disease. 2009 , 2009,	34
1066	Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides. 2009 , 18, 295-303	25
1065	Computational insights into the development of novel therapeutic strategies for Alzheimer's disease. 2009 , 1, 119-35	3

1064	Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts under cellular copper deficiency conditions: implications for Alzheimer disease. 2009 , 284, 21899-21907	48
1063	Intracellular trafficking of presenilin 1 is regulated by beta-amyloid precursor protein and phospholipase D1. 2009 , 284, 12145-52	31
1062	Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. 2009 , 106, 381-6	227
1061	Reduced amyloid deposition in mice overexpressing RTN3 is adversely affected by preformed dystrophic neurites. 2009 , 29, 9163-73	48
1060	Alcadein cleavages by amyloid beta-precursor protein (APP) alpha- and gamma-secretases generate small peptides, p3-Alcs, indicating Alzheimer disease-related gamma-secretase dysfunction. 2009 , 284, 36024-36033	34
1059	Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity. 2009 , 29, 4640-51	79
1058	Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts. 2009 , 284, 3793-803	119
1057	Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. 2009 , 23, 3315-24	166
1056	Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. 2009 , 6, 87-94	59
1055	Epigenetic control of aquaporin 1 expression by the amyloid precursor protein. 2009 , 23, 4158-67	44
1054	Differential processing of amyloid-beta precursor protein directs human embryonic stem cell proliferation and differentiation into neuronal precursor cells. 2009 , 284, 23806-17	52
1053	Regulation of prion gene expression by transcription factors SP1 and metal transcription factor-1. 2009 , 284, 1291-301	51
1052	MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. 2009 , 284, 1971-81	243
1051	Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease. 2009 , 6, 258-62	25
1050	Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease. 2009 , 15, 3644-55	83
1049	Neuronal protein trafficking associated with Alzheimer disease: from APP and BACE1 to glutamate receptors. 2009 , 3, 118-28	53
1048	Are circulating monocytes as microglia orthologues appropriate biomarker targets for neuronal diseases?. 2009 , 9, 307-30	28
1047	Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury. 2009 , 110, 1227-37	113

1046	Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer's disease. 2009 , 16, 1806-20	46
1045	New perspectives for the diagnosis of Alzheimer's disease. 2009 , 4, 160-81	11
1044	A new specific BACE-1 inhibitor from the stem bark extract of <i>Vitis vinifera</i> . 2009 , 75, 537-40	31
1043	Ginsenoside Rg1 inhibits beta-secretase activity in vitro and protects against A β -induced cytotoxicity in PC12 cells. 2009 , 11, 604-12	53
1042	Molecular insights into beta-galactoside alpha2,6-sialyltransferase secretion in vivo. 2009 , 19, 479-87	35
1041	The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. 2009 , 6, 213-23	107
1040	Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. 2009 , 23, 3819-28	45
1039	Induced dimerization of the amyloid precursor protein leads to decreased amyloid-beta protein production. 2009 , 284, 28943-52	71
1038	A β APP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis. 2009 , 29, 5666-70	34
1037	BRI3 inhibits amyloid precursor protein processing in a mechanistically distinct manner from its homologue dementia gene BRI2. 2009 , 284, 15815-25	39
1036	Novel role of RanBP9 in BACE1 processing of amyloid precursor protein and amyloid beta peptide generation. 2009 , 284, 11863-72	66
1035	Accurate determination of carboxyl-terminal fragment of presenilin 1 in various tissues from rat and cell lines. 2009 , 146, 141-8	
1034	Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. 2009 , 122, 3703-14	99
1033	MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. 2009 , 33, 422-8	319
1032	Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. 2009 , 34, 525-34	107
1031	Focal cerebral ischemia in rats alters APP processing and expression of A β peptide degrading enzymes in the thalamus. 2009 , 35, 103-13	57
1030	ErbB receptors and the development of the nervous system. 2009 , 315, 611-8	99
1029	Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production. 2009 , 13, 574-88	105

1028	Membrane-targeted strategies for modulating APP and Abeta-mediated toxicity. 2009 , 13, 249-61	3
1027	Calcium in the initiation, progression and as an effector of Alzheimer's disease pathology. 2009 , 13, 2787-99	40
1026	Lack of association between the polymorphisms of beta-site APP-cleaving enzyme 2 (BACE2) 5'-flanking region and sporadic Alzheimer's disease. 2009 , 1257, 10-5	6
1025	Die Alzheimer-Demenz: von der Pathologie zu therapeutischen Ansätzen. 2009 , 121, 3074-3105	37
1024	Combinatorial library synthesis and biological evaluation of pyrazolo[4,3-e][1,4]diazepine as a potential privileged structure. 2009 , 4, 733-7	13
1023	Structure and modeling in the design of β and β secretase inhibitors. 2009 , 70, 70-93	21
1022	Amyloid-beta up-regulates complement factor B in retinal pigment epithelial cells through cytokines released from recruited macrophages/microglia: Another mechanism of complement activation in age-related macular degeneration. 2009 , 220, 119-28	80
1021	The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system. 2009 , 1, 223-35	63
1020	Inhibition by KMI-574 leads to dislocalization of BACE1 from lipid rafts. 2009 , 87, 360-8	13
1019	Intracellular sAPP retention in response to Abeta is mapped to cytoskeleton-associated structures. 2009 , 87, 1449-61	19
1018	The two-hydrophobic domain tertiary structure of reticulon proteins is critical for modulation of beta-secretase BACE1. 2009 , 87, 2963-72	11
1017	Alzheimer's disease: from pathology to therapeutic approaches. 2009 , 48, 3030-59	467
1016	Alzheimer Mechanismen und therapeutische Ansätze. Warum wir im Alter dement werden. 2009 , 39, 92-100	
1015	Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease. 2009 , 247, 1213-21	109
1014	Interaction models of substrate peptides and beta-secretase studied by NMR spectroscopy and molecular dynamics simulation. 2009 , 27, 651-6	7
1013	Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 2009 , 116, 1169-78	22
1012	Formation of amyloid-beta oligomers in brain vascular smooth muscle cells transiently exposed to iron-induced oxidative stress. 2009 , 117, 557-67	21
1011	S655 phosphorylation enhances APP secretory traffic. 2009 , 328, 145-54	39

1010	Oligodendrocytes are a novel source of amyloid peptide generation. 2009 , 34, 2243-50	21
1009	Glycoconjugate glycosyltransferases. 2009 , 26, 987-98	2
1008	Mitochondria and Alzheimer's disease: amyloid-beta peptide uptake and degradation by the presequence protease, hPreP. 2009 , 41, 447-51	39
1007	Alphabeta hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures. 2009 , 39, 248-55	18
1006	Role of synucleins in Alzheimer's disease. 2009 , 16, 306-17	59
1005	Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors. 2009 , 66, 2299-318	92
1004	Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. 2001 , 76, 173-81	701
1003	Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. 2009 , 4, 1	128
1002	The interactome of the amyloid beta precursor protein family members is shaped by phosphorylation of their intracellular domains. 2009 , 4, 28	62
1001	Expression of reticulon 3 in Alzheimer's disease brain. 2009 , 35, 178-88	18
1000	The LEARN model: an epigenetic explanation for idiopathic neurobiological diseases. 2009 , 14, 992-1003	165
999	Real-time monitoring of enzyme activity in a mesoporous silicon double layer. 2009 , 4, 255-8	171
998	Cell biology, regulation and inhibition of beta-secretase (BACE-1). 2009 , 276, 1845-59	54
997	An E3 ubiquitin ligase, Synoviolin, is involved in the degradation of immature nicastrin, and regulates the production of amyloid beta-protein. 2009 , 276, 5832-40	13
996	Analysis of the nicastrin promoter rs10752637 polymorphism and its association with Alzheimer's disease. 2009 , 30, 1831-6	8
995	A novel reciprocal and biphasic relationship between membrane cholesterol and beta-secretase activity in SH-SY5Y cells and in human platelets. 2009 , 108, 341-9	33
994	Enhanced generation of Alzheimer's amyloid-beta following chronic exposure to phorbol ester correlates with differential effects on alpha and epsilon isozymes of protein kinase C. 2009 , 108, 319-30	31
993	The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. 2009 , 108, 1045-56	186

992	Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. 2009 , 109, 248-56	86
991	Identification of a cis-acting element involved in the regulation of BACE1 mRNA alternative splicing. 2009 , 109, 1008-16	6
990	Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity. 2009 , 110, 275-83	14
989	Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. 2009 , 110, 697-706	108
988	Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. 2009 , 110, 1377-87	20
987	alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Abeta generation. 2009 , 111, 1369-82	51
986	Significance of interactions of BACE1-Arg235 with its ligands and design of BACE1 inhibitors with P2 pyridine scaffold. 2009 , 19, 2435-9	32
985	Synthesis and evaluation of a new class of tertiary alcohol based BACE-1 inhibitors. 2009 , 65, 10047-10059	12
984	Alzheimer's disease: new approaches to drug discovery. 2009 , 13, 303-8	100
983	Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta. 2009 , 17, 8102-12	10
982	Molecular modeling, synthesis, and activity studies of novel biaryl and fused-ring BACE1 inhibitors. 2009 , 19, 264-74	14
981	Structure-based design and synthesis of macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors. 2009 , 19, 1361-5	34
980	Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo. 2009 , 19, 1366-70	51
979	Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics. 2009 , 19, 3664-8	41
978	Prolonged stability by cyclization: Macrocyclic phosphino dipeptide isostere inhibitors of beta-secretase (BACE1). 2009 , 19, 4427-31	16
977	Measurement of cellular beta-site of APP cleaving enzyme 1 activity and its modulation in neuronal assay systems. 2009 , 387, 208-20	6
976	Development of sandwich enzyme-linked immunosorbent assay systems for plasma beta-galactoside alpha2,6-sialyltransferase, a possible hepatic disease biomarker. 2009 , 631, 116-20	9
975	Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors. 2009 , 52, 6314-23	102

974	Elucidation of O-glycosylation structures of the beta-amyloid precursor protein by liquid chromatography-mass spectrometry using electron transfer dissociation and collision induced dissociation. 2009 , 8, 631-42	107
973	An NSAID-like compound, FT-9, preferentially inhibits gamma-secretase cleavage of the amyloid precursor protein compared to its effect on amyloid precursor-like protein 1. 2009 , 48, 10894-904	7
972	Intramembrane proteolysis. 2009 , 109, 1599-612	106
971	Hybrid structure-based virtual screening protocol for the identification of novel BACE1 inhibitors. 2009 , 49, 647-57	24
970	Liquid crystal multiplexed protease assays reporting enzymatic activities as optical bar charts. 2009 , 81, 5503-9	49
969	Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. 2009 , 1790, 615-28	72
968	The unsolved relationship of brain aging and late-onset Alzheimer disease. 2009 , 1790, 1124-32	64
967	The interaction of beta-amyloid protein with cellular membranes stimulates its own production. 2009 , 1788, 964-72	69
966	Calcium enhances the proteolytic activity of BACE1: An in vitro biophysical and biochemical characterization of the BACE1-calcium interaction. 2009 , 1788, 1933-8	33
965	Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. 2009 , 386, 284-8	74
964	Splicing of intron 3 of human BACE requires the flanking introns 2 and 4. 2009 , 388, 434-8	1
963	Alzheimer's disease and Notch signaling. 2009 , 390, 1093-7	96
962	Linking vascular disorders and Alzheimer's disease: potential involvement of BACE1. 2009 , 30, 1535-44	30
961	PSEN1 polymorphisms alter the rate of cognitive decline in sporadic Alzheimer's disease patients. 2009 , 30, 1992-9	13
960	Exacerbation of poststroke dementia by type 2 diabetes is associated with synergistic increases of beta-secretase activation and beta-amyloid generation in rat brains. 2009 , 161, 1045-56	51
959	Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. 2009 , 20, 191-200	91
958	Function, regulation and therapeutic properties of beta-secretase (BACE1). 2009 , 20, 175-82	65
957	Capsaicin promotes the amyloidogenic route of brain amyloid precursor protein processing. 2009 , 54, 426-30	15

956	Oxidative stress promotes JNK-dependent amyloidogenic processing of normally expressed human APP by differential modification of alpha-, beta- and gamma-secretase expression. 2009 , 55, 662-70	69
955	Clathrin-mediated endocytosis and Alzheimer's disease: an update. 2009 , 8, 147-9	61
954	CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia. 2009 , 283, 109-15	62
953	[Morphologic and molecular neuropathology of Alzheimer's disease]. 2009 , 67, 127-35	3
952	Progress in the development of beta-secretase inhibitors for Alzheimer's disease. 2009 , 48, 133-61	31
951	Aging of the Brain and Alzheimer's Disease. 2009 , 187-195	3
950	Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. 2009 , 69, 8-12	52
949	Computational insights into aspartyl protease activity of presenilin 1 (PS1) generating Alzheimer amyloid beta-peptides (Abeta40 and Abeta42). 2009 , 113, 2990-9	32
948	Platelet alpha- and beta-secretase activities: A preliminary study in normal human subjects. 2009 , 20, 29-34	8
947	Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease. 2009 , 52, 2163-76	41
946	Secretase inhibitors and modulators for Alzheimer's disease treatment. 2009 , 9, 661-79	110
945	Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. 2009 , 26, 537-55	67
944	Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. 2009 , 15, 448-54	52
943	The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. 2009 , 29, 12787-94	418
942	Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein. 2009 , 21, 386-406	35
941	RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. 2009 , 23, 2639-49	94
940	Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-alpha. 2009 , 87, 581-93	41
939	Recent progress in the drug discovery of non-peptidic BACE1 inhibitors. 2009 , 4, 391-416	47

938	Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease. 2009 , 69, 18-21	6
937	microRNA involvement in developmental and functional aspects of the nervous system and in neurological diseases. 2009 , 466, 55-62	89
936	A potential role for alterations of zinc and zinc transport proteins in the progression of Alzheimer's disease. 2009 , 16, 471-83	63
935	Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. 2009 , 16, 211-24	57
934	Large scale refolding and purification of the catalytic domain of human BACE-2 produced in E. coli. 2009 , 16, 121-31	5
933	Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics. 2009 , 9, 1688-704	6
932	The high pH and pH-shift refolding technology. 2010 , 11, 293-9	3
931	Biogenesis and regulation of microRNA: implication in Alzheimer's disease. 2010 , 5, 839-850	2
930	Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer's disease. 2010 , 22, 631-9	92
929	Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. 2010 , 20 Suppl 1, S127-41	80
928	Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. 2010 , 20, 637-46	54
927	Do amyloid-associated factors co-deposit with A β in mouse models for Alzheimer's disease?. 2010 , 22, 345-55	13
926	Magnesium modulates amyloid-beta protein precursor trafficking and processing. 2010 , 20, 1091-106	40
925	Approaches to Amyloid Therapies for the Treatment of Alzheimer's Disease. 2010 , 329-404	
924	The enhancement of amyloid precursor protein and beta-site amyloid cleavage enzyme 1 interaction: amyloid-beta production with aging. 2010 , 25, 401-7	10
923	Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. 2010 , 19, 1007-19	106
922	Synthesis and preliminary evaluation of peptidomimetic inhibitors of human beta-secretase. 2010 , 45, 2089-94	1
921	Design of pentapeptidic BACE1 inhibitors with carboxylic acid bioisosteres at P1' and P4 positions. 2010 , 18, 3175-86	23

920	Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. 2010 , 119, 523-41	267
919	Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. 2010 , 120, 185-93	226
918	Copper in the brain and Alzheimer's disease. 2010 , 15, 61-76	330
917	APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis. 2010 , 214, 111-26	80
916	In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model. 2010 , 39, 1571-80	20
915	Regulation of β cleavage of amyloid precursor protein. 2010 , 26, 417-27	9
914	An overview of APP processing enzymes and products. 2010 , 12, 1-12	386
913	BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease. 2010 , 42, 127-33	13
912	Rationalizing fragment based drug discovery for BACE1: insights from FB-QSAR, FB-QSSR, multi objective (MO-QSPR) and MIF studies. 2010 , 24, 843-64	36
911	A nonhuman primate model of Alzheimer's disease generated by intracranial injection of amyloid- β 2 and thiorphan. 2010 , 25, 277-84	16
910	Comparative molecular field analysis and comparative molecular similarity indices analysis of hydroxyethylamine derivatives as selective human BACE-1 inhibitor. 2010 , 14, 39-49	17
909	BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis. 2010 , 35, 181-210	34
908	High-level expression of a human β site APP cleaving enzyme in transgenic tobacco chloroplasts and its immunogenicity in mice. 2010 , 19, 1099-108	17
907	gamma-secretases: from cell biology to therapeutic strategies. 2010 , 9, 215-26	136
906	Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological A β species: relevance for immunotherapy. 2010 , 229, 248-55	12
905	Indirubin-3'-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer's disease. 2010 , 39, 156-68	45
904	Searching for new animal models of Alzheimer's disease. 2010 , 626, 57-63	36
903	Amyloid beta and APP as biomarkers for Alzheimer's disease. 2010 , 45, 23-9	88

902	Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. 2010 , 45, 5-14	103
901	Effects of galantamine on β -amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells. 2010 , 45, 842-7	21
900	Protein secretion: unconventional exit by exophagy. 2010 , 20, R415-8	49
899	Vesicle transport: a new player in APP trafficking. 2010 , 20, R413-5	12
898	The organellar peptidasome, PreP: a journey from Arabidopsis to Alzheimer's disease. 2010 , 1797, 1076-80	20
897	MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases. 2010 , 1338, 58-66	59
896	Ameliorative effects of a non-competitive BACE1 inhibitor TAK-070 on A β peptide levels and impaired learning behavior in aged rats. 2010 , 1361, 146-56	18
895	Syntheses of Two Potential Ligands for Tc-99m Labeling as Diagnosis Agents of Alzheimer's Disease. 2010 , 21, 824-832	3
894	Alzheimer Disease: Protein Misfolding, Model Systems, and Experimental Therapeutics. 2010 , 231-258	1
893	Current and Future Therapies for Alzheimer Disease. 2010 , 711-774	
892	Structural design, solid-phase synthesis and activity of membrane-anchored β -secretase inhibitors on A β generation from wild-type and Swedish-mutant APP. 2010 , 16, 14412-23	21
891	RTN/Nogo in forming Alzheimer's neuritic plaques. 2010 , 34, 1201-6	20
890	Binding of beta-secretase to a peptide inhibitor-carrying SAM. 2010 , 78, 155-62	2
889	Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors. 2010 , 20, 2068-73	36
888	Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core. 2010 , 45, 870-82	18
887	Design and synthesis of 1,4-dihydropyridine derivatives as BACE-1 inhibitors. 2010 , 45, 2578-90	26
886	BACE1 ^{-/-} mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. 2010 , 5, 31	71
885	BACE1 gene variants do not influence BACE1 activity, levels of APP or A β isoforms in CSF in Alzheimer's disease. 2010 , 5, 37	4

884	Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated. 2010 , 5, 40	100
883	Tetrapeptides, as small-sized peptidic inhibitors; synthesis and their inhibitory activity against BACE1. 2010 , 16, 257-62	3
882	Pharmacology of epigenetics in brain disorders. 2010 , 159, 285-303	47
881	BACE1 and BACE2 enzymatic activities in Alzheimer's disease. 2010 , 112, 1045-53	79
880	Glycosaminoglycan-induced activation of the beta-secretase (BACE1) of Alzheimer's disease. 2010 , 112, 1552-61	23
879	Abeta promotes Alzheimer's disease-like cytoskeleton abnormalities with consequences to APP processing in neurons. 2010 , 113, 761-71	48
878	2,2',4'-trihydroxychalcone from Glycyrrhiza glabra as a new specific BACE1 inhibitor efficiently ameliorates memory impairment in mice. 2010 , 114, 374-85	43
877	SCFFbx2-E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function. 2010 , 9, 1018-31	64
876	Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2. 2010 , 9, 160-72	19
875	Animal models of amyloid-beta-related pathologies in Alzheimer's disease. 2010 , 277, 1389-409	74
874	beta-Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. 2010 , 277, 1503-18	21
873	An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production. 2010 , 17, 151-8	68
872	The development of new therapeutics for Alzheimer's disease. 2010 , 88, 475-86	80
871	A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis. 2010 , 20, 138-53	70
870	ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. 2010 , 29, 3020-32	429
869	Mutant ubiquitin-mediated beta-secretase stability via activation of caspase-3 is related to beta-amyloid accumulation in ischemic striatum in rats. 2010 , 30, 566-75	18
868	Protein aggregation diseases: pathogenicity and therapeutic perspectives. 2010 , 9, 237-48	534
867	The turn formation at positions 22 and 23 in the 42-mer amyloid beta peptide: the emerging role in the pathogenesis of Alzheimer's disease. 2010 , 10 Suppl 1, S169-79	17

866	. 2010 ,	4
865	Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. 2010 , 2, 8	126
864	gamma-Secretase dependent production of intracellular domains is reduced in adult compared to embryonic rat brain membranes. 2010 , 5, e9772	7
863	Immunomodulation of APP processing alleviates amyloid- β -related pathology in Alzheimer's disease transgenic mice. 2010 , 22, 469-82	6
862	Converging pathways of chromogranin and amyloid metabolism in the brain. 2010 , 20, 1039-49	17
861	Amyloid-Beta Peptide, Oxidative Stress and Inflammation in Alzheimer's Disease: Potential Neuroprotective Effects of Omega-3 Polyunsaturated Fatty Acids. 2010 , 2010, 1-10	16
860	Amyloid- β production via cleavage of amyloid- β protein precursor is modulated by cell density. 2010 , 22, 683-984	19
859	Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. 2010 , 391, 861-72	31
858	beta-Secretase inhibitor potency is decreased by aberrant beta-cleavage location of the "Swedish mutant" amyloid precursor protein. 2010 , 285, 1634-42	32
857	Ubiquitin regulates GGA3-mediated degradation of BACE1. 2010 , 285, 24108-19	81
856	Applications of molecular imaging. 2010 , 95, 237-98	16
855	BACE1 deficiency causes altered neuronal activity and neurodegeneration. 2010 , 30, 8819-29	123
854	PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. 2010 , 51, 2611-8	71
853	Brain endothelial cells produce amyloid {beta} from amyloid precursor protein 770 and preferentially secrete the O-glycosylated form. 2010 , 285, 40097-103	76
852	Proteomic identification of sorting nexin 6 as a negative regulator of BACE1-mediated APP processing. 2010 , 24, 2783-94	74
851	Aging-Related Memory DisordersAlzheimer's Disease. 2010 , 292-319	1
850	Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. 2010 , 107, 1630-5	216
849	Network excitability dysfunction in Alzheimer's disease: insights from in vitro and in vivo models. 2010 , 21, 153-71	31

848	Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions. 2010 , 391, 849-59	30
847	Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents. 2010 , 16, 2818-36	42
846	Alzheimer's disease and the amyloid-beta peptide. 2010 , 19, 311-23	806
845	Molecular mechanisms of neurodegeneration in Alzheimer's disease. 2010 , 19, R12-20	434
844	Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice. 2010 , 30, 9228-40	86
843	Distribution of neprilysin and deposit patterns of Abeta subtypes in the brains of aged squirrel monkeys (<i>Saimiri sciureus</i>). 2010 , 17, 75-82	26
842	The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. 2010 , 30, 4833-44	267
841	Design of Anti-Alzheimer's Disease Agents Focusing on a Specific Interaction with Target Biomolecules. 2018 , 207-228	1
840	p75 neurotrophin receptor interacts with and promotes BACE1 localization in endosomes aggravating amyloidogenesis. 2018 , 144, 302-317	24
839	Pulse pressure is associated with plasma amyloid- β transport dysfunction. 2018 , 36, 569-579	10
838	Cu(II) binding to various forms of amyloid- β peptides. Are they friends or foes?. 2018 , 2018, 7-15	24
837	Protection against β amyloid neurotoxicity by a non-toxic endogenous N-terminal β amyloid fragment and its active hexapeptide core sequence. 2018 , 144, 201-217	14
836	Nucleic acid aptamers for neurodegenerative diseases. 2018 , 145, 73-83	30
835	Functional dissection of astrocyte-secreted proteins: Implications in brain health and diseases. 2018 , 162, 37-69	72
834	Molecular mechanisms underlying monosynaptic sensory-motor circuit development in the spinal cord. 2018 , 247, 581-587	10
833	Consequences of Rab GTPase dysfunction in genetic or acquired human diseases. 2018 , 9, 158-181	29
832	The physical approximation of APP and BACE-1: A key event in Alzheimer's disease pathogenesis. 2018 , 78, 340-347	48
831	Prostaglandin J2 promotes O-GlcNAcylation raising APP processing by β - and γ -secretases: relevance to Alzheimer's disease. 2018 , 62, 130-145	5

830	Expression of BC1 Impairs Spatial Learning and Memory in Alzheimer's Disease Via APP Translation. 2018 , 55, 6007-6020	32
829	Exercise decreases BACE and APP levels in the hippocampus of a rat model of Alzheimer's disease. 2018 , 86, 25-29	30
828	Dimerization leads to changes in APP (amyloid precursor protein) trafficking mediated by LRP1 and SorLA. 2018 , 75, 301-322	23
827	Localization of endogenous amyloid- β to the coeruleo-cortical pathway: consequences of noradrenergic depletion. 2018 , 223, 267-284	10
826	Ethanol Alters APP Processing and Aggravates Alzheimer-Associated Phenotypes. 2018 , 55, 5006-5018	22
825	Modulation of β and γ Secretases as Early Prevention Against Alzheimer's Disease. 2018 , 83, 320-327	41
824	Role of Pyridines in Medicinal Chemistry and Design of BACE1 Inhibitors Possessing a Pyridine Scaffold. 2018 ,	21
823	Amyloid Beta Hypothesis: Attention to β and γ Secretase Modulators. 2018 ,	
822	Mild heat stress induces hormetic effects in protecting the primary culture of mouse prefrontal cerebrocortical neurons from neuropathological alterations. 2018 , 5, 110-115	3
821	Visualization of Alzheimer's Disease Related β -/ γ / γ Secretase Ternary Complex by Bimolecular Fluorescence Complementation Based Fluorescence Resonance Energy Transfer. 2018 , 11, 431	5
820	Contribution of the Endosomal-Lysosomal and Proteasomal Systems in Amyloid- β Precursor Protein Derived Fragments Processing. 2018 , 12, 435	12
819	Bojungikgi-Tang, a Traditional Herbal Formula, Exerts Neuroprotective Effects and Ameliorates Memory Impairments in Alzheimer's Disease-Like Experimental Models. 2018 , 10,	13
818	Molecular Recipe for γ Secretase Modulation from Computational Analysis of 60 Active Compounds. 2018 , 3, 18078-18088	17
817	Discovery and Chemical Development of JNJ-50138803, a Clinical Candidate BACE1 Inhibitor. 2018 , 91-114	
816	Preclinical Identification and Development of AM-6138: An Inhibitor of BACE1 for the Treatment of Alzheimer's Disease. 2018 , 29-52	1
815	Discovery and Chemical Development of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease. 2018 , 53-89	
814	Microglia CREB-Phosphorylation Mediates Amyloid- β Induced Neuronal Toxicity. 2018 , 66, 333-345	5
813	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. 2018 , 14, 639-652	257

812	Purification and characterization of β secretase inhibitory peptide from sea hare (<i>Aplysia kurodai</i>) by enzymatic hydrolysis. 2018 , 21,	5
811	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. 2018 , 18, 847-857	47
810	A Free Radical-Generating System Regulates Amyloid Oligomers: Involvement of Cathepsin B. 2018 , 66, 1397-1408	7
809	An Apoptotic and Endosymbiotic Explanation of the Warburg and the Inverse Warburg Hypotheses. 2018 , 19,	4
808	The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease. 2018 , 10,	68
807	Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. 2018 , 10,	41
806	Laboratory diagnostics in dementia. 2018 , 42, 121-130	1
805	A new era for understanding amyloid structures and disease. 2018 , 19, 755-773	357
804	Inhibition of hematopoietic cell kinase dysregulates microglial function and accelerates early stage Alzheimer's disease-like neuropathology. 2018 , 66, 2700-2718	10
803	Passive Immunotherapy in Alzheimer's Disease. 2018 ,	2
802	Scutellarin Ameliorates Learning and Memory Deficit via Suppressing β Amyloid Formation and Microglial Activation in Rats with Chronic Cerebral Hypoperfusion. 2018 , 46, 1203-1223	14
801	Abnormal clotting of the intrinsic/contact pathway in Alzheimer disease patients is related to cognitive ability. 2018 , 2, 954-963	21
800	Biophenols: Enzymes (β secretase, Cholinesterases, histone deacetylase and tyrosinase) inhibitors from olive (<i>Olea europaea</i> L.). 2018 , 128, 118-129	33
799	Reduced $A\beta$ secretion by human neurons under conditions of strongly increased BACE activity. 2018 , 147, 256-274	3
798	Exosomes, Stem Cells and MicroRNA. 2018 ,	
797	Salivary biomarkers for the diagnosis and monitoring of neurological diseases. 2018 , 41, 63-87	78
796	Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β secretase (BACE1) Inhibitors via Active Conformation Stabilization. 2018 , 61, 5525-5546	22
795	Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid- β clearance in human astrocytes. 2018 , 293, 11341-11357	32

794	Potential value of soluble APP ^β and APP ^γ in CSF as biomarkers of dementia disorders: Unresolved issues and perspectives. 2018 , 6, 89-93	2
793	Proteolytic ectodomain shedding of membrane proteins in mammals—hardware, concepts, and recent developments. 2018 , 37,	118
792	Aging and Disease: The Epigenetic Bridge. 2018 , 935-973	
791	Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function. 2018 , 84, 478-487	28
790	The Unmet Promise of a Miracle Drug for Alzheimer's Disease: Implications for Practice, Policy, and Research. 2018 , 19, 557-559	2
789	A New Fluorogenic Small-Molecule Labeling Tool for Surface Diffusion Analysis and Advanced Fluorescence Imaging of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Based on Silicone Rhodamine: SiR-BACE1. 2018 , 61, 6121-6139	18
788	Neohesperidin Prevents Aβ-Induced Apoptosis in Primary Cultured Hippocampal Neurons by Blocking the S-Nitrosylation of Protein-Disulphide Isomerase. 2018 , 43, 1736-1744	13
787	Biomarker for Alzheimer's Disease. 2018 , 333-349	0
786	Heme Oxygenase-1 Activity as a Correlate to Exercise-Mediated Amelioration of Cognitive Decline and Neuropathological Alterations in an Aging Rat Model of Dementia. 2018 , 2018, 7212861	16
785	The Prenylflavonoid Xanthohumol Reduces Alzheimer-Like Changes and Modulates Multiple Pathogenic Molecular Pathways in the Neuro2a/APP Cell Model of AD. 2018 , 9, 199	17
784	Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. 2018 , 5, 1037-1047	17
783	Machine Learning-based Virtual Screening and Its Applications to Alzheimer's Drug Discovery: A Review. 2018 , 24, 3347-3358	52
782	Atherosclerosis is exacerbated by chitinase-3-like-1 in amyloid precursor protein transgenic mice. 2018 , 8, 749-766	18
781	A peptide-WS nanosheet based biosensing platform for determination of β-secretase and screening of its inhibitors. 2018 , 143, 4585-4591	12
780	Analyzing the Behavior of Neuronal Pathways in Alzheimer's Disease Using Petri Net Modeling Approach. 2018 , 12, 26	9
779	Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease. 2018 , 12, 25	366
778	Autotaxin?Lysophosphatidic Acid Signaling in Alzheimer's Disease. 2018 , 19,	28
777	Anti-BACE1 and Antimicrobial Activities of Steroidal Compounds Isolated from Marine Urechis unicinctus. 2018 , 16,	14

776	Results of Beta Secretase-Inhibitor Clinical Trials Support Amyloid Precursor Protein-Independent Generation of Beta Amyloid in Sporadic Alzheimer's Disease. 2018 , 6,	14
775	Dietary arachidonic acid: a Janus face actor in brain and Alzheimer's disease?. 2018 , 25, D406	4
774	BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains. 2018 , 13, e0200344	6
773	Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment. 2018 , 6, 178	91
772	Inhibition of PKC δ reduces amyloid- β levels and reverses Alzheimer disease phenotypes. 2018 , 215, 1665-1677	28
771	Stem Cell Therapies for Neurodegenerative Diseases. 2018 , 1056, 61-84	39
770	BACE1 elevation engendered by GGA3 deletion increases β amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice. 2018 , 13, 6	13
769	A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer's disease. 2018 , 152, 570-589	72
768	Rational Design of Novel 1,3-Oxazine Based β Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust A β Reduction in the Brain. 2018 , 61, 5122-5137	23
767	Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study. 2018 , 10, 85	43
766	Amyloid- β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure. 2018 , 7, 5	26
765	Novel multi-target compounds in the quest for new chemotherapies against Alzheimer's disease: An experimental and theoretical study. 2018 , 26, 4823-4840	6
764	Are N- and C-terminally truncated A β species key pathological triggers in Alzheimer's disease?. 2018 , 293, 15419-15428	52
763	Understanding the Twisted Structure of Amyloid Fibrils via Molecular Simulations. 2018 , 122, 11302-11310	4
762	Prophylactic and Therapeutic Applications of Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer's Disease. 2018 , 139-161	1
761	SIRT3 activator Honokiol attenuates β Amyloid by modulating amyloidogenic pathway. 2018 , 13, e0190350	42
760	Neuroprotective Effects of Ginsenoside Rf on Amyloid- β Induced Neurotoxicity in vitro and in vivo. 2018 , 64, 309-322	30
759	Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients. 2019 , 269, 963-972	15

758	Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies. 2019 , 356, 18-40	38
757	CDK5 Participates in Amyloid- β Production by Regulating PPAR β Phosphorylation in Primary Rat Hippocampal Neurons. 2019 , 71, 443-460	5
756	Pioglitazone Reduces β Amyloid Levels Inhibition of PPAR β Phosphorylation in a Neuronal Model of Alzheimer's Disease. 2019 , 11, 178	7
755	Overcoming Challenging Substituent Perturbations with Multisite β Dynamics: A Case Study Targeting β Secretase 1. 2019 , 10, 4875-4880	10
754	Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases. 2019 , 33, 883-904	14
753	Multiple BACE1 inhibitors abnormally increase the BACE1 protein level in neurons by prolonging its half-life. 2019 , 15, 1183-1194	12
752	17 β Estradiol Modulates SIRT1 and Halts Oxidative Stress-Mediated Cognitive Impairment in a Male Aging Mouse Model. 2019 , 8,	45
751	Developing Practical Therapeutic Strategies that Target Protein SUMOylation. 2019 , 20, 960-969	6
750	Human Albumin Impairs Amyloid β peptide Fibrillation Through its C-terminus: From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease. 2019 , 17, 963-971	7
749	Multi-Target β Protease Inhibitors from : In Silico and In Vitro Studies. 2019 , 8,	14
748	Copper imbalance in Alzheimer's disease: Convergence of the chemistry and the clinic. 2019 , 397, 168-187	33
747	Paricalcitol accelerates BACE1 lysosomal degradation and inhibits calpain-1 dependent neuronal loss in APP/PS1 transgenic mice. 2019 , 45, 393-407	9
746	Localization of amyloid beta peptides to locus coeruleus and medial prefrontal cortex in corticotropin releasing factor overexpressing male and female mice. 2019 , 224, 2385-2405	6
745	Characterization of Cerebrospinal Fluid BACE1 Species. 2019 , 56, 8603-8616	4
744	Size-Dependent Interaction of Amyloid β Oligomers with Brain Total Lipid Extract Bilayer-Fibrillation Versus Membrane Destruction. 2019 , 35, 11940-11949	13
743	A Snapshot on the Current Status of Alzheimer's Disease, Treatment Perspectives, in-Vitro and in-Vivo Research Studies and Future Opportunities. 2019 , 67, 1030-1041	4
742	Potential anti-Alzheimer effects of selected Lamiaceae plants through polypharmacology on glycogen synthase kinase-3 β Secretase, and casein kinase 1 α 2019 , 138, 111431	10
741	Ozone Inhibits APP/A β Production and Improves Cognition in an APP/PS1 Transgenic Mouse Model. 2019 , 418, 110-121	2

740	Long Non-coding RNA BACE1-AS May Serve as an Alzheimer's Disease Blood-Based Biomarker. 2019 , 69, 351-359	39
739	Peripheral Amyloid Precursor Protein Derivative Expression in Fragile X Syndrome. 2019 , 13, 49	5
738	Biological, Diagnostic and Therapeutic Advances in Alzheimer's Disease. 2019 ,	0
737	Effect of Caffeine and Other Methylxanthines on A β Homeostasis in SH-SY5Y Cells. 2019 , 9,	12
736	Tau deletion reduces plaque-associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease. 2019 , 38, e102345	14
735	Performance evaluation of molecular docking and free energy calculations protocols using the D3R Grand Challenge 4 dataset. 2019 , 33, 1031-1043	7
734	Comparison of affinity ranking using AutoDock-GPU and MM-GBSA scores for BACE-1 inhibitors in the D3R Grand Challenge 4. 2019 , 33, 1011-1020	22
733	Trifluoromethyl Dihydrothiazine-Based β -Secretase (BACE1) Inhibitors with Robust Central β -Amyloid Reduction and Minimal Covalent Binding Burden. 2019 , 14, 1894-1910	5
732	Amyloid Precursor Protein Mediates Neuronal Protection from Rotenone Toxicity. 2019 , 56, 5471-5482	8
731	Dual role of cofilin in APP trafficking and amyloid- β clearance. 2019 , 33, 14234-14247	3
730	Editorial: Implications for BACE1 Inhibitor Clinical Trials: Adult Conditional BACE1 Knockout Mice Exhibit Axonal Organization Defects in the Hippocampus. 2019 , 6, 78-84	14
729	p35 Hemizygous Deletion in 5xFAD Mice Increases A β Plaque Load in Males but Not in Females. 2019 , 417, 45-56	2
728	Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease. 2019 , 10, 3885	117
727	Isorhynchophylline ameliorates cognitive impairment via modulating amyloid pathology, tau hyperphosphorylation and neuroinflammation: Studies in a transgenic mouse model of Alzheimer's disease. 2019 , 82, 264-278	18
726	Targeting Autophagy for the Treatment of Alzheimer's Disease: Challenges and Opportunities. 2019 , 12, 203	54
725	BACE1 Inhibition Using 2'-OMePS Steric Blocking Antisense Oligonucleotides. 2019 , 10,	4
724	Regulation of BACE1 expression after injury is linked to the p75 neurotrophin receptor. 2019 , 99, 103395	2
723	Emerging Alternative Proteinases in APP Metabolism and Alzheimer's Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP. 2019 , 11, 244	25

722	The effect of BACE1-AS on β amyloid generation by regulating BACE1 mRNA expression. 2019 , 20, 23	18
721	Development of an Efficient Enzyme Production and Structure-Based Discovery Platform for BACE1 Inhibitors. 2019 , 58, 4424-4435	7
720	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. 2019 , 179, 312-339	721
719	Rationally Engineered Nucleic Acid Architectures for Biosensing Applications. 2019 , 119, 11631-11717	114
718	Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease. 2019 , 72, S145-S176	19
717	β Secretase BACE1 Is Required for Normal Cochlear Function. 2019 , 39, 9013-9027	7
716	Reduction of the expression of the late-onset Alzheimer's disease (AD) risk-factor does not affect amyloid pathology in an AD mouse model. 2019 , 294, 4477-4487	18
715	β Secretase Studied by Atomistic Molecular Dynamics Simulations: Global Dynamics, Enzyme Activation, Water Distribution and Lipid Binding. 2018 , 6, 640	19
714	The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease. 2019 , 25, 661-672	15
713	Epigenetic and Neurological Impairments Associated with Early Life Exposure to Persistent Organic Pollutants. 2019 , 2019, 2085496	32
712	Lack of β amyloid cleaving enzyme-1 (BACE1) impairs long-term synaptic plasticity but enhances granule cell excitability and oscillatory activity in the dentate gyrus in vivo. 2019 , 224, 1279-1290	6
711	A Diet Enriched in Palmitate and Deficient in Linoleate Exacerbates Oxidative Stress and Amyloid- β Burden in the Hippocampus of 3xTg-AD Mouse Model of Alzheimer's Disease. 2019 , 68, 219-237	4
710	A short perspective on the long road to effective treatments for Alzheimer's disease. 2019 , 176, 3636-3648	9
709	The β Secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid- β reduction to downstream disease-relevant effects. 2019 , 176, 3435-3446	11
708	BACE1 Translation: At the Crossroads Between Alzheimer's Disease Neurodegeneration and Memory Consolidation. 2019 , 3, 113-148	3
707	Intertwined Pathologies of Amyloid- β and Metal Ions in Alzheimer's Disease: Metal- β amyloid- β 2019 , 48, 951-960	12
706	Trafficking and proteolytic processing of amyloid precursor protein and secretases in Alzheimer's disease development: An up-to-date review. 2019 , 856, 172415	29
705	Electroacupuncture Mitigates Hippocampal Cognitive Impairments by Reducing BACE1 Deposition and Activating PKA in APP/PS1 Double Transgenic Mice. 2019 , 2019, 2823679	12

704	NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer's models. 2019 , 116, 12516-12523	62
703	Natural Products from Cyanobacteria: Focus on Beneficial Activities. 2019 , 17,	96
702	Regulation of the alternative β secretase meprin β by ADAM-mediated shedding. 2019 , 76, 3193-3206	12
701	O-GlcNAcylation of Amyloid- β Protein Precursor by Insulin Signaling Reduces Amyloid- β Production. 2019 , 69, 1195-1211	8
700	pHluorin-BACE1-mCherry Acts as a Reporter for the Intracellular Distribution of Active BACE1 In Vitro and In Vivo. 2019 , 8,	3
699	Novel Therapeutic Potentials of Taxifolin for Amyloid- β -Associated Neurodegenerative Diseases and Other Diseases: Recent Advances and Future Perspectives. 2019 , 20,	15
698	Palmitic Acid-Induced NAD Depletion is Associated with the Reduced Function of SIRT1 and Increased Expression of BACE1 in Hippocampal Neurons. 2019 , 44, 1745-1754	6
697	Fibrinogen β C domain: Its importance in physiopathology. 2019 , 3, 173-183	5
696	AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease. 2019 , 459, 95-112	33
695	An update on the interactions between Alzheimer's disease, autophagy and inflammation. 2019 , 705, 157-166	38
694	Fluoro-benzimidazole derivatives to cure Alzheimer's disease: In-silico studies, synthesis, structure-activity relationship and in vivo evaluation for β secretase enzyme inhibition. 2019 , 88, 102936	9
693	Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-CTF (C99). 2019 , 39, 5255-5268	65
692	The YENPTY motif of APP: Progress and insights toward a targeted therapy for Alzheimer's disease patients. 2019 , 52, 120-128	8
691	Therapeutic potential of cyanobacterial pigment protein phycoerythrin: in silico and in vitro study of BACE1 interaction and in vivo A β reduction. 2019 , 134, 368-378	11
690	Structure-Based Design of Selective β Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2. 2019 , 62, 5080-5095	17
689	BACE-1 and β Secretase as Therapeutic Targets for Alzheimer's Disease. 2019 , 12,	49
688	Complex formation of APP with GABA receptors links axonal trafficking to amyloidogenic processing. 2019 , 10, 1331	55
687	Panax ginseng components and the pathogenesis of Alzheimer's disease (Review). 2019 , 19, 2975-2998	32

- 686 Elevated cellular cholesterol in Familial Alzheimer's presenilin 1 mutation is associated with lipid raft localization of β amyloid precursor protein. **2019**, 14, e0210535 23
- 685 The Role of Nutrition for the Aging Population: Implications for Cognition and Alzheimer's Disease. **2019**, 10, 619-639 27
- 684 The Complex Work of Proteases and Secretases in Wallerian Degeneration: Beyond Neuregulin-1. **2019**, 13, 93 8
- 683 DNA Aptamers Targeting BACE1 Reduce Amyloid Levels and Rescue Neuronal Deficiency in Cultured Cells. **2019**, 16, 302-312 6
- 682 BACE1-AS prevents BACE1 mRNA degradation through the sequestration of BACE1-targeting miRNAs. **2019**, 98, 87-96 27
- 681 Influence of the familial Alzheimer's disease-associated T43I mutation on the transmembrane structure and β secretase processing of the C99 peptide. **2019**, 294, 5854-5866 4
- 680 Elucidating the inhibitory potential of Vitamin A against fibrillation and amyloid associated cytotoxicity. **2019**, 129, 333-338 20
- 679 Korean Thistle (var. (Maxim.) Matsum.): A Potential Dietary Supplement against Diabetes and Alzheimer's Disease. **2019**, 24, 10
- 678 Ingredients in Zijuan Pu'er Tea Extract Alleviate β Amyloid Peptide Toxicity in a Model of Alzheimer's Disease Likely through DAF-16. **2019**, 24, 16
- 677 Inhibition of β site amyloid precursor protein cleaving enzyme 1 and cholinesterases by pterosins via a specific structure-activity relationship with a strong BBB permeability. **2019**, 51, 1-18 17
- 676 Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study. **2019**, 125, 94-99 15
- 675 Tiny Models to Answer Big Questions: The Worm and the Yeast as Tools in Human Genetics Research. **2019**, 49-68
- 674 Mitigating Alzheimer's Disease with Natural Polyphenols: A Review. **2019**, 16, 529-543 27
- 673 Synaptic Elimination in Neurological Disorders. **2019**, 17, 1071-1095 25
- 672 BACE1 partial deletion induces synaptic plasticity deficit in adult mice. **2019**, 9, 19877 10
- 671 Potential microRNA-related targets in clearance pathways of amyloid- β novel therapeutic approach for the treatment of Alzheimer's disease. **2019**, 9, 91 19
- 670 The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer's Disease. **2019**, 13, 1154 42
- 669 Synapsin 1 promotes A β generation via BACE1 modulation. **2019**, 14, e0226368 6

668	Emerging roles of N- and C-terminally truncated A β species in Alzheimer's disease. 2019 , 23, 991-1004	24
667	Oligopeptides Generated by Neprilysin Degradation of β -Amyloid Have the Highest Cu(II) Affinity in the Whole A β Family. 2019 , 58, 932-943	15
666	27-hydroxycholesterol promotes A β accumulation via altering A β metabolism in mild cognitive impairment patients and APP/PS1 mice. 2019 , 29, 558-573	15
665	Proteomic analysis of protein homeostasis and aggregation. 2019 , 198, 98-112	17
664	Transcriptional repression of the ectodomain sheddase ADAM10 by TBX2 and potential implication for Alzheimer's disease. 2019 , 76, 1005-1025	4
663	Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies. 2019 , 174, 53-89	137
662	BAP31 deficiency contributes to the formation of amyloid- β plaques in Alzheimer's disease by reducing the stability of RTN3. 2019 , 33, 4936-4946	11
661	Palmitate-Induced SREBP1 Expression and Activation Underlies the Increased BACE 1 Activity and Amyloid Beta Genesis. 2019 , 56, 5256-5269	5
660	Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease. 2019 , 62, 4252-4264	18
659	Amyloid precursor protein-mediated mitochondrial regulation and Alzheimer's disease. 2019 , 176, 3464-3474	15
658	Recognition of the amyloid precursor protein by human β -secretase. <i>Science</i> , 2019 , 363, 33-3	140
657	Down syndrome: Neurobiological alterations and therapeutic targets. 2019 , 98, 234-255	39
656	Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer's disease. 2019 , 39, 1730-1778	11
655	Black phosphorus nanosheets based sensitive protease detection and inhibitor screening. 2019 , 197, 270-276	25
654	Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis. 2019 , 20, 94-108	142
653	Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice. 2019 , 294, 2714-2731	44
652	The role of membrane trafficking in the processing of amyloid precursor protein and production of amyloid peptides in Alzheimer's disease. 2019 , 1861, 697-712	39
651	Structural Modeling of β -Secretase A β Complex Formation and Substrate Processing. 2019 , 10, 1826-1840	14

650	Licoflavonol Reduces A β Secretion by Increasing BACE1 Phosphorylation to Facilitate BACE1 Degradation. 2019 , 63, e1800474	2
649	High resolution approaches for the identification of amyloid fragments in brain. 2019 , 319, 7-15	1
648	Proamyloidogenic effects of membrane type 1 matrix metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking. 2019 , 33, 2910-2927	15
647	Structure-Based Survey of the Binding Modes of BACE1 Inhibitors. 2019 , 10, 880-889	7
646	Azure B affects amyloid precursor protein metabolism in PS70 cells. 2019 , 299, 88-93	3
645	Alzheimer's Disease and Dementia. 2019 , 25-82	0
644	Functions and dysfunctions of nitric oxide in brain. 2019 , 1865, 1949-1967	80
643	Synthesis, molecular modeling and BACE-1 inhibitory study of tetrahydrobenzo[b] pyran derivatives. 2019 , 84, 202-210	18
642	Role of Rab GTPases in Alzheimer's Disease. 2019 , 10, 828-838	13
641	Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities. 2019 , 30, 1450-1499	50
640	Amyloid beta peptides, locus coeruleus-norepinephrine system and dense core vesicles. 2019 , 1702, 46-53	5
639	Bsecretase inhibitors for Alzheimer's disease: identification using pharmacoinformatics. 2019 , 37, 503-522	11
638	The relationship between cholesterol level and Alzheimer's disease-associated APP proteolysis/A β metabolism. 2019 , 22, 453-463	17
637	Partial loss of endothelial nitric oxide leads to increased cerebrovascular beta amyloid. 2020 , 40, 392-403	16
636	Discovery of AM-6494: A Potent and Orally Efficacious Bsite Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2. 2020 , 63, 2263-2281	19
635	Genetic intolerance analysis as a tool for protein science. 2020 , 1862, 183058	3
634	Macromolecular complex in recognition and proteolysis of amyloid precursor protein in Alzheimer's disease. 2020 , 61, 1-8	11
633	The Structure and Function of β , γ and Bsecretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review. 2019 , 18, 657-667	9

632	The interplay between aging-associated loss of protein homeostasis and extracellular vesicles in neurodegeneration. 2020 , 98, 262-283	15
631	A combinational treatment of carotenoids decreases A β secretion in human neurons via β secretase inhibition. 2020 , 158, 47-55	4
630	Insights into membrane-bound presenilin 2 from all-atom molecular dynamics simulations. 2020 , 38, 3196-3210	10
629	Hydroxycinnamic acids and human health: recent advances. 2020 , 100, 483-499	52
628	The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer's disease. 2020 , 98, 28-41	109
627	Deep neural network affinity model for BACE inhibitors in D3R Grand Challenge 4. 2020 , 34, 201-217	4
626	Role of Cdk5 in Amyloid-beta Pathology of Alzheimer's Disease. 2019 , 16, 1206-1215	5
625	BHBA treatment improves cognitive function by targeting pleiotropic mechanisms in transgenic mouse model of Alzheimer's disease. 2020 , 34, 1412-1429	22
624	A novel two-photon ratiometric fluorescent probe for imaging and sensing of BACE1 in different regions of AD mouse brain. 2020 , 11, 2215-2224	14
623	Sampling and refinement protocols for template-based macrocycle docking: 2018 D3R Grand Challenge 4. 2020 , 34, 179-189	5
622	Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease. 2020 , 87, 103995	7
621	Do herpesviruses play a role in Alzheimer's disease pathogenesis?. 2020 , 32, 21-26	1
620	Mechanistic Insights into the Racemization of Fused Cyclopropyl Isoxazolines. 2020 , 22, 2113-2117	2
619	Characterising the brain metalloproteome in Down syndrome patients with concomitant Alzheimer's pathology. 2020 , 12, 114-132	
618	Mouse brain proteomics establishes MDGA1 and CACHD1 as in vivo substrates of the Alzheimer protease BACE1. 2020 , 34, 2465-2482	10
617	Novel multifunctional iron chelators of the aroyl nicotinoyl hydrazone class that markedly enhance cellular NAD ⁺ /NADH ratios. 2020 , 177, 1967-1987	6
616	Normal brain aging and Alzheimer's disease are associated with lower cerebral pH: an in vivo histidine H-MR spectroscopy study. 2020 , 87, 60-69	15
615	ATP Controls the Aggregation of A β Peptides. 2020 , 124, 210-223	22

614	Mapping pathogenic processes contributing to neurodegeneration in Drosophila models of Alzheimer's disease. 2020 , 10, 338-350	3
613	Electrochemical Synthesis of Hindered Primary and Secondary Amines via Proton-Coupled Electron Transfer. 2020 , 142, 468-478	48
612	Upregulation of Cisd2 attenuates Alzheimer's-related neuronal loss in mice. 2020 , 250, 299-311	13
611	Emerging roles of GSK-3 β in pathophysiology: Emphasis on cardio-metabolic disorders. 2020 , 1867, 118616	14
610	1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease. 2020 , 187, 111916	18
609	Serum beta-secretase 1 (BACE1) activity as candidate biomarker for late-onset Alzheimer's disease. 2020 , 42, 159-167	23
608	The Combined Therapy of Berberine Treatment with lncRNA BACE1-AS Depletion Attenuates A β Induced Neuronal Injury Through Regulating the Expression of miR-132-3p in Neuronal Cells. 2020 , 45, 741-751	17
607	Lupeol, a Plant-Derived Triterpenoid, Protects Mice Brains against A β Induced Oxidative Stress and Neurodegeneration. 2020 , 8,	9
606	Vitamin D deficiency exacerbates Alzheimer-like pathologies by reducing antioxidant capacity. 2020 , 161, 139-149	11
605	β Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. 2020 , 12, 130	2
604	PICALM Rescues Endocytic Defects Caused by the Alzheimer's Disease Risk Factor APOE4. 2020 , 33, 108224	17
603	Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer's disease therapy. 2020 , 6,	45
602	Balancing neurotrophin pathway and sortilin function: Its role in human disease. 2020 , 1874, 188429	9
601	Analyzing microglial-associated A β in Alzheimer's disease transgenic mice with a novel mid-domain A β antibody. 2020 , 10, 10590	1
600	Beyond Haemostasis and Thrombosis: Platelets in Depression and Its Co-Morbidities. 2020 , 21,	9
599	Temporal Raman Spectroscopy for Monitoring Replication Kinetics of Epstein-Barr Virus Infection in Glial Cells. 2020 , 5, 29547-29560	17
598	Macrophage-specific deletion of BACE1 does not enhance macrophage recruitment to the injured peripheral nerve. 2020 , 349, 577423	3
597	Tau and other proteins found in Alzheimer's disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans. 2020 , 12,	13

596	What are the Prevalence and Risk Factors of Alzheimer’s Disease in China and the United States?. 2020 , 185, 03031	
595	Altered Hinge Conformations in APP Transmembrane Helix Mutants May Affect Enzyme-Substrate Interactions of β Secretase. 2020 , 11, 4426-4433	1
594	Preferred Endocytosis of Amyloid Precursor Protein from Cholesterol-Enriched Lipid Raft Microdomains. 2020 , 25,	7
593	The Dichotomous Role of Extracellular Vesicles in the Central Nervous System. 2020 , 23, 101456	7
592	Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models. 2020 , 21,	8
591	Penetrating Ballistic-Like Brain Injury Leads to MicroRNA Dysregulation, BACE1 Upregulation, and Amyloid Precursor Protein Loss in Lesioned Rat Brain Tissues. 2020 , 14, 915	7
590	Fyn Tyrosine Kinase Elicits Amyloid Precursor Protein Tyr682 Phosphorylation in Neurons from Alzheimer’s Disease Patients. 2020 , 9,	7
589	Transmissible Endosomal Intoxication: A Balance between Exosomes and Lysosomes at the Basis of Intercellular Amyloid Propagation. 2020 , 8,	9
588	Dysfunction of the Blood-Brain Barrier-A Key Step in Neurodegeneration and Dementia. 2020 , 12, 185	17
587	The physiological roles of tau and A β implications for Alzheimer’s disease pathology and therapeutics. 2020 , 140, 417-447	88
586	Endosomal Acid-Base Homeostasis in Neurodegenerative Diseases. 2020 , 1	3
585	Time-Resolved Observation of Evolution of Amyloid- β Oligomer with Temporary Salt Crystals. 2020 , 11, 6176-6184	3
584	Extracellular vesicles: where the amyloid precursor protein carboxyl-terminal fragments accumulate and amyloid- β oligomerizes. 2020 , 34, 12922-12931	14
583	AP-2 reduces amyloidogenesis by promoting BACE1 trafficking and degradation in neurons. 2020 , 21, e47954	19
582	Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease. 2020 , 13, 137	24
581	High-fat diet exacerbates cognitive and metabolic abnormalities in neuronal BACE1 knock-in mice - partial prevention by Fenretinide. 2020 , 1-18	1
580	Increased levels of Stress-inducible phosphoprotein-1 accelerates amyloid- β deposition in a mouse model of Alzheimer’s disease. 2020 , 8, 143	7
579	Brain region-specific lipid alterations in the PLB4 hBACE1 knock-in mouse model of Alzheimer’s disease. 2020 , 19, 201	2

578	Gallic acid is a dual β / β secretase modulator that reverses cognitive impairment and remediates pathology in Alzheimer mice. 2020 , 295, 16251-16266	15
577	Revisiting the Amyloid Cascade Hypothesis: From Anti-A β Therapeutics to Auspicious New Ways for Alzheimer's Disease. 2020 , 21,	42
576	Effect of a Lens Protein in Low-Temperature Culture of Novel Immortalized Human Lens Epithelial Cells (iHLEC-NY2). 2020 , 9,	1
575	Synaptic Loss in Alzheimer's Disease: Mechanistic Insights Provided by Two-Photon Imaging of Transgenic Mouse Models. 2020 , 14, 592607	5
574	Experimental Evidence of the Benefits of Acupuncture for Alzheimer's Disease: An Updated Review. 2020 , 14, 549772	8
573	Sulfuretin exerts diversified functions in the processing of amyloid precursor protein. 2021 , 8, 867-881	2
572	Synthesis and biological evaluation of 2'-Aminochoalcone: A multi-target approach to find drug candidates to treat Alzheimer's disease. 2020 , 103, 104201	5
571	Identification of Structural Calcium Binding Sites in Membrane-Bound Presenilin 1 and 2. 2020 , 124, 4697-47112	
570	Alzheimer's Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor β . 2020 , 9,	10
569	Green Tea Seed Isolated Theasaponin E1 Ameliorates AD Promoting Neurotoxic Pathogenesis by Attenuating A β Peptide Levels in SweAPP N2a Cells. 2020 , 25,	3
568	A possible role of glycation in the regulation of amyloid β precursor protein processing leading to amyloid β accumulation. 2020 , 142, 109799	3
567	Anti-HIV drugs promote β amyloid deposition and impair learning and memory in BALB/c mice. 2020 , 32, 257-264	2
566	Can Reduce Amyloid Beta and Reverse Cognitive Impairment and Memory Dysfunction in Alzheimer's Disease Mouse Model. 2020 , 9,	4
565	The impact of capsaicinoids on APP processing in Alzheimer's disease in SH-SY5Y cells. 2020 , 10, 9164	2
564	The biogenesis and biology of amyloid β oligomers in the brain. 2020 , 16, 1561-1567	8
563	GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease. 2020 , 16, 1312-1329	25
562	Synthesis, pharmacological evaluation and mechanistic study of scutellarin methyl ester -4'-dipeptide conjugates for the treatment of hypoxic-ischemic encephalopathy (HIE) in rat pups. 2020 , 101, 103980	0
561	Expression of BACE1 in the Rat Carotid Body. 2020 , 11, 505	0


560	Is the p3 Peptide (A β 7-40, A β 7-42) Relevant to the Pathology of Alzheimer's Disease?1. 2020 , 74, 43-53	7
559	Focusing on cellular biomarkers: The endo-lysosomal pathway in Down syndrome. 2020 , 251, 209-243	6
558	Real-time nanoscale organization of amyloid precursor protein. 2020 , 12, 8200-8215	10
557	Neuropathological Mechanisms Associated with Pesticides in Alzheimer's Disease. 2020 , 8,	14
556	PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [F]PF-06684511. 2020 , 47, 2429-2439	3
555	Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease. 2020 , 25,	56
554	The Bewildering Effect of AMPK Activators in Alzheimer's Disease: Review of the Current Evidence. 2020 , 2020, 9895121	17
553	The Quest for Cellular Prion Protein Functions in the Aged and Neurodegenerating Brain. 2020 , 9,	8
552	Insights into lncRNAs in Alzheimer's disease mechanisms. 2021 , 18, 1037-1047	13
551	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. 2020 ,	30
550	The Nerve to Give BACE Inhibitors a Second Chance?. 2020 , 17, 966-967	
549	Sorting Out the Role of the in Alzheimer's Disease. 2020 , 4, 123-140	7
548	Proximity ligation assay reveals both pre- and postsynaptic localization of the APP-processing enzymes ADAM10 and BACE1 in rat and human adult brain. 2020 , 21, 6	8
547	Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands. 2020 , 97, 103649	39
546	LVFFARK-PEG-Stabilized Black Phosphorus Nanosheets Potently Inhibit Amyloid- β Fibrillogenesis. 2020 , 36, 1804-1812	17
545	The Alzheimer's Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease: JACC Focus Seminar. 2020 , 75, 952-967	47
544	cGMP favors the interaction between APP and BACE1 by inhibiting Rab5 GTPase activity. 2020 , 10, 1358	1
543	Transition metal complexes as imaging or therapeutic agents for neurodegenerative diseases. 2020 , 8, 4715-4725	13

542	Computer-Aided Drug Design of β Secretase, β Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics. 2020 , 21,	19
541	A Novel Dual Fluorochrome Near-Infrared Imaging Probe for Potential Alzheimer's Enzyme Biomarkers-BACE1 and Cathepsin D. 2020 , 25,	3
540	Docking interactions determine early cleavage events in insulin proteolysis by pepsin: Experiment and simulation. 2020 , 149, 1151-1160	6
539	Progress in Target Drug Molecules for Alzheimer's Disease. 2020 , 20, 4-36	17
538	Deciphering the neuroprotective and neurogenic potential of soluble amyloid precursor protein alpha (sAPP β). 2020 , 77, 2315-2330	15
537	Perturbation of bulk and selective macroautophagy, abnormal UPR activation and their interplay pave the way to immune dysfunction, cancerogenesis and neurodegeneration in ageing. 2020 , 58, 101026	9
536	Dendritic Spines in Alzheimer's Disease: How the Actin Cytoskeleton Contributes to Synaptic Failure. 2020 , 21,	23
535	A systematic review on anti-Alzheimer's disease activity of prescription Kangen-karyu. 2020 , 14, 61-66	2
534	Novel Anti-Alzheimer's Therapeutic Molecules Targeting Amyloid Precursor Protein Processing. 2020 , 2020, 7039138	27
533	Pharmacological BACE Inhibition Improves Axonal Regeneration in Nerve Injury and Disease Models. 2020 , 17, 973-988	2
532	Enhancement of Amyloid β Production in the Lens Epithelium of Japanese Type 2 Diabetic Patients. 2020 , 8,	
531	Clinical Trials in Alzheimer's Disease: A Hurdle in the Path of Remedy. 2020 , 2020, 5380346	33
530	Glycation-induced protein aggregation and cellular toxicity: an insight into the disease realm of high dietary sugar intake. 2020 , 251-275	
529	Hebbian and Homeostatic Synaptic Plasticity-Do Alterations of One Reflect Enhancement of the Other?. 2020 , 14, 50	6
528	The β Secretase BACE1 in Alzheimer's Disease. 2021 , 89, 745-756	107
527	The Ups and Downs of BACE1: Walking a Fine Line between Neurocognitive and Other Psychiatric Symptoms of Alzheimer's Disease. 2021 , 27, 222-234	1
526	LncRNA BACE1-AS Promotes Autophagy-Mediated Neuronal Damage Through The miR-214-3p/ATG5 Signalling Axis In Alzheimer's Disease. 2021 , 455, 52-64	24
525	Early detection and personalized medicine: Future strategies against Alzheimer's disease. 2021 , 177, 157-173	1

524	Harpertrioate A, an A,B,D--Limonoid with Promising Biological Activity against Alzheimer's Disease from Twigs of (Blanco) Merr. 2021 , 23, 262-267	3
523	Glucose metabolism: A link between traumatic brain injury and Alzheimer's disease. 2021 , 24, 5-10	6
522	Pulse-Chase Proteomics of the App Knockin Mouse Models of Alzheimer's Disease Reveals that Synaptic Dysfunction Originates in Presynaptic Terminals. 2021 , 12, 141-158.e9	10
521	Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives. 2021 , 64, 926-937	2
520	Membrane dynamics of β secretase with the anterior pharynx-defective 1B subunit. 2021 , 122, 69-85	6
519	Inhibitory Effect of Hexahydrocurcumin on Memory Impairment and Amyloidogenesis in Dexamethasone-Treated Mice. 2021 , 39, 266-276	2
518	Astrocytes & Astrocyte derived Extracellular Vesicles in Morphine Induced Amyloidopathy: Implications for Cognitive Deficits in Opiate Abusers. 2021 , 12, 1389-1408	2
517	Amyloid Beta. 2021 , 1-17	
516	Treatment for alzheimer's disease: The present and future. 2021 , 271, 03018	
515	Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy. 2021 , 15, 9-20	8
514	Stem cell-based therapy as a promising approach in Alzheimer's disease: current perspectives on novel treatment. 2021 , 22, 339-353	5
513	Applications of liquid crystals in biosensing. 2021 , 17, 4675-4702	24
512	Is β secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?. 2021 , 296, 100489	15
511	Spatiotemporal processing of neural cell adhesion molecules 1 and 2 by BACE1 in vivo. 2021 , 296, 100372	5
510	Trichostatin A ameliorates Alzheimer's disease-related pathology and cognitive deficits by increasing albumin expression and A β clearance in APP/PS1 mice. 2021 , 13, 7	7
509	Environmental exposures and the etiopathogenesis of Alzheimer's disease: The potential role of BACE1 as a critical neurotoxic target. 2021 , 35, e22694	2
508	Cell Adhesion Molecules Involved in Neurodevelopmental Pathways Implicated in 3p-Deletion Syndrome and Autism Spectrum Disorder. 2020 , 14, 611379	4
507	Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy. 2021 , 79, 275-287	2

506	Determination of plasma β amyloids by rolling circle amplification chemiluminescent immunoassay for noninvasive diagnosis of Alzheimer's disease. 2021 , 188, 24	0
505	Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies. 2021 , 16, 1	9
504	Flexible and Accurate Substrate Processing with Distinct Presenilin/ β Secretases in Human Cortical Neurons. 2021 , 8,	2
503	Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer's disease. 2021 , 1753, 147264	0
502	DYRK1A role in microtubule-based axonal transport regulates the retrograde dynamics of APP vesicles in human neurons.	
501	Genetics of Alzheimer's disease. 2021 , 171, 249-256	0
500	Mitochondria-associated endoplasmic reticulum membranes: At the crossroad between familiar and sporadic Alzheimer's disease. 2021 , 75, e22196	2
499	Implication of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase and Its Inhibitors in Alzheimer's Disease Murine Models. 2021 , 10,	6
498	Cardiac electrical remodeling and neurodegenerative diseases association. 2021 , 267, 118976	
497	Using stable isotope labeling to advance our understanding of Alzheimer's disease etiology and pathology. 2021 , 159, 318-329	0
496	A Structure-Based Discovery Platform for BACE2 and the Development of Selective BACE Inhibitors. 2021 , 12, 581-588	0
495	The Role of Butyrylcholinesterase and Iron in the Regulation of Cholinergic Network and Cognitive Dysfunction in Alzheimer's Disease Pathogenesis. 2021 , 22,	5
494	Nutraceutical based SIRT3 activators as therapeutic targets in Alzheimer's disease. 2021 , 144, 104958	4
493	Screening Platform Based on Inductively Coupled Plasma Mass Spectrometry for β Site Amyloid Protein Cleaving Enzyme 1 (BACE1) Inhibitors. 2021 , 12, 1093-1099	2
492	The influence of BACE1 on macrophage recruitment and activity in the injured peripheral nerve. 2021 , 18, 71	2
491	Mass spectrometry analysis of tau and amyloid-beta in iPSC-derived models of Alzheimer's disease and dementia. 2021 , 159, 305-317	1
490	Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease. 2021 , 108, 104681	20
489	A β promotes amyloidogenic processing of APP through a Go/G β signaling.	

488	Dieckol Ameliorates A β Production via PI3K/Akt/GSK-3 β Regulated APP Processing in SweAPP N2a Cell. 2021 , 19,	7
487	Racemization in Post-Translational Modifications Relevance to Protein Aging, Aggregation and Neurodegeneration: Tip of the Iceberg. 2021 , 13,	1
486	The fluid biomarkers of Alzheimer's disease. 2021 , 7, 1-16	
485	NHE6-Depletion Corrects ApoE4-Mediated Synaptic Impairments and Reduces Amyloid Plaque Load.	0
484	The Potential Role of Protein Kinase R as a Regulator of Age-Related Neurodegeneration. 2021 , 13, 638208	3
483	Recent advances in pre-clinical diagnosis of Alzheimer's disease. 2021 , 1	
482	The emerging role of β Secretases in cancer. 2021 , 40, 147	4
481	The Potential Role of Ferroptosis in Alzheimer's Disease. 2021 , 80, 907-925	11
480	Cognition. 1-76	
479	In Vitro Enzymatic and Kinetic Studies, and In Silico Drug-Receptor Interactions, and Drug-Like Profiling of the 5-Styrylbenzamide Derivatives as Potential Cholinesterase and β Secretase Inhibitors with Antioxidant Properties. 2021 , 10,	3
478	An APP ectodomain mutation outside of the A β domain promotes A β production in vitro and deposition in vivo. 2021 , 218,	2
477	Endosomal-lysosomal dysfunctions in Alzheimer's disease: Pathogenesis and therapeutic interventions. 2021 , 36, 1087-1100	3
476	Computer-assisted evaluation of plant-derived β Secretase inhibitors in Alzheimer's disease. 2021 , 22,	5
475	Neuroprotective effects of Actinidia eriantha cv. Bidan kiwifruit on amyloid beta-induced neuronal damages in PC-12 cells and ICR mice. 2021 , 79, 104398	4
474	Molecular Characteristics of Amyloid Precursor Protein (APP) and Its Effects in Cancer. 2021 , 22,	2
473	Effect of cholesterol on the dimerization of C99-A molecular modeling perspective. 2021 , 16, 031002	1
472	Neoline Improves Memory Impairment and Reduces Amyloid- β Level and Tau Phosphorylation Through AMPK Activation in the Mouse Alzheimer's Disease Model. 2021 , 81, 507-516	1
471	Selective Secretase Targeting for Alzheimer's Disease Therapy. 2021 , 81, 1-17	11

470	Biomarkers and Their Implications in Alzheimer's Disease: A Literature Review. 2021 , 000, 000-000	1
469	PET Agents in Dementia: An Overview. 2021 , 51, 196-229	10
468	Role of lysosomes in physiological activities, diseases, and therapy. 2021 , 14, 79	15
467	Alzheimer's disease BIN1 coding variants increase intracellular A β by interfering with BACE1 recycling.	
466	   2021 , 86, 831-844	
465	BACE1 controls synaptic function through modulating release of synaptic vesicles. 2021 ,	2
464	Effect of Global Brain Ischemia on Amyloid Precursor Protein Metabolism and Expression of Amyloid-Degrading Enzymes in Rat Cortex: Role in Pathogenesis of Alzheimer's Disease. 2021 , 86, 680-692	0
463	Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor. 2021 , 64, 8076-8100	2
462	Role of amyloid β peptide in the pathogenesis of age-related macular degeneration. 2021 , 6, e000774	2
461	An Overview of β Amyloid Cleaving Enzyme 1 (Bace1) in Alzheimer's Disease Therapy Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor. 2021 ,	2
460	P38 β -MAPK phosphorylates Snapin and reduces Snapin-mediated BACE1 transportation in APP-transgenic mice. 2021 , 35, e21691	0
459	Amyloid- β (25-35) regulates neuronal damage and memory loss via SIRT1/Nrf2 in the cortex of mice. 2021 , 114, 101945	4
458	Amyloid β production along the neuronal secretory pathway: Dangerous liaisons in the Golgi?. 2021 , 22, 319-327	4
457	Lipid flippase dysfunction as a novel therapeutic target for endosomal anomalies in Alzheimer's disease.	
456	Identification of Novel Cathepsin B Inhibitors with Implications in Alzheimer's Disease: Computational Refining and Biochemical Evaluation. 2021 , 10,	2
455	ST6GAL1 and β 2-6 Sialylation Regulates IL-6 Expression and Secretion in Chronic Obstructive Pulmonary Disease. 2021 , 12, 693149	3
454	N-Truncated A β Starting at Position Four-Biochemical Features, Preclinical Models, and Potential as Drug Target in Alzheimer's Disease. 2021 , 13, 710579	4
453	Alzheimer's Disease and β Secretase Inhibition: An Update With a Focus on Computer-Aided Inhibitor Design. 2021 ,	2

452	Suppression of amyloid- β secretion from neurons by cis-9, trans-11-octadecadienoic acid, an isomer of conjugated linoleic acid. 2021 , 159, 603-617	0
451	New insights in drug development for Alzheimer's disease based on microglia function. 2021 , 140, 111703	5
450	Multifaceted Alzheimer's Disease: Building a Roadmap for Advancement of Novel Therapies. 2021 , 46, 2832-2851	3
449	Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery. 2021 , 16, 55	10
448	Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure. 2021 , 8, e2101462	10
447	Noradrenaline in the aging brain: Promoting cognitive reserve or accelerating Alzheimer's disease?. 2021 , 116, 108-124	6
446	Green Tea Suppresses Amyloid β Levels and Alleviates Cognitive Impairment by Inhibiting APP Cleavage and Preventing Neurotoxicity in 5XFAD Mice. 2021 , 65, e2100626	4
445	Peptide Sequence Mapping around Bisecting GlcNAc-Bearing -Glycans in Mouse Brain. 2021 , 22,	3
444	Deconstructing Alzheimer's Disease: How to Bridge the Gap between Experimental Models and the Human Pathology?. 2021 , 22,	7
443	Looking at Alzheimer's Disease Pathogenesis from the Nuclear Side. 2021 , 11,	0
442	PLGA-Based Curcumin Delivery System: An Interesting Therapeutic Approach in Treatment of Alzheimer's Disease. 2021 ,	3
441	Cellular functions regulated by deubiquitinating enzymes in neurodegenerative diseases. 2021 , 69, 101367	4
440	Lipid Rafts and Development of Alzheimer's Disease.	0
439	Synaptic tau: A pathological or physiological phenomenon?. 2021 , 9, 149	5
438	Delta- and beta- secretases crosstalk amplifies the amyloidogenic pathway in Alzheimer's disease. 2021 , 204, 102113	1
437	Dysregulation of the secretory pathway connects Alzheimer's disease genetics to aggregate formation. 2021 , 12, 873-884.e4	1
436	Alzheimer's disease BIN1 coding variants increase intracellular A β levels by interfering with BACE1 recycling. 2021 , 297, 101056	2
435	Pregabalin Treatment does not Affect Amyloid Pathology in 5XFAD Mice. 2021 , 18, 283-297	1

434	Protective Role of a Donepezil-Huprine Hybrid against the β Amyloid (1-42) Effect on Human Erythrocytes. 2021 , 22,	1
433	Oxidative Stress and Beta Amyloid in Alzheimer's Disease. Which Comes First: The Chicken or the Egg?. 2021 , 10,	7
432	Citrullination of Amyloid- β Peptides in Alzheimer's Disease. 2021 , 12, 3719-3732	2
431	Mitochondrial defects: An emerging theranostic avenue towards Alzheimer's associated dysregulations. 2021 , 285, 119985	2
430	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. 2021 , 17, 703-714	9
429	Ameliorative effect of myrcene in mouse model of Alzheimer's disease. 2021 , 911, 174529	1
428	Chronic MC-LR exposure promoted A β and p-tau accumulation via regulating Akt/GSK-3 β signal pathway. 2021 , 794, 148732	0
427	BACE2 suppression in mice aggravates the adverse metabolic consequences of an obesogenic diet. 2021 , 53, 101251	2
426	Amyloid beta acts synergistically as a pro-inflammatory cytokine. 2021 , 159, 105493	4
425	Further insights for the role of Morin in mRTBI: Implication of non-canonical Wnt/PKC- β and JAK-2/STAT-3 signaling pathways. 2021 , 100, 108123	1
424	The Role of Sphingolipids and Specialized Pro-Resolving Mediators in Alzheimer's Disease. 2020 , 11, 620348	3
423	Region-specific amyloid- β accumulation in the olfactory system influences olfactory sensory neuronal dysfunction in 5xFAD mice. 2021 , 13, 4	4
422	The Role of Cathepsin B in the Degradation of A β and in the Production of A β Peptides Starting With Ala2 in Cultured Astrocytes. 2020 , 13, 615740	3
421	Synthesis and biological evaluation of 2-arylbenzofuran derivatives as potential anti-Alzheimer's disease agents. 2021 , 36, 1346-1356	4
420	Membrane organization Regulated Intramembrane Proteolysis (Rip). 2021 , 846-853	
419	Beneficial Effects of Citrus-Derived Polymethoxylated Flavones for Central Nervous System Disorders. 2021 , 13,	6
418	The Role of Presenilins in the Cell Cycle and Apoptosis. 2005 , 30-41	1
417	Ectodomain shedding of receptor activator of NF-kappaB ligand. 2007 , 602, 15-21	14

416	Gene Arrays, Cell Lines, Stem Cells, and Sensory Regeneration in Mammalian Ears. 257-307	4
415	Zinc and Zinc Transport and Sequestration Proteins in the Brain in the Progression of Alzheimer's Disease. 2011 , 669-693	1
414	Macrocyclic Protease Inhibitors Constrained into a β -Strand Geometry. 2013 , 181-192	2
413	Effects of Mild and Severe Oxidative Stress on BACE1 Expression and APP Amyloidogenic Processing. 2016 , 1303, 101-16	9
412	The Function of the Amyloid Precursor Protein Family. 2007 , 37-51	2
411	Amyloid Oligomers, Protofibrils and Fibrils. 2019 , 93, 471-503	5
410	The Ubiquitin System in Alzheimer's Disease. 2020 , 1233, 195-221	25
409	Demenz. 2017 , 1377-1465	1
408	Functional genomics of Down syndrome: a multidisciplinary approach. 2001 , 131-48	5
407	Approach towards an integrative drug treatment of Alzheimer's disease. 2000 , 59, 301-13	6
406	Drug Development for Neurodegenerative Diseases. 2015 , 183-216	2
405	The Role of A β and Tau Oligomers in the Pathogenesis of Alzheimer's Disease. 2012 , 135-188	5
404	Translating the Knowledge of Functional Dynamics Toward Designing Inhibitors of BACE1, a Key Aspartate Protease in Alzheimer's Disease. 2017 , 171-193	1
403	The β -Secretase Protease Complexes in Neurodegeneration, Cancer and Immunity. 2017 , 47-87	2
402	Neurobiological Mechanisms Involved in the Pathogenesis of Alzheimer's Disease. 2019 , 235-269	2
401	Napsin A. 2004 , 52-53	1
400	Biometals and Alzheimer's Disease. 2017 , 1-17	3
399	Neuronal Protein Trafficking in Alzheimer's Disease and Niemann-Pick Type C Disease. 2007 , 391-411	2

398	Aging-Related Memory Disorders. 2003 , 337-366	1
397	The development of a structurally distinct series of BACE1 inhibitors via the (Z)-fluoro-olefin amide bioisosteric replacement. 2020 , 30, 127240	1
396	Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins.	1
395	Amyloid β peptide and Alzheimer's disease. 2014 , 56, 99-110	18
394	The cellular expression and proteolytic processing of the amyloid precursor protein is independent of TDP-43. 2020 , 40,	2
393	Amyloid precursor protein beta-secretase (BACE) mRNA expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines and growth factors. 2000 , 20, 289-96	39
392	Increased neuronal and glial expression of protein kinase C isoforms in neocortex of transgenic Tg2576 mice with amyloid pathology. 2001 , 13, 269-278	3
391	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain	1
390	Quantitative secretome analysis establishes the cell type-resolved mouse brain secretome.	1
389	Dysregulation of the secretory pathway connects Alzheimer's disease genetics to aggregate formation.	1
388	The Cholesteryl Ester Transfer Protein (CETP) raises Cholesterol Levels in the Brain and affects Presenilin-mediated Gene Regulation.	0
387	Contribution of the endosomal-lysosomal and proteasomal systems in Amyloid- β Precursor Protein derived fragments processing.	1
386	Deep neural network affinity model for BACE inhibitors in D3R Grand Challenge 4.	1
385	AAV mediated delivery of a novel anti-BACE1 VHH reduces A β in an Alzheimer's disease mouse model.	3
384	Detangling Alzheimer's disease. New insights into the biological bases of the most common cause of dementia are pointing to better diagnostics and possible therapeutics. 2003 , 2003, oa2	6
383	Targeting the role of the endosome in the pathophysiology of Alzheimer's disease: a strategy for treatment. 2006 , 2006, re2	30
382	BREAKTHROUGH OF THE YEAR: Peering Into 2000. <i>Science</i> , 1999 , 286, 2240-2240	33-3 2
381	The brain's susceptibility to amyloid plaques. <i>Science</i> , 2001 , 293, 1434	33-3 14

380	Physiologic and Pathologic Events Mediated by Intramembranous and Juxtamembranous Proteolysis. 2003 , 2003, re4-re4	2
379	Structural Diagnostics of Biological Systems Based on X-Ray Absorption Spectroscopy. 2020 , 65, 813-820	0
378	BACE2, a conditional β secretase, contributes to Alzheimer's disease pathogenesis. 2019 , 4,	31
377	LRP in Alzheimer's disease: friend or foe?. 2000 , 106, 1077-9	31
376	The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. 2005 , 115, 2793-800	151
375	Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. 2008 , 118, 671-82	258
374	Inhibition of GSK3 β mediated BACE1 expression reduces Alzheimer-associated phenotypes. 2013 , 123, 224-35	243
373	Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer's disease. 2013 , 123, 2523-38	74
372	Proteolytic processing and cell biological functions of the amyloid precursor protein. 2000 , 113, 1857-1870	418
371	Identification of beta-secretase (BACE1) substrates using quantitative proteomics. 2009 , 4, e8477	140
370	Phenylbutyric acid rescues endoplasmic reticulum stress-induced suppression of APP proteolysis and prevents apoptosis in neuronal cells. 2010 , 5, e9135	54
369	Identification of an archaeal presenilin-like intramembrane protease. 2010 , 5, e13072	27
368	Activation of PKR causes amyloid β peptide accumulation via de-repression of BACE1 expression. 2011 , 6, e21456	40
367	BACE1 inhibition induces a specific cerebrospinal fluid β amyloid pattern that identifies drug effects in the central nervous system. 2012 , 7, e31084	60
366	Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β secretase in a mouse model of Alzheimer's disease. 2013 , 8, e55091	50
365	Ferulic acid is a nutraceutical β secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. 2013 , 8, e55774	118
364	Long-term oral administration of hop flower extracts mitigates Alzheimer phenotypes in mice. 2014 , 9, e87185	15
363	Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. 2014 , 9, e89998	36

362	A novel blood-brain barrier co-culture system for drug targeting of Alzheimer's disease: establishment by using acitretin as a model drug. 2014 , 9, e91003	34
361	Multiplex assay for live-cell monitoring of cellular fates of amyloid- β precursor protein (APP). 2014 , 9, e98619	9
360	The resveratrol trimer miyabenol C inhibits β secretase activity and β amyloid generation. 2015 , 10, e0115973	18
359	Total Lignans of Schisandra chinensis Ameliorates A β -42-Induced Neurodegeneration with Cognitive Impairment in Mice and Primary Mouse Neuronal Cells. 2016 , 11, e0152772	26
358	Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid- β or Pathologic Phenotype. 2016 , 11, e0159119	7
357	Cystatin C Shifts APP Processing from Amyloid- β Production towards Non-Amyloidgenic Pathway in Brain Endothelial Cells. 2016 , 11, e0161093	10
356	Concurrent Treatment with Taxifolin and Cilostazol on the Lowering of β Amyloid Accumulation and Neurotoxicity via the Suppression of P-JAK2/P-STAT3/NF- κ B/BACE1 Signaling Pathways. 2016 , 11, e0168286	37
355	Nuclear localization of amyloid- β precursor protein-binding protein Fe65 is dependent on regulated intramembrane proteolysis. 2017 , 12, e0173888	6
354	An optimized quantitative proteomics method establishes the cell type-resolved mouse brain secretome. 2020 , 39, e105693	19
353	N-Terminally Truncated A β Peptide Variants in Alzheimer's Disease. 107-122	2
352	Interpretation and applicability of microRNA data to the context of Alzheimer's and age-related diseases. 2010 , 2, 166-9	58
351	Effects of senescence and angiotensin II on expression and processing of amyloid precursor protein in human cerebral microvascular endothelial cells. 2018 , 10, 100-114	8
350	The antigen-binding fragment of human gamma immunoglobulin prevents amyloid β peptide folding into β sheet to form oligomers. 2017 , 8, 41154-41165	4
349	β Secretase regulates the β -secretase cleavage of the Alzheimer's disease, amyloid precursor protein.	2
348	Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. 2008 , 14, 451-64	362
347	Long-term behavioral, histological, biochemical and hematological evaluations of amyloid beta-induced Alzheimer's disease in rat. 2018 , 78, 51-59	3
346	Blood-based Biomarkers of Alzheimer's Disease: The Long and Winding Road. 2020 , 26, 1300-1315	7
345	The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer's Disease and Parkinson Disease. 2020 , 26, 509-516	4

344	Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies. 2020 , 21, 148-166	7
343	Molecular Links Between Alzheimer's Disease and Gastrointestinal Microbiota: Emphasis on Helicobacter pylori Infection Involvement. 2019 , 20, 3-12	7
342	Elevated A β 2 in aged, non-demented individuals with cerebral atherosclerosis. 2013 , 10, 785-9	12
341	The normal and pathologic roles of the Alzheimer's β secretase, BACE1. 2014 , 11, 441-9	37
340	Potential for Stem Cells Therapy in Alzheimer's Disease: Do Neurotrophic Factors Play Critical Role?. 2017 , 14, 208-220	39
339	Associations of Plasma BACE1 Level and BACE1 C786G Gene Polymorphism with Cognitive Functions in Patients with Type 2 Diabetes: A Cross- Sectional Study. 2020 , 17, 355-364	4
338	Advances in Studies on Stroke-Induced Secondary Neurodegeneration (SND) and Its Treatment. 2020 , 20, 1154-1168	4
337	Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease. 2010 , 8, 211-7	66
336	Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. 2013 , 11, 338-78	313
335	Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer's Disease Immunotherapy. 2013 , 11, 491-8	41
334	Mechanisms of Melatonin in Alleviating Alzheimer's Disease. 2017 , 15, 1010-1031	89
333	Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential. 2019 , 17, 563-579	22
332	Cardiovascular dementia - a different perspective. 2010 , 4, 29-52	21
331	Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?. 2009 , 3, 27-44	6
330	Trypsin inhibition by ferrocene. 2005 , 203-213	1
329	BACE2 distribution in major brain cell types and identification of novel substrates. 2018 , 1, e201800026	27
328	Alzheimer's disease. 2000 , 2, 91-100	38
327	Fleshing out the amyloid cascade hypothesis: the molecular biology of Alzheimer's disease. 2000 , 2, 101-10	6

326	Genetic studies in Alzheimer's disease. 2003 , 5, 17-26	22
325	CSF tau and β Amyloid as biomarkers for mild cognitive impairment. 2004 , 6, 379-90	16
324	Mechanism-based treatments for Alzheimer's disease. 2009 , 11, 159-69	13
323	Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, β APP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow. 2020 , 2, 90-114	4
322	Molecular Regulation of BACE1 and Its Function at The Early Onset of Alzheimer's Disease. 2012 , 39, 709-714	3
321	Cytoprotective Effects of Phaeophyta Extracts from the Coast of Jeju Island in HT-22 Mouse Neuronal Cells. 2014 , 43, 224-230	7
320	In Vitro Screening for Anti-Dementia Activities of Seaweed Extracts. 2016 , 45, 966-972	8
319	NKX6.3 protects against gastric mucosal atrophy by downregulating β Amyloid production. 2019 , 25, 330-345	2
318	Ginsenoside Rg1 reduces β -amyloid levels by inhibiting CD β 5-induced PPAR γ ; phosphorylation in a neuron model of Alzheimer's disease. 2020 , 22, 3277-3288	3
317	Justicidin A Reduces β Amyloid via Inhibiting Endocytosis of β Amyloid Precursor Protein. 2019 , 27, 276-282	1
316	Beta secretase activity in peripheral nerve regeneration. 2017 , 12, 1565-1574	9
315	Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. 2018 , 13, 616-623	57
314	Could autophagy dysregulation link neurotropic viruses to Alzheimer's disease?. 2019 , 14, 1503-1506	13
313	Knowledge domain and emerging trends in Alzheimer's disease: a scientometric review based on CiteSpace analysis. 2019 , 14, 1643-1650	30
312	Novel Combinatorial Therapeutic Targeting of PAI-1 (SERPINE1) Gene Expression in Alzheimer's Disease. 2012 , 1, 106	18
311	High Fibre Diets and Alzheimer's Disease. 2014 , 05, 410-424	12
310	Magnesium Therapy Prevents Senescence with the Reversal of Diabetes and Alzheimer's Disease. 2016 , 08, 694-710	4
309	Absence of Nitric Oxide Synthase 3 Increases Amyloid β Protein Pathology in Tg-5xFAD Mice. 2013 , 4, 84-91	6

308	Screening and Optimal Extraction of a New Antidementia β Secretase Inhibitor-Containing Mushroom. 2008 , 36, 195-7	9
307	Synthesis and Biological Evaluation of 3-Amino-4-aryl-piperidine Derivatives as BACE 1 Inhibitors. 2006 , 27, 1371-1376	7
306	Flavonoids lower Alzheimer's A β production via an NFB dependent mechanism. 2011 , 6, 229-36	27
305	APP and APLP2 interact with the synaptic release machinery and facilitate transmitter release at hippocampal synapses. 2015 , 4, e09743	52
304	A non canonical subtilase attenuates the transcriptional activation of defence responses in. 2016 , 5,	14
303	Lycopene alleviates oxidative stress via the PI3K/Akt/Nrf2 pathway in a cell model of Alzheimer's disease. 2020 , 8, e9308	11
302	β Barrels and Amyloids: Structural Transitions, Biological Functions, and Pathogenesis. 2021 , 22,	0
301	ATP Synthase and Mitochondrial Bioenergetics Dysfunction in Alzheimer's Disease. 2021 , 22,	5
300	The Swedish dilemma - the almost exclusive use of APP ^{swe} -based mouse models impedes adequate evaluation of alternative β secretases. 2021 , 119164	1
299	NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load. 2021 , 10,	1
298	Brothers in arms: proBDNF/BDNF and sAPP β /A β signaling and their common interplay with ADAM10, TrkB, p75NTR, sortilin, and sorLA in the progression of Alzheimer's disease. 2022 , 403, 43-71	1
297	Structure-activity relationship study of hydroxyethylamine isostere and P1' site structure of peptide mimetic BACE1 inhibitors. 2021 , 50, 116459	1
296	Genetic Factors and the Role of Calcium in Alzheimer's Disease Pathogenesis. 2000 , 607-623	1
295	Clinical and Genetic Aspects of Hereditary Cerebral Hemorrhage with Amyloidosis Dutch Type (HCHW A-D). 2000 , 103-119	1
294	Amyloid β protein accumulation in the human brain during aging. 2001 , 233-240	
293	References. 2001 , 192-224	
292	Chemical Communication Between Cells. 2001 , 1741-1829	
291	The Putative Role of Presenilins in the Transmembrane Domain Cleavage of Amyloid Precursor Protein and Other Integral Membrane Proteins. 2001 , 129-140	

- 290 ??????????????????????. **2001**, 47, 184-190 1
- 289 The Value of Transgenic Models for the Study of Neurodegenerative Diseases. **2001**, 67-86
- 288 Detangling Alzheimer's disease. **2001**, 2001, oa2 1
- 287 β Secretase I A Target for Alzheimer's Disease. **2002**, 79-83
- 286 4)?????????????????. **2002**, 91, 148-151
- 285 Development of Anti-Dementia Drugs for Alzheimer's Disease: Present And Future. **2002**, 223-228
- 284 Proprotein Convertases.
- 283 Amyloid β Precursor Protein (APP).
- 282 Regulated Intramembrane Proteolysis I New Lessons from Lipid Metabolism and the Unfolded Protein Response. **2002**, 1-17
- 281 β Secretase and Presenilin. **2003**, 47-62
- 280 Memapsin 2. **2004**, 66-69
- 279 Memapsin 1. **2004**, 64-66
- 278 Genetic and Toxicological Models of Neurodegenerative Diseases. **2004**, 107-121
- 277 Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. **2005**, 051213091414049
- 276 Analysis of Amyloid Precursor Protein Processing Protease β Secretase. **2004**,
- 275 Immunocytochemical Analysis of Amyloid Precursor Protein and Its Derivatives. **2004**,
- 274 Pathological Detection of AB and APP in Brain. **2004**,
- 273 Biochemical Characterization of Amyloid Precursor Protein. **2004**,

- 272 β Amyloid Therapeutic Strategies for Alzheimer's Disease. 0
- 271 Cysteine Proteases as beta-Secretases for Abeta Production in the Major Regulated Secretory Pathway of Neurons. **2005**, 327-342
- 270 Oxidative Stress and AbetaPP Processing. **2005**, 235-246
- 269 Intra- or Intercomplex Binding to the β Secretase Enzyme. **2006**, 281, 31279-31289 7
- 268 Beta Secretase. **2007**, 1-8
- 267 Secretase Processing of Amyloid Precursor Protein (APP) and Neurodegeneration. **2007**, 469-514
- 266 3. ??????????????. **2007**, 38, 189-195
- 265 A β Induced Toxicity Mediated by Caspase Cleavage of the Amyloid Precursor Protein (APP). **2008**, 145-155
- 264 Alzheimer's Disease BACE Proteases. **2008**, 261-284
- 263 Alternative pathways for production of β Amyloid peptides of Alzheimer's disease. **2008**, 080808070126964-37 1
- 262 Isoaspartate containing amyloid precursor protein derived peptides alter efficacy and specificity of potential β Secretases. **2008**, 080808070219541-30
- 261 Amyloid and Neurodegeneration: Alzheimer's Disease and Retinal Degeneration. **2009**, 131-163
- 260 Role of A β Degrading Enzymes in Synaptic Plasticity and Neurogenesis in Alzheimer's Disease. **2009**, 3-12
- 259 Proteases In β Amyloid Metabolism: Potential Therapeutic Targets Against Alzheimer's Disease. **2009**, 385-402
- 258 Potential Therapeutic Strategies for Neurodegenerative Diseases. **2010**, 325-382 1
- 257 Drosophila Melanogaster as a Model Organism for Dementia. **2011**, 223-240
- 256 Pathological Validation of Animal Models of Dementia. **2011**, 99-141
- 255 The Genetics of Alzheimer's Disease and Parkinson's Disease. **2011**, 695-755 0

254 Genetics of Alzheimer's Disease. **2010**, 238-251

253 Chapter 6:Discovery of the Cysteine Protease Cathepsin B as a Drug Target for Alzheimer's Disease. **2011**, 145-168

252 Demenz. **2011**, 1240-1319

251 Epigenetics and Nutrition: B-Vitamin Deprivation and its Impact on Brain Amyloid. **2011**, 2271-2283

250 Copper and Alzheimer Disease: The Good, the Bad and the Ugly. **2012**, 609-645

249 Morbus Alzheimer und Altersveränderungen des Gehirns. **2012**, 193-208

248 New Small Molecule Drug Discovery for Alzheimer's Disease. **2012**, 163-210

247 Proteases in the Nervous System. **2013**, 319-371

1

246 Melatonin's Neuroprotective Actions on Hippocampal Neurons. **2014**, 353-366

245 Insulin Receptor and the Pathophysiology of Alzheimer Disease. 31-50

244 Stem Cell Therapies for Age Associated Neurodegeneration. **2014**, 2299-2314

243 Linking Molecular Neurobiology to Therapeutic Approaches for Alzheimer's Disease with PET. **2014**, 451-478

242 A Mini Review on Aβ Oligomers and its Pathogenicity. **2014**, 7, 79-86

241 Effects of Polygalae Radix on β Amyloid Accumulation and Memory Impairment Induced by Chronic Cerebral Hypoperfusion in Rats. **2014**, 29, 73-83

1

240 Alzheimer's Disease. **2015**, 223-261

239 The BRICHOS Domain. **2015**, 1-28

238 Sulodexide and Alzheimer's Disease: A Preliminary Prospective Study. **2016**, 06, 54-71

3

237 Demenz. **2016**, 1-89

- 236 Neuropsychological Screening and Advanced Neuropsychological Tests. **2016**, 51-90
- 235 SARS Vaccines. **2016**, 942-954
- 234 Fluorescence fluctuation analysis of BACE1-GFP fusion protein in cultured HEK293 cells. **2016**,
- 233 Verubecestat. **2017**, 204-251
- 232 Loss of Ataxin-1 Elevates BACE1 Expression and Impairs Axonal Targeting in the Cerebrum.
- 231 Neuroprotection: Pharmacological Approaches. **2018**,
- 230 ALZHEIMERIO LIGOS GYDYMOMETODIPAIETIKA: KLINIKINIITYRIMIKRYPTYS. **2018**, 22, 21-30
- 229 The unique nested geneALZASas a potential source of A β peptides in Alzheimer's disease.
- 228 Structural Modeling of β Secretase A β Complex Formation and Substrate Processing. 0
- 227 Amyloid Beta. **2019**, 235-251 1
- 226 Recent Advances in the Quest for Treatment and Management of Alzheimer and Other Dementia. **2019**, 09, 1-35 1
- 225 Biological Activities and Potential Application in Food Industry. **2019**, 163-274
- 224 AD "Statin": Alzheimer's Disorder is a "Fast" Disease Preventable by Therapeutic Intervention Initiated Even Late in Life and Reversible at the Early Stages. **2020**, 2, 75-89 3
- 223 Pharmacophore Modeling and Docking Studies to Investigate Potential Leads for the Development of β Secretase APP Cleavage Enzyme-1 (BACE-1) Inhibitors. **2019**, 16, 775-784 3
- 222 A Novel Preclinical Rat Model of Alzheimer's Disease. **2020**, 69-98
- 221 Peptidomimetic Synthesis: Drug Discovery for Alzheimer's Disease. **2020**, 2103, 215-223
- 220 Peptidomimetic Modulators of BACE1. **2020**, 73, 366 1
- 219 Preferred endocytosis of amyloid precursor protein from cholesterol-enriched lipid raft microdomains. 0

- 218 The γ -Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer's Disease. **2020**, 19, 184-194 0
- 217 High-fat diet induced discrepant peripheral and central nervous systems insulin resistance in APP^{swe}/PS1^{dE9} and wild-type C57BL/6J mice. **2020**, 13, 1236-1250 0
- 216 Is It the Twilight of BACE1 Inhibitors?. **2021**, 19, 61-77 2
- 215 Immunotherapy Targeting Amyloid- β Peptides in Alzheimer's Disease. 23-49 1
- 214 Structural and functional properties of meprin (metallopeptidase with regard to cell signaling. **2022**, 1869, 119136 1
- 213 The Role of A β in the Development of Alzheimer's Disease and its Mechanisms. **2020**, 218, 03041
- 212 Changing fate. **2020**, 617-630
- 211 Optical Imaging Probes for Amyloid Diseases in Brain. **2020**, 157-182
- 210 Implications of alpha- and beta-secretase expression and function in Alzheimer's disease. **2020**, 245-259
- 209 Purification of Full-Length γ -Secretase Involved in Alzheimer's Disease, and Proteomic Identification of Binding Partners. **2020**, 13, 1-12
- 208 Applying C. elegans to the Industrial Drug Discovery Process to Slow Aging. **2021**, 2, 0
- 207 From Bench to Bedside. 322-328
- 206 From Bench to Bedside. 118-124 0
- 205 Therapeutic Approaches with Protease Inhibitors in Neurodegenerative and Neurological Diseases. **2002**, 189-197 1
- 204 β -Secretase: Physiological Role and Target Validation. 59-76
- 203 Genetics and Neurobiology of Alzheimer's Disease and Frontotemporal Dementias. **2006**, 1130-1141
- 202 Amyloid β Peptide and Central Cholinergic Neurons: Involvement in Normal Brain Function and Alzheimer's Disease Pathology. **2007**, 159-178
- 201 Physiologic and Neurotoxic Properties of A β Peptides. **2007**, 179-197

200	Impact of β Amyloid on the Tau Pathology in Tau Transgenic Mouse and Tissue Culture Models. 2007 , 198-215	
199	Tiermodelle in der biomedizinischen Forschung. 2008 , 207-241	
198	Amyloid beta acts synergistically as a pro-inflammatory cytokine.	
197	Suppression of amyloid- β secretion from neurons by cis-9, trans-11-octadecadienoic acid, an isomer of conjugated linoleic acid.	
196	[The future of dementia prevention and treatment strategies]. 2020 , 57, 374-396	
195	Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. 2004 , 29, 427-41	224
194	Pharmacotherapy in the treatment of Alzheimer's disease: an update. 2004 , 3, 84-8	4
193	Inhibition of BACE1 for therapeutic use in Alzheimer's disease. 2010 , 3, 618-28	34
192	Lowering of amyloid beta peptide production with a small molecule inhibitor of amyloid- β precursor protein dimerization. 2012 , 1, 75-87	14
191	Leptin signaling and Alzheimer's disease. 2012 , 1, 245-65	44
190	Comparable dimerization found in wildtype and familial Alzheimer's disease amyloid precursor protein mutants. 2013 , 2, 15-28	6
189	An exploration of the potential mechanisms and translational potential of five medicinal plants for applications in Alzheimer's disease. 2013 , 2, 70-88	7
188	Natural Modulators of Amyloid-Beta Precursor Protein Processing. 2012 ,	2
187	ER-stress in Alzheimer's disease: turning the scale?. 2013 , 2, 247-65	37
186	Divalent cation tolerance protein binds to β secretase and inhibits the processing of amyloid precursor protein. 2013 , 8, 991-9	2
185	CHOLESTEROL AND NEURONAL SUSCEPTIBILITY TO BETA-AMYLOID TOXICITY. 2010 , 5, 35-56	5
184	Cycle on Wheels: Is APP Key to the AppBp1 Pathway?. 2014 , 1,	6
183	Downregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer's disease. 2015 , 8, 1565-74	53

182	The association of three BACE1 gene polymorphisms (exon5 C/G, intron 5 T/G and 3'UTR T/A) with sporadic Alzheimer's disease susceptibility: a meta-analysis. 2015 , 8, 12264-74	
181	The Role of the Renin-Angiotensin System in Amyloid Metabolism of Alzheimer's Disease. 2014 , 30, 114-8	3
180	Amyloid-beta immunotherapy: the hope for Alzheimer disease?. 2016 , 47, 203-212	21
179	Mechanisms that synergistically regulate β secretase processing of APP and A β protein levels: relevance to pathogenesis and treatment of Alzheimer's disease. 2017 , 23, 121-128	5
178	Expression analysis of beta-secretase 1 (BACE1) enzyme in peripheral blood of patients with Alzheimer's disease. 2019 , 10, 276-280	2
177	Protein-Encoding RNA-to-RNA Information Transfer in Mammalian Cells: Principles of RNA-Dependent mRNA Amplification. 2019 , 1,	6
176	Protein-Encoding RNA to RNA Information Transfer in Mammalian Cells: RNA-dependent mRNA Amplification. Identification of Chimeric RNA Intermediates and Putative RNA End Products. 2019 , 1, 23-47	6
175	Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent APP mRNA Amplification. An Engine that Drives Alzheimer's Disease. 2019 , 1, 61-74	3
174	A novel assay for the determination of PreScission protease by capillary electrophoresis.. 2021 , 281, 106696	
173	Anti-Stroke Chinese Herbal Medicines Inhibit Abnormal Amyloid- β Protein Precursor Processing in Alzheimer's Disease. 2021 ,	1
172	Presenilin/ β secretase activity is located in acidic compartments of live neurons. 2021 ,	1
171	Deer antler extracts reduce amyloid-beta toxicity in a Caenorhabditis elegans model of Alzheimer's disease. 2021 , 114850	1
170	MiR-191-5p alleviates microglial cell injury by targeting Map3k12 (mitogen-activated protein kinase kinase 12) to inhibit the MAPK (mitogen-activated protein kinase) signaling pathway in Alzheimer's disease. 2021 ,	1
169	Biological Mechanism-based Neurology and Psychiatry: a BACE1/2 and Downstream Pathway Model. 2021 ,	0
168	Koronare Herzerkrankung: Amyloid-beta β Option als Biomarker f \ddot{u} rdie Kardiologie.	
167	Role of a EphA-4 receptor tyrosine kinase in the pathogenesis of Alzheimer's Disease.. 2022 ,	1
166	Amyloid β (A β)ELISA of Human iPSC-Derived Neuronal Cultures. 2021 , 1	
165	Synaptic dysfunction in early phases of Alzheimer's Disease.. 2022 , 184, 417-438	2

164	The regulation of neuronal autophagy and cell survival by MCL1 in Alzheimer's disease.. 2022 , 1, 42-55	1
163	Mechanistic Link between Vitamin B12 and Alzheimer's Disease.. 2022 , 12,	2
162	Segregation of the membrane cargoes, BACE1 and amyloid precursor protein (APP) throughout the Golgi apparatus.. 2022 ,	2
161	Role of proline-rich tyrosine kinase 2 (Pyk2) in the pathogenesis of Alzheimer's Disease.. 2021 ,	0
160	Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's Disease.. 2022 ,	2
159	Revisiting APP secretases: an overview on the holistic effects of retinoic acid receptor stimulation in APP processing.. 2022 , 79, 101	1
158	Oral nimodipine treatment has no effect on amyloid pathology or neuritic dystrophy in the 5XFAD mouse model of amyloidosis.. 2022 , 17, e0263332	1
157	Application of Disulfiram and its Metabolites in Treatment of Inflammatory Disorders.. 2021 , 12, 795078	2
156	Physiology and pharmacology of amyloid precursor protein.. 2022 , 235, 108122	4
155	Amyloid Interaction with model cell membranes - What are the toxicity-defining properties of amyloid A 2022 , 200, 520-531	1
154	Multimodal data integration via mediation analysis with high-dimensional exposures and mediators.. 2022 ,	0
153	Optimal Formula of Angelica sinensis Ameliorates Memory Deficits in Amyloid Protein-induced Alzheimer's Disease Rat Model.. 2022 , 42, 39-47	1
152	Electrophysiological alterations of the Purkinje cells and deep cerebellar neurons in a mouse model of Alzheimer disease (Electrophysiology on cerebellum of AD mice).. 2022 ,	0
151	BACE1: More than just a secretase.. 2022 , e13430	3
150	Molecular evidences on anti-inflammatory, anticancer, and memory-boosting effects of frankincense.. 2022 ,	1
149	Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimer's disease.. 2022 , 25, 103869	1
148	In Silico Studies to Develop New GSK3 Inhibitors Effective in Alzheimer's Disease. 2022 , 19,	1
147	A study of protein-drug interaction based on solvent-induced protein aggregation by fluorescence correlation spectroscopy.. 2022 ,	

146	Cathepsin B - A Neuronal Death Mediator in Alzheimer's Disease Leads to Neurodegeneration.. 2022,	1
145	Fragment-Based Drug Discovery by NMR. Where Are the Successes and Where can It Be Improved?. 2022, 9, 834453	3
144	Alzheimer's disease protease-containing plasma extracellular vesicles transfer to the hippocampus via the choroid plexus.. 2022, 77, 103903	3
143	Inhibition of A β Peptide Aggregation by Small Molecules and Their Permeation through POPC Lipid Bilayer: Insight from Molecular Dynamics Simulation Study.. 2022,	0
142	Early Endosome Capture Proteomics and its Application to Amyloid Precursor Protein Intramembrane Processing by γ and β Secretases.	
141	AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model.. 2022, e09824	2
140	Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology.. 2022,	1
139	Females outperform males in spatial learning despite increased amyloid plaques and microgliosis in a TgF344-AD rat model of Alzheimer's disease.	0
138	Enhanced cleavage of APP by co-expressed Bace1 alters the distribution of APP and its fragments in neuronal and non-neuronal cells.. 2022, 1	0
137	Modulation of amyloid precursor protein cleavage by β Secretase activating protein through phase separation.. 2022, 119, e2122292119	1
136	Alzheimer's disease - the journey of a healthy brain into organ failure.. 2022, 17, 18	3
135	Connecting the Dots Between Hypercholesterolemia and Alzheimer's Disease: A Potential Mechanism Based on 27-Hydroxycholesterol.. 2022, 16, 842814	1
134	Endothelial BACE1 Impairs Cerebral Small Vessels via Tight Junctions and eNOS.. 2022, 101161CIRCRESAHA121320183	
133	A β Assemblies Promote Amyloidogenic Processing of APP and Intracellular Accumulation of A β 2 Through Go/G β Signaling.. 2022, 10, 852738	1
132	BACE1 Overexpression Reduces SH-SY5Y Cell Viability Through a Mechanism Distinct from Amyloid- β Peptide Accumulation: Beta Prime-Mediated Competitive Depletion of sAPP β .. 2022, 86, 1201-1220	
131	Pharmacological evaluation of bromelain in mouse model of Alzheimer's disease.. 2022, 90, 19-34	1
130	Cleavage of Kv2.1 by BACE1 decreases potassium current and reduces neuronal apoptosis.. 2022, 105310	0
129	Identification of potential lead compounds against BACE1 through in-silico screening of phytochemicals of Medhya rasayana plants for Alzheimer's disease management.. 2022, 145, 105422	

128	Cerebrovascular insulin receptors are defective in Alzheimer's disease.	0
127	Early lysosome defects precede neurodegeneration with amyloid- β and tau aggregation in NHE6-null rat brain.. 2021 ,	0
126	Sex-specific regulation of β Secretase: a novel estrogen response element (ERE)-dependent mechanism in Alzheimer's disease.. 2021 ,	3
125	Amelioration of Alzheimer's Disease by Gut-Pancreas-Liver-Brain Interaction in an App Knock-In Mouse Model.. 2021 , 12,	0
124	Intercellular signaling by ectodomain shedding at the synapse.. 2022 ,	0
123	Enhanced ion mobility resolution of A β isomers from human brain using high-resolution demultiplexing software.. 2022 , 1	1
122	Ammonia induces amyloidogenesis in astrocytes by promoting amyloid precursor protein translocation into the endoplasmic reticulum.. 2022 , 101933	0
121	Salt, Fat, Acid, Heat: Modulators of Signal Transduction. 1-9	
120	Transcranial Direct Current Stimulation Alleviates Neurovascular Unit Dysfunction in Mice With Preclinical Alzheimer's Disease.. 2022 , 14, 857415	0
119	Data_Sheet_1.pdf. 2019 ,	
118	Video_1.MPG. 2019 ,	
117	Video_2.MPG. 2019 ,	
116	Video_3.MPG. 2019 ,	
115	Video_4.MPG. 2019 ,	
114	Video_5.MPG. 2019 ,	
113	Video_6.MPG. 2019 ,	
112	Video_7.MPG. 2019 ,	
111	Table_1.XLSX. 2020 ,	

110 Table_2.XLSX. 2020,

109 Table_3.XLSX. 2020,

108 Data_Sheet_1.docx. 2018,

107 Image_1.TIF. 2018,

106 Image_2.TIF. 2018,

105 Image_3.TIF. 2018,

104 Image_4.TIF. 2018,

103 Image_5.TIF. 2018,

102 Image_6.TIF. 2018,

101 Image_1.PDF. 2018,

100 Table_1.DOC. 2018,

99 Data_Sheet_1.docx. 2019,

98 Data_Sheet_1.pdf. 2018,

97 Biophysical characterization as a tool to predict amyloidogenic and toxic properties of amyloid- β peptides.. 2022, 0

96 (-)-Spiroganoapplanin A, a complex polycyclic meroterpenoid dimer from Ganoderma applanatum displaying potential against Alzheimer's disease. 0

95 Evaluation of Inhibitory Activities of Sophora flavescens and Angelica gigas Nakai Root Extracts against Monoamine Oxidases, Cholinesterases, and β Secretase. 2022, 10, 880 1

94 Therapeutic Targeting of Rab GTPases: Relevance for Alzheimer's Disease. 2022, 10, 1141 2

93 LncRNAs as the Regulators of Brain Function and Therapeutic Targets for Alzheimer's Disease. 2022, 13, 837 1

92	Structural Polymorphism of Lysozyme Amyloid Fibrils. 2022 , 16, 259-267	0
91	Developmental Neuropathology and Neurodegeneration of Down Syndrome: Current Knowledge in Humans. 2022 , 10,	1
90	Quantitative Proteomics Reveals That ADAM15 Can Have Proteolytic-Independent Functions in the Steady State. 2022 , 12, 578	0
89	Physiological Roles of Monomeric Amyloid- β and Implications for Alzheimer's Disease Therapeutics. 2022 , 31, 65-88	3
88	Friedelin Attenuates Neuronal Dysfunction and Memory Impairment by Inhibition of the Activated JNK/NF- κ B Signalling Pathway in Scopolamine-Induced Mice Model of Neurodegeneration. 2022 , 27, 4513	1
87	P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. 2022 , 14,	0
86	Opinion: The Potential Role of Amyloid Beta Peptides as Biomarkers of Subconcussion and Concussion. 13,	0
85	Evaluation of ¹⁸ F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amyloid load in Alzheimer's disease.	0
84	Oxygen sensing in neurodegenerative diseases: current mechanisms, implication of transcriptional response and pharmacological modulation.	1
83	Amyloid precursor protein (APP) and amyloid β interact with cell adhesion molecules: Implications in Alzheimer's disease and normal physiology. 10,	0
82	Repurposing food molecules as a potential BACE1 inhibitor for Alzheimer's disease. 14,	2
81	Forest Biomass as a Promising Source of Bioactive Essential Oil and Phenolic Compounds for Alzheimer's Disease Therapy. 2022 , 23, 8812	
80	Amyloid- β plaque formation and BACE1 accumulation in the brains of a 5xFAD Alzheimer's disease mouse model is associated with altered distribution and not proteolysis of BACE1 substrates Sez6 and Sez6L. 2022 , 111726	
79	Endoplasmic reticulum stress induces Alzheimer disease-like phenotypes in the neuron derived from the induced pluripotent stem cell with D678H mutation on amyloid precursor protein.	
78	Current progress of cerebral organoids for modeling Alzheimer's disease origins and mechanisms.	
77	In-Depth Characterization of Endo-Lysosomal A β in Intact Neurons. 2022 , 12, 663	1
76	Identifying Optimal Neuroinflammation Treatment Using Nanoligomer Discovery Engine.	0
75	Alzheimer's Drug PBT2 Interacts with the Amyloid β 42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs. 2022 , 61, 14626-14640	1

74	Multifunctional Therapeutic Cyclodextrin-Appended Dendrimer Complex for Treatment of Systemic and Localized Amyloidosis. 2022 , 14, 40599-40611	0
73	Vitamin B12 Attenuates Changes in Phospholipid Levels Related to Oxidative Stress in SH-SY5Y Cells. 2022 , 11, 2574	0
72	Alzheimer's disease: Pathophysiology and dental pulp stem cells therapeutic prospects. 10,	0
71	The metabolism of human soluble amyloid precursor protein isoforms is quantifiable by a stable isotope labeling-tandem mass spectrometry method. 2022 , 12,	0
70	The amyloid precursor protein regulates synaptic transmission at medial perforant path synapses.	0
69	Effect and Mechanism of Exogenous Melatonin on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic review and Meta-analysis. 2022 ,	0
68	Differential regulation of insulin signaling by monomeric and oligomeric amyloid beta-peptide.	0
67	The Aqueous Extract of Humulus japonicus Ameliorates Cognitive Dysfunction in Alzheimer's Disease Models via Modulating the Cholinergic System.	0
66	Therapeutic Potential of Targeting Regulated Intramembrane Proteolysis Mechanisms of Voltage-Gated Ion Channel Subunits and Cell Adhesion Molecules. 2022 , 74, 1030-1050	0
65	An insight into the neuroprotective effects and molecular targets of pomegranate (Punica granatum) against Alzheimer's disease. 1-22	0
64	CK2 and protein kinases of the CK1 superfamily as targets for neurodegenerative disorders. 9,	0
63	BACE1 in PV interneuron tunes hippocampal CA1 local circuits and resets priming of fear memory extinction.	0
62	Discrepant Modulating Effects of Dietary Docosahexaenoic Acid on Cerebral Lipids, Fatty Acid Transporter Expression and Soluble Beta-Amyloid Levels in ApoE -/- and C57BL/6J mice.	0
61	The therapeutic potential of triptolide and celastrol in neurological diseases. 13,	1
60	Discovery of Compounds That Selectively Repress the Amyloidogenic Processing of the Amyloid Precursor Protein: Design, Synthesis and Pharmacological Evaluation of Diphenylpyrazoles. 2022 , 23, 13111	0
59	Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics. 2022 , 13,	0
58	Synaptogenic effect of APP -Swedish mutation in familial Alzheimer's disease. 2022 , 14,	4
57	Cerebrovascular insulin receptors are defective in Alzheimer's disease.	1

56	Deciphering the Molecular Mechanism of Inhibition of β -Secretase (BACE1) Activity by a 2-Amino-imidazol-4-one Derivative. 2022 , 7,	1
55	A general approach to discover conformational epitope-directed binders for selective inhibition of protein proteolytic activation.	0
54	Myelin repair in Alzheimer's disease: a review of biological pathways and potential therapeutics. 2022 , 11,	1
53	Functional consequences of brain exposure to saturated fatty acids: From energy metabolism and insulin resistance to neuronal damage.	0
52	Postnatal neuronal Bace1 deletion impairs neuroblast and oligodendrocyte maturation.	0
51	Interdisciplinary Approaches to Deal with Alzheimer's Disease—From Bench to Bedside: What Feasible Options Do Already Exist Today?. 2022 , 10, 2922	0
50	Females exhibit higher GluA2 levels and outperform males in active place avoidance despite increased amyloid plaques in TgF344-Alzheimer's rats. 2022 , 12,	0
49	Aspartic Proteases of Alzheimer's Disease: β and β -Secretases. 2016 , 950-959	0
48	Identifying an Optimal Neuroinflammation Treatment Using a Nanoligomer Discovery Engine. 2022 , 13, 3247-3256	1
47	Circulating Small Extracellular Vesicle-Derived miR-342-5p Ameliorates Beta-Amyloid Formation via Targeting Beta-site APP Cleaving Enzyme 1 in Alzheimer's Disease. 2022 , 11, 3830	1
46	Physiological Roles of β -Amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology.	1
45	BACE2: A Promising Neuroprotective Candidate for Alzheimer's Disease. 2022 , 1-13	0
44	Differential effects of familial Alzheimer's disease-causing mutations on amyloid precursor protein (APP) trafficking, proteolytic conversion, and synaptogenic activity.	0
43	The significance of lysosome in the diagnosis and subclassification of Alzheimer's disease.	0
42	New Insights into lncRNAs in A β Cascade Hypothesis of Alzheimer's Disease. 2022 , 12, 1802	0
41	Artificial Neural Network Models Driven Novel Virtual Screening Workflow for the Identification and Biological Evaluation of BACE1 Inhibitors..	0
40	Apolipoprotein E intersects with amyloid- β within neurons.	0
39	Oligomer Formation by Amyloid- β 2 in a Membrane-Mimicking Environment in Alzheimer's Disease. 2022 , 27, 8804	0

- 38 The PSEN1 E280G mutation leads to increased amyloid- β 3 production in induced pluripotent stem cell neurons and deposition in brain tissue. ○
- 37 Morphology and Enzyme-Mimicking Activity of Copper Nanoassemblies Regulated by Peptide: Mechanism, Ultrasensitive Assaying of Trypsin, and Screening of Trypsin Inhibitors. **2022**, 94, 18099-18106 ○
- 36 PS1 Affects the Pathology of Alzheimer's Disease by Regulating BACE1 Distribution in the ER and BACE1 Maturation in the Golgi Apparatus. **2022**, 23, 16151 ○
- 35 The Impact of Software Used and the Type of Target Protein on Molecular Docking Accuracy. **2022**, 27, 9041 ○
- 34 Apolipoprotein E4 inhibits β secretase activity via binding to the β secretase complex. ○
- 33 Experimental approaches for altering the expression of Abeta-degrading enzymes. 1
- 32 Maternal High Fat Diet Anticipates the AD-like Phenotype in 3xTg-AD Mice by Epigenetic Dysregulation of A β Metabolism. **2023**, 12, 220 ○
- 31 A Genome-Wide Functional Screen Identifies Enhancer and Protective Genes for Amyloid Beta-Peptide Toxicity. **2023**, 24, 1278 ○
- 30 The interactions of amyloid β aggregates with phospholipid membranes and the implications for neurodegeneration. ○
- 29 New Monoterpenoid Indole Alkaloids from *Tabernaemontana crassa* Inhibit β Amyloid42 Production and Phospho-Tau (Thr217). **2023**, 24, 1487 ○
- 28 Ex vivo analysis platforms for monitoring amyloid precursor protein cleavage. 15, ○
- 27 The US9-Derived Protein gPTB9TM Modulates APP Processing Without Targeting Secretase Activities. ○
- 26 Animal Models of Amyloid/PS-1 Pathology. **2011**, 15-38 ○
- 25 Atomic Resolution Insights into pH Shift Induced Deprotonation Events in LS-Shaped A β (1-42) Amyloid Fibrils. **2023**, 145, 2161-2169 ○
- 24 The Pursuit of the Inside of the Amyloid Hypothesis: C99 a Promising Therapeutic Target for Alzheimer's Disease?. **2023**, 12, 454 ○
- 23 APLP2 is predominantly cleaved by β secretase and β secretase in the human brain. ○
- 22 Potential cost-effectiveness of individualized medicine in prodromal Alzheimer's disease by demographic, clinical and cerebrospinal fluid proteomics factors. ○
- 21 A tailored tetravalent peptide displays dual functions to inhibit amyloid β production and aggregation. **2023**, 6, ○

- 20 Amyloid Pathology in Alzheimer's disease: A nano delivery approach. **2023**, 126, 103510 ○
- 19 Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease. **2023**, 229, 109478 ○
- 18 Development of a micro-Raman system for in vivo studying the mechanism of laser biological effects. **2023**, 291, 122382 ○
- 17 Mumefural prevents insulin resistance and amyloid-beta accumulation in the brain by improving lowered interstitial fluid pH in type 2 diabetes mellitus. **2023**, 44, 17-29 ○
- 16 Mechanisms of amyloid- β 4 generation indicate a pivotal role for BACE1 in amyloid homeostasis. **2023**, 13, ○
- 15 Mechanistic and therapeutic role of NLRP3 inflammasome in the pathogenesis of Alzheimer's disease. ○
- 14 The Alzheimer's disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130. **2023**, 18, ○
- 13 Copper homeostasis and the ubiquitin proteasome system. **2023**, 15, ○
- 12 The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging. **2023**, 12, 763 ○
- 11 Heparan sulfate proteoglycan in Alzheimer's disease: aberrant expression and functions in molecular pathways related to amyloid- β metabolism. **2023**, 324, C893-C909 ○
- 10 A Polyaminobiaryl-Based β -secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1 Δ E9 Mice Model of Amyloid Pathology. **2023**, 24, 5285 1
- 9 Synthesis of beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors BI 1147560 and BI 1181181 labeled with carbon-14 and deuterium. ○
- 8 Cathepsin B Deficiency Improves Memory Deficits and Reduces Amyloid- β in hAPP Mouse Models Representing the Major Sporadic Alzheimer's Disease Condition. **2023**, 1-14 ○
- 7 Association of APP gene polymorphisms and promoter methylation with essential hypertension in Guizhou: a case-control study. **2023**, 17, ○
- 6 Brain p3-A β peptide restores neuronal viability impaired by Alzheimer's amyloid β peptide. ○
- 5 Genetic Phenotypes of Alzheimer's Disease: Mechanisms and Potential Therapy. ○
- 4 Association of overexpressed carboxyl-terminal amyloid precursor protein in brains with altered glucose metabolism and liver toxicity. **2023**, 27, 103-111 ○
- 3 Imbalance of Essential Metals in Traumatic Brain Injury and Its Possible Link with Disorders of Consciousness. **2023**, 24, 6867 ○

- 2 Deciphering mechanisms of action of ACE inhibitors in neurodegeneration using *Drosophila* models of Alzheimer's disease. 17, ○
- 1 Inhibition of NLRP1 inflammasome improves autophagy dysfunction and A β disposition in APP/PS1 mice. 2023, 19, ○